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Abstract 
 
Introduction: Doxorubicin (DOX), infamously known as the “red devil,” is considered the 
most effective antineoplastic drug utilized in oncologic practice today. However, its clinical 
use is hampered due to cumulative, dose-dependent cardiotoxicity, which can lead to reduced 
quality of life, irreversible heart failure and death. The mechanisms involved in the 
pathogenesis of cardiotoxicity have not been fully elucidated, but have previously been 
demonstrated to involve oxidative stress, calcium dysregulation and mitochondrial 
dysfunction. Since the mitochondria play a critical role in generation of reactive oxygen 
species, the maintenance of calcium homeostasis and are the most extensively damaged by 
DOX, they have become the main focus of novel therapeutic interventions. The morphology 
and function of these dynamic organelles are regulated in part by mitochondrial fission and 
fusion events, as well as mitochondrial quality control systems. Since mitochondrial 
morphology is often associated with crucial cellular functions, this study aimed to investigate 
the long-term effects of DOX on mitochondrial dynamics and the mitochondrial quality 
control systems, mitophagy and the ubiquitin-proteasome pathway (UPP). Additionally, since 
the mitochondria and the endoplasmic reticulum (ER) are two interconnected organelles, and 
both play a role in maintaining calcium homeostasis, this study further assessed the effects of 
chronic DOX treatment on ER function and calcium status. 
 
Materials and Methods: In order to fully establish the effect of chronic DOX treatment in 
vitro, two cardiac cell lines were utilized in this study. H9C2 cardiomyoblasts and human-
derived Girardi heart cells were cultured under standard culture conditions until ± 70-80% 
confluency was reached, where after treatment commenced. Cells were treated daily with 0.2 
and 1.0 µM of DOX for 96 and 120 hours in order to simulate chronic, cumulative 
cardiotoxicity. Cell viability and apoptotic cell death were assessed with the MTT assay and 
Caspase Glo 3/7 assays, respectively. The expression of proteins involved in mitochondrial 
dynamics, mitochondrial biogenesis, the ubiquitin-proteasome pathway, mitophagy and ER 
stress were determined with Western blotting. Organelle morphology was visualized with 
fluorescence microscopy, and flow cytometry was used to assess mitochondrial and ER load. 
In order to determine the oxidative capacity, stress and status within the cells following 
treatment, the Oxygen radical absorbance capacity (ORAC), Thiobarbituric acid reactive 
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substances (TBARS) and Glutathione (GSH) assays were employed respectively. Finally, 
intracellular and mitochondrial calcium was assessed and quantified with superresolution 
structured illumination microscopy (SR-SIM) and flow cytometry respectively.  
 
Results:  DOX significantly reduced cell viability and increased apoptosis in both in vitro 
cardiac cell models. This study further demonstrated that the expression of mitochondrial 
fusion proteins, Mfn 1 and Mfn 2 were significantly downregulated, whilst the regulators of 
fission, Drp1 and hFis1, were significantly elevated, therefore shifting the balance of 
mitochondrial dynamics towards fission. Unopposed and elevated mitochondrial fission was 
clearly evident from the morphology of these organelles, which displayed short, highly 
fragmented mitochondria with a dispersed network following treatment. Chronic DOX also 
downregulated the regulator of mitochondrial biogenesis, PGC-1α, thus inhibiting the 
formation of new, functional mitochondria. The E3 ligases, MARCH5 and Parkin were 
highly upregulated following treatment, indicating activation of the UPP and mitophagy. 
Although chronic DOX stimulated K48 ubiquitination following treatment, it inhibited the 
catalytic activity of the 26S proteasome, therefore blocking proteasomal degradation.  
Although the antioxidant capacity (measured as ORAC) was significantly enhanced by both 
concentrations of DOX, an increase in oxidative stress status was shown following DOX 
treatment. In this regard lipid peroxidation significantly increased, while redox status of the 
endogenous antioxidant, glutathione, significantly decreased. Additionally chronic DOX 
treatment induced ER stress, which lead to an increase in cytosolic and mitochondrial 
calcium. In response to ER stress, the unfolded protein response (UPR) was then stimulated.      
 
Discussion:  Results from this study indicate that chronic DOX treatment disrupts the 
balance of mitochondrial dynamics, favouring mitochondrial fission. Mitochondrial 
fragmentation is mediated by the downregulation of fusion proteins regulated by the E3 
ubiquitin ligase, MARCH5 as well as by the increase in mitochondrial calcium. 
Mitochondrial fission results in mitophagy, an adaptive response to protect the cardiac cell 
against damaged mitochondria. This study also indicates that during chronic DOX-induced 
cardiotoxicity ER stress and the UPR are induced, which is possibly responsible for the 
disruption in calcium homeostasis. The inhibition of mitochondrial biogenesis coupled with 
elevated mitophagy as observed in this chronic study, elucidates a plausible mechanism 
whereby DOX induces mitochondrial dysfunction. Unregulated mitochondrial fragmentation 
and inhibited mitochondrial biogenesis are known to regulate various cardiomyopathies, 
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therefore since both these effects are induced by chronic DOX treatment suggests a 
mechanism whereby cardiotoxicity, and ultimately heart failure are produced. This study 
provides new insight into the role of chronic DOX plays in altering mitochondrial dynamics 
and mitochondrial quality control systems. Further investigations targeted at limiting 
mitochondrial fission may reduce the cardiovascular side effects associated with DOX.   
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Uittreksel 
 
Inleiding: Doksorubisien (DOX), ook bekend as die “rooiduiwel,” word beskou as die mees 
effektiewe anti-neoplastiese middel wat tans in onkologie praktyke gebruik word.  Die 
kliniese gebruik hiervan word gerem deur die kumulatiewe dosis-afhanklike kardiotoksisiteit 
wat tot verlaagde lewenskwaliteit, onomkeerbare hartversaking, en tot die dood kan lei.  Die 
meganismes wat by die kardiotoksiese patogenese betrokke is, is nog onbekend, maar die 
meganisme het moontlik te doen met oksidatiewe stres, kalsiumwanregulering en 
mitochondriale wanfunksionering.  Omrede die mitochondria ‘n kritieke rol in die vorming 
van reaktiewe suurstofspesies speel, asook die handhawing van kalsiumhomeostase en die 
mees beskadigde organelle deur DOX, het die hooffokus na nuwe terapeutiese intervensies 
verskuif.  Die morfologie en funskie van hierdie dinamiese organelle word gereguleer deels 
deur mitochondriale fragmentering en fussie, asook mitochondriale kwaliteitsbeheersisteme.  
Omrede mitochondriale morfologie geassosieer is met noodsaaklike sellulêre funksies, het 
hierdie studie gepoog om die langtermyneffkte van DOX op mitochondriale dinamika en die 
mitochondriale kwaliteitsbeheersisteme, mitofagie en die ubikwitien-proteosoomweg (UPW) 
te ondersoek.  Siende dat die mitochondria en die endoplasmiese retikulum (ER) twee 
interverweefde organelle is, en beide ‘n rol speel in die handhawing van kalsiumhomeostase, 
het hierdie studie verder die effekte van chroniese DOX behandeling op ER funksie en 
kalsiumstatus ondersoek. 
 
Materiaal en Metodes:  Om die effek van chroniese DOX behandeling in vitro te verstaan in 
hierdie studie, is twee hartsellyne gebruik. H9C2 kardiomioblaste en menslike Girardi 
hartselle is onder standaardtoestande tot ± 70-80% konfluensie bereik is gekweek, waarna 
behandeling begin is. Selle is daagliks met 0.2 en 1.0 µM DOX vir 96 en 120 uur behandel 
om chroniese en kumulatiewe kardiotoksisiteit n ate boots.  Selvatbaarheid en apoptotiese 
seldood is onderskeidelik ondersoek deur middel van die MTT en Caspase Glo 3/7 toetse. 
Die proteïenuitdrukking betrokke by mitochondriale dinamika, mitochondriale biogenese, die 
ubikwitien-proteosoom weg, mitofagie en ER stres is deur middel van westerse afblatting 
bepaal. Organelmorfologie is deur middel van fluoresensie mikroskopie gevisualiseer, en 
vloeisitometrie was gebruik om die aantal mitochondria en ER lading te bepaal.  Om die 
oksidatiewe kapasiteit, stres en status binne die selle na behandeling te bepaal, is die ORAC, 
TBARS en GSH toetse onderskeidelik gebruik.  Laastens was die intrasellulêre en 
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mitochondriale kalsium ondersoek en gekwantifiseer met superresolussie gestruktureerde 
illuminasie mikroskopie (SR-SIM) en vloeisitomerie. 
 
Resultate:  DOX het selvatbaarheid betekenisvol verlaag en apoptose in beide in vitro 
kardiale selmodelle verhoog. Hierdie studie het verder aangetoon dat die uitdrukking van 
mitochondriale fussie proteïene, Mfn 1 en Mfn 2 betekenisvol afgereguleer is, terwyl die 
reguleerders van fragmentering, Drp1 en hFis1, betekenisvol verhoog is en daardeur die 
balans van mitochondriale dinamika na fussie verskuif. Onverhinderde en verhoogde 
mitochondriale fragmentering is duidelik sigbaar deur die morfologie van die organelle, wat 
as kort, hoogsgefragmenteerde mitochondria met ‘n verspreide netwerk na behandeling 
vertoon.  Chroniese DOX het ook die mitochondriale biogenese reguleerder, PGC-1α, 
afgereguleer en daardeur die vorming van nuwe, funksionele mitochondria geinhibeer. Die 
E3 ligase, MARCH5 en Parkin is hoogs opgereguleer na behandeling, wat aktivering van 
UPW en mitofagie aantoon. Alhoewel chroniese DOX K48 ubikwitinering na behandeling 
gestimuleer het, het dit die katalitiese aktiwiteit van die 26S proteasoom geinhibeer en dus 
die proteosomale degradasie geblokkeer.  Antioksidantkapasiteit en oksidatiewe status was 
betekenisvol na behandeling wat gevolglik tot hoë vlakke oksidatiewe skade binne die selle 
gelei het.  Addisioneel het chroniese DOX behandeling ER stres geïnduseer wat tot ‘n 
toename in sitosoliese en mitochondriale kalsium gelei het.  In reaksie op die ER stres is die 
UPW gestimuleer. 
 
Bespreking:  Resultate van hierdie studie het aangetoon dat chroniese DOX behandeling die 
balans van mitochondriale dinamika onderbreek en sodoende mitochondriale fragmentering 
bevoordeel.  Mitochondriale fragmentering word gemediëer deur die afregulering van fussie 
proteïene wat deur die E3 ubikwitienligase, MARCH5, gereguleer word, en ook deur die 
toename in mitochondriale kalsium. Mitochondriale fragmentering induseer mitofagie, ‘n 
aanpassingsreaksie om die hartselle teen beskadigde mitochondria te beskerm.  Hierdie studie 
toon verder ook dat gedurende chroniese DOX-geïnduseerde ER stres, word die UPW ook 
geïnduseer, wat moontlik dan verantwoordelik is vir die ontwrigting van kalsiumhomeostase. 
Die inhibering van mitochondriale biogenese gekoppel met verhoogde mitofagie soos 
waargeneem in hierdie studie, verklaar ‘n moontlike meganisme waardeur DOX 
mitochondriale wanfunksionering veroorsaak. Ongereguleerde mitochondriale fragmentering 
en geinhibeerde mitochondriale biogenese is bekend om verskeie kardiomiopatieë te reguleer.  
Omrede beide hierdie effekte geinduseer word deur chroniese DOX behandeling kan dit 
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moontlik ‘n meganisme voorstel waarby kardiotokiese en uiteindelik hartversaking 
ontwikkel.  Hierdie studie bied nuwe insig in die rol wat chroniese DOX speel in die 
wysiging van mitochondriale- dinamika en kwaliteitskontrole sisteme. Verdere ondersoeke 
wat die mitochondriale fragmentering kan verminder mag moontlik die kardiovaskulêre 
newe-effekte wat met DOX behandeling geassosieer is, verlaag. 
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Chapter 1 - Literature Review  
1.1 Introduction 
 
Every year, approximately 14 million people are diagnosed with cancer, and in South Africa 
alone it has been predicted that the number of new cancer cases will increase up to 78% by 
the year 2030 (Bray et al., 2012; Globocan, 2012). Although cancer remains one of the 
leading causes of death worldwide, research over the last two decades has brought us no 
closer to discovering a cure, but has lead to significant advances in therapeutic interventions. 
Since their discovery in the early 1960’s anthracyclines (ANTs), a class of chemotherapeutic 
agents, still remain amongst the most effective anti-cancer drugs utilized in oncologic 
practice today (Aubel-Sadron et al., 1984; Gharanei et al., 2014).  
 
Doxorubicin (DOX, Adriamycin), infamously known as the “red devil” chemotherapy, 
together with its cousin daunorubicin (DNR), belong to the family of ANTs (Figure 1.1) and 
are considered essential antineoplastics used in the treatment of breast cancer and pediatric 
cancers such as childhood solid tumors, leukemia, aggressive lymphomas and soft tissue 
sarcomas (Minotti et al., 2004; Octavia et al., 2012). However, unlike other 
chemotherapeutic agents, the clinical use of DOX is limited due to its cumulative, dose-
dependent cardiotoxicity, which may lead to a reduced quality of life, irreversible congestive 
heart failure (CHF) or worse, death (Lefrak et al., 1973; Swain et al., 2003; Minotti et al., 
2004). 
 
Cancer is fast becoming more manageable due to early diagnosis and advances in both basic 
and clinical cancer research (DeVita and Chu, 2008; Gharanei et al., 2013), however the 
adverse cardiotoxic effects of DOX and other systemic anticancer agents are still a major 
health concern (Swain et al., 2003; Doyle et al., 2005). This highlights the importance of 
understanding both the cellular and molecular mechanisms involved in the pathophysiology 
of DOX-induced cardiomyopathy, in order to establish novel adjuvant therapies that will 
offer cardioprotection without affecting DOX’s antineoplastic properties. Therapeutic 
interventions involving the use of β-blockers, antioxidants, renin-angiotensin system 
inhibitors and free radical scavengers have all been unsuccessful due to their negative side 
effects and interactions associated with DOX (Boucek, 1997a; Granger, 2006; Gharanei et 
al., 2013). Based on the unsuccessful nature of these interventions, it is clear that there is still 
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a lot that we do not know about DOX-induced toxicity. Moreover, results from these studies 
suggest that other mechanisms, other than those already proposed, may be involved in 
inducing the detrimental effects of DOX.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.1: The Family of Anthracyclines. Epirubicin and Idarubicin are derived from the 
original anthracyclines, Doxorubicin and Daunorubicin respectively. However all 
anthracyclines share a common chemical backbone, with minor changes in their chemical 
moieties. The quinone moieties at the 5 and 13 positions are responsible for the cardiotoxic 
effects of anthracyclines. Image sourced from Gem Pharmaceuticals  
1.2 Anthracycline Induced Cardiotoxicity 
 
In patients undergoing DOX chemotherapy, both acute and chronic cardiovascular effects 
have been reported, each with distinct signs and symptoms. Researchers have thus classified 
the cardiotoxicity into three main categories: acute, chronic and delayed-onset cardiotoxicity.  
1.2.1 Acute Cardiotoxicity 
 
Acute cardiotoxicity begins within the first few minutes of DOX administration and lasts for 
approximately 24 hours (De Beer et al., 2001; Octavia et al., 2012). This is an extremely rare 
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condition that can occur independently of ANT-dose, and rather depends on a patient’s 
individual susceptibility to the drug. Symptoms of acute cardiotoxicity include changes in 
electrocardiogram (ECG), sinus tachycardia (Singal et al., 1997), arrhythmias, premature 
supraventricular and ventricular complexes (Barrett-Lee et al., 2009), hypotension and 
myocarditis (De Beers et al., 2001). These effects are usually described as minor and the 
prognosis at this stage remains fairly optimistic, as the majority of these cardiac conditions 
are clinically manageable and are asymptomatic. It has been reported that these acute-side 
effects resolve spontaneously following completion of a treatment course (De Beers et al, 
2001).  
 
Due to its high sensitivity and specificity, an endomyocardial biopsy of the right ventricle is 
the most favoured diagnostic tool utilized in the detection of acute DOX-induced 
cardiotoxicity. Tissue from the biopsy will indicate typical histopathological changes 
associated with acute cardiotoxicity. These include cytoplasmic vacuolization and the loss of 
myofibrils via electron microscopy (Chatterjee et al., 2010). Depending on the severity of 
these changes, the biopsy sample can be scored between 1 – 3, where a score of 2.5 or greater 
is considered high risk for cardiac dysfunction, resulting in termination of DOX infusion 
(Bristow, 1982). However, even though obtaining a biopsy sample is considered the most 
effective diagnostic procedure, it is rarely used as it is considered a high-risk procedure and is 
extremely invasive. More favoured procedures include monitoring ECG abnormalities, 
assessing both adrenergic denervation and energy metabolism via radionuclide scanning, and 
evaluating cellular injury through the measurement of cardiac biomarkers, such as cardiac 
troponin-T or troponin I (Lipshultz et al., 1997; Sparano et al., 2002; Takemura and 
Fujiwara, 2007) 
 
Within this class, there is also sub-acute ANT cardiotoxicity, which is an even more 
uncommon form of DOX–induced acute cardiotoxicity, occurring in only 1.4 - 2% of all 
reported cases (Buzdar et al., 1985). Symptoms only appear several weeks to months 
following the last dose of ANT therapy (Hengel et al., 2006).  Similarly to acute 
cardiotoxicity, the sub-acute form occurs independently of ANT dose administrated.  
Succeeding treatment, sub-acute cardiotoxicity most commonly manifests itself in the form 
of pericarditis-myocarditis, which is defined as inflammation of the pericardium, and 
ultimately reduces a patient’s quality of life (Hengel et al., 2006). Other symptoms include 
left ventricular wall thickening and interstitial myocardial edema and as consequence has 
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been associated with approximately 60% mortality (Octavia et al., 2012; Montagaine et al, 
2012; Barrett-Lee et al, 2009). This myocardial dysfunction is however described as being 
reversable.  
 
1.2.2 Chronic Cardiotoxicity 
 
In contrast to the acute forms of ANT cardiotoxicity, the life-threatening chronic 
cardiotoxicity may not become apparent until a few months following the last treatment dose 
of DOX (De Beer et al., 2001; Octavia et al., 2012; Takemura and Fujiwara, 2007). Chronic 
ANT-induced cardiotoxicity has been clinically defined as the most detrimental type of 
toxicity, as it leads to irreversible cardiomyopathies and CHF. Moreover, this type of chronic 
cardiomyopathy is dose-dependent and associated with repetitive and cumulative ANT 
regimes, as demonstrated in Figure 1.2 (Von Hoff et al., 1979). Clinical symptoms indicative 
of chronic cardiotoxicity include a rapid decline in blood pressure and ejection fraction, 
tachycardia, dilated cardiomyopathy, ventricular failure and eventually CHF (Singal et al., 
1997; De Beer et al., 2001; Minotti et al., 2004). The ultrastructural features characterized 
from a patient’s endomyocardial biopsy demonstrates the loss of myofibrils, sarcoplasmic 
Figure 1.2: The Effect of Cumulative Doxorubicin Treatment on the Development of 
Chronic Heart Failure. The graph represents the cumulative risk for developing heart failure 
(%) vs. cumulative dose of doxorubicin treatment (mg/m2). Reproduced from Von Hoff et al., 
1979. 
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reticulum dilation, cytoplasmic vacuolization, mitochondrial swelling and increased 
lysosome formation (Minotti et al., 2004).  
 
Studies have shown that life-time cumulative doses of DOX that exceed 550 mg/m2 induce an 
increasing prevalence of chronic DOX-related cardiotoxicity and a 26% chance of developing 
heart failure (Figure 1.2) (Yeh and Bickford, 2009; Von Hoff et al., 1979). Therefore, in 
order to minimize the risk of developing cardiomyopathy while continuing treatment with a 
relatively “safe” dose of DOX, the maximum cumulative dose of DOX has been cautiously 
set to 500 - 550 mg/m2  (Minotti et al., 2004; De Beer et al., 2001). However by setting an 
empirical dose limit, patients are deprived of an effective anticancer treatment regime in 
order to try and eliminate the incidence of cardiomyopathies. These findings highlight the 
importance of fully understanding and identifying the molecular mechanisms responsible for 
chronic DOX-induced cardiotoxicity. In this manner, researchers will be able to establish 
novel adjuvant therapy regimes and ensure that patients are receiving the best possible 
medical care in fighting cancer. 
 
1.2.3 Delayed Cardiotoxicity 
 
Late-onset or delayed ANT-induced cardiotoxicity usually occurs years or even decades after 
ANT treatment, and commonly occurs in patients who have received relatively low doses of 
ANT treatment for longer periods of time (Lipshultz et al., 2008; Bernaba et al., 2010). The 
pathogenesis of late-onset cardiotoxicity is not very well defined in the literature, but what 
we do know is that this form of toxicity presents itself as either dilated or restrictive 
cardiomyopathy or as myocardial arrhythmias (Bernaba et al., 2010). Studies by Leandro et 
al. (1994) and Lipshultz et al. (2008) further suggest that this form of ANT-induced 
cardiotoxicity is most likely to occur in patients who previously underwent rigorous, 
childhood chemotherapy. Moreover, this type of cardiotoxicity can clinically manifest over a 
number of years until it is triggered by various cardiovascular stressors, such as pregnancy or 
viral infections (Sereno et al., 2008; Ali et al., 2004). Despite on-going research, the cellular 
mechanisms for the delayed cardiotoxicity and explanation of its astonishing molecular so-
called “dose-memory” are still poorly understood (Lebrecht et al., 2003; Bernaba et al., 
2010). What is clear from the literature is that cardiotoxicity is not governed by a single 
mechanism, but is rather a multi-factorial process (Minotti et al., 2004). It is thus imperative 
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to understand and define these multi-factorial mechanisms in order to find effective 
therapeutic strategies that would prevent or delay the onset of chronic cardiotoxicity.  
 
1.3 Doxorubicin Antitumor Activity  
 
It is clear that following treatment with DOX, detrimental chronic-cardiotoxic side effects 
arise.  Yet, the mechanisms of DOX’s antitumor activity are different from those mechanisms 
that mediate cardiotoxicity (Chatterjee et al., 2010; Yang et al., 2014).  
 
1.3.1 DNA Intercalation 
 
In the late 1950’s the first anthracycline antibiotic, DNR, was first isolated from 
Streptomyces peucetius, a bacterium species located in soil, which was found to have active 
anticancer properties (Mross et al., 2006). It was only later in 1969 that DOX was 
successfully isolated and purified from a mutant of the original Streptomyces species, which 
was found near the Adriatic Sea (hence the DOX’s alternate name, Adriamycin) (Mross et 
al., 2006). It was around the same time, that Lerman (1961) introduced the term 
“intercalation” for the first time. Since this idealistic concept was introduced nearly 55 years 
ago, enormous progress has been made in understanding the mechanism of DNA 
intercalation as well as identifying ANTs, such as DOX as DNA-intercalators.  
 
Intercalating agents are clinically used today as antibacterial, antiparasitic and antitumor 
drugs, since DNA intercalation inhibits DNA replication and thereby inhibits further cell 
growth (Berman and Young, 1981; Denny, 2002; Sasikala and Mukherjee, 2013).  One of the 
mechanisms whereby DOX can inhibit cancer growth and promote cell death is through its 
intercalation into the cell’s nuclear DNA. DOX and other ANTs are more likely to affect 
cancerous cells through DNA intercalation, as a result of the fast growth rate of these cells. 
Normal cells are however not spared in this process as they too are indirectly targeted by 
these drugs (Sasikala and Mukherjee, 2013). 
 
Literature has described that DOX prefers to intercalate DNA at sites on the helix containing 
guanine-cytosine base pairs (Figure 1.3). This is most likely due to the specific hydrogen-
bond formation between DOX and the Guanine residue (Chaires et al., 1987; Chen et al., 
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1986; Yang et al., 2014). This is evident from previous studies that have demonstrated that 
DOX-DNA adduct formation causes DNA damage and leads to cell death (Coldwell et al., 
2008). Despite the accumulating evidence of DOX-DNA adduct formation during DOX 
treatment is not thought to be the major mechanism involved in DOX’s anticancer 
capabilities (Yang et al., 2014).  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.3: Structure of doxorubicin-DNA complex. Doxorubicin (shown in black) forms a 
covalent bond (shown in red) with guanine (shown in blue) on a strand of DNA. Image 
sourced from Yang et al., 2014  
 
1.3.2 Topoisomerase II Poisoning 
 
Topoisomerases are isomerase enzymes involved in regulating the topology of DNA and 
plays an important role in regulating DNA replication and transcription, as well as other 
nuclear processes (Pommier et al., 2010; Minotti et al., 2004). They are able to temporarily 
‘cut’ and ‘reseal’ both single-stranded (topoisomerase I) and double-stranded (topoisomerase 
II) DNA, in order to rearrange the twisting or winding status of the DNA double helix, 
ultimately preventing DNA supercoiling during DNA replication (Figure 1.4) (Minotti et al., 
2004).  
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Topoisomerase II is an ATP-dependent enzyme, which exists as two isoforms; topoisomerase 
IIα that is found in animals and rodents, and topoisomerase IIβ found in humans. This 
enzyme is not only essential for releasing torsional stress, which results from supercoiling of 
DNA during its unwinding for DNA replication, but is also involved with decatenation of 
DNA during mitosis (Yang et al., 2014). Damage to or deficiency of topoisomerase II can 
prevent normal cytokinesis and result in programmed cell death via apoptosis and necrosis 
(Minotti et al., 2004; Carpenter et al., 2004). Etoposide is a known topoisomerase II poison, 
which acts by trapping topoisomerase at its breakage sites and thereby inhibiting DNA 
resealing (Wu et al., 2011; Yang et al., 2014). Many studies have hypothesized that DOX’s 
action on topoisomerase II is similar to that of Etoposide (Minotti et al., 2004; Nitiss, 2009). 
Furthermore, Burgess and colleagues (2008) demonstrated that the levels of topoisomerase II 
directly determined the effectiveness of DOX in a mouse model of lymphoma. Although 
there are numerous cases in support of the notion that DOX inhibits topoisomerase function, 
there are just as many studies indicating that DOX induces cell death independently of 
topoisomerase (Sorensen et al., 1992; Swift et al., 2006; Pang et al., 2013). Based on the 
above, it is clear that DOX-induced topoisomerase inhibition and the resulting cell death is 
still a matter of intense debate.  
 
 
Figure 1.4: The Action of Topoisomerase I and II.  Topoisomerase prevents DNA 
supercoiling during DNA replication and unwinding. (A) Action of Topoisomerase I: 
Temporarily cuts and reseals supercoiled single-stranded DNA, resulting in the uncoiling of 1 
supercoil. (B) Action of Topoisomerase II: Temporarily cuts and reseals supercoiled double-
stranded DNA, resulting in the uncoiling of 2 supercoils. Image sourced from Biosiva  
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1.3.3 Generation of Reactive Oxygen Species  
 
The chemical structure of DOX consists of both aglyconic and sugar moieties (Figure 1.5). 
The aglyconic subunit consists of a tetracyclic ring with adjacent quinone-hydroquinone 
groups, whereas the sugar, daunosamine, is attached to the aglyconic subunit via a glycosidic 
bond (Minotti et al., 2004). Due to the presence of these quionone groups on the structure of 
DOX, it is thus prone to the generation of free radicals (Myers, 1998; Minotti et al., 2004). 
By oxidizing the quinone structure with the addition of a single electron, a semiquinone 
radical is formed. Furthermore, by removing a hydrogen atom (dehydrogenation) from the 
hydroquinone groups an additional semiquinone radical is formed. These semiquinone 
radicals are very unstable, and quickly react with oxygen to generate the free radicals, 
superoxide and hydrogen peroxide, which then induce DNA damage (Myers, 1998).  
 
The semiquinone radicals formed are also able to oxidize the glyosidic bond between 
daunosamine and the aglyconic subunit. By detaching the sugar from the aglycone, 
increasing the aglycones lipid solubility, allows it to intercalate into the biologic membrane 
and induce reactive oxygen species (ROS) production (Gille and Nohl, 1997; Licata et al., 
2000). This one-electron redox cycling of DOX is accompanied by the release of iron from 
its intracellular stores (Minotti et al., 2004). In patients undergoing chemotherapy for 
leukemia or bone marrow transplantation, the body’s iron stores become disrupted as a result 
Figure 1.5: The Chemical Structure of Doxorubicin.  Doxorubicin contains aglyconic and 
sugar moieties.  Black square: Tetracyclic ring; Red square: Quinone-hydroquinone groups; 
Blue square: Daunosamine, the sugar moiety. Image adapted from Minotti et al., 2004 
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of blood transfusions, blood loss or iron supplementation. In these situations iron overload 
can develop (Barton and Bertoli, 2000). Due to the high availability of iron, DOX-iron 
complexes form, which in turn act as catalysts and convert hydrogen peroxide to highly 
reactive hydroxyl radicals (Myers, 1998; Minotti et al., 1999). The production and release of 
these free radicals from DOX causes oxidative stress within the cancer cells, resulting in 
DNA damage and ultimately cell death. It is in this manner that oxidative stress is considered 
as one of the major mechanisms of ANT antitumor activity.   
 
1.3.4 Ceramide Overproduction 
 
DOX treatment not only increases oxidative stress within cells, but it also increases ceramide 
levels (Yang et al., 2014). Ceramide is a naturally occurring lipid molecule also named a 
membrane sphingolipid (Steinbrecher et al., 2004). It is involved in a variety of processes, 
such as growth arrest and other functions, and has long been considered a pro-apoptotic 
mediator (Senchenkov et al., 2001; Steinbrecher et al., 2004). Literature indicates that 
ceramide production sensitizes the cancer cells to DOX chemotherapy, allowing DOX to 
have full effect within these cells by inducing cell death (Ji et al., 2010). It is speculated that 
ceramides, which are lipid second messengers, generated as a result of DOX-induced 
oxidative stress trigger signaling cascades involving apoptosis (Martínez et al., 2009).  
 
1.4 Mechanisms for Doxorubicin-induced Cardiotoxicity 
 
1.4.1 Oxidative Stress 
 
DOX-induced free radical production and associated ROS generation, is not only the major 
mechanism associated with the drugs antitumor capabilities, but is also thought to be the 
major mechanism contributing to the development of DOX-induced cardiotoxicity 
(Horenstein et al., 2000; Xu et al., 2001; Simůnek et al., 2009; Yang et al., 2014). As 
discussed previously, DOX induces ROS from a variety of sources, ranging from 
mitochondria to DOX-iron complexes. The problem is that the heart is vulnerable to ROS and 
oxidative stress irrespective of its source (Doroshow et al., 1980). This is because the 
myocardium has a relatively poor antioxidant defense system, and as such makes it prone to 
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oxidative damage (Horestein et al., 2000). When ROS levels rise in the myocardium causing 
oxidative stress, cardiomyocytes enzymatic defenses become overwhelmed. The absence of 
enzymatic protection allows ROS to interact with regulatory proteins and directly modify 
myocardial gene expression (Octavia et al., 2012). It is also widely accepted in the literature 
that these free radicals target the cell membrane and induce lipid peroxidation, a process 
known to kill cardiomyocytes (Goormaghtigh et al., 1990; Xu et al., 2001). This particularly 
targets membrane bound G-proteins and directly affects myocardial intercellular signaling 
(Dhalla et al., 2000; Octavia et al., 2012; Zhang and Mende, 2011). G-protein mediated 
signal transduction is essential for the regulation of cardiovascular function as it regulates 
heart rate and contraction, myocardial growth and vascular tone. Therefore by disrupting this 
signaling mechanism, pathophysiological changes such as hypertrophy, myocardial fibrosis, 
arrthymias and heart failure can occur (Sugamura and Keaney, 2011; Zhang and Mende, 
2011).  
 
In addition proteins are major targets for oxidative modification in cells (Chondrogianni et 
al., 2012). ROS can induce structural changes of protein tertiary structures via the oxidation 
of the covalent bonds (Octavia et al., 2012). This can result in the accumulation of misfolded 
or damaged proteins and thereby place strain on the myocardium’s proteolytic systems. 
Proteins thus loose their biochemical functions, and as a consequence, can have detrimental 
downstream effects on intracellular signaling pathways (Chondrogianni et al., 2012).  
 
1.4.2 The Oxidative Stress Hypothesis 
 
Since free radical formation and ROS production was thought to account for the majority of 
DOX-mediated cell death, researchers proposed that treatment with antioxidants or free 
radical scavengers in conjunction with DOX would protect the heart against DOX 
cardiotoxicity (De Beer et al., 2001; Wergeland et al., 2011). However, very few free radical 
scavengers have thus far demonstrated protection in the heart against DOX-induced 
cardiotoxicity. They include dexrazoxane (DXZ) hydrochloride (Zinecard or Cardioaxane) 
and flavonoids (De Beer et al., 2001). Currently DXZ is the only agent utilized in clinical 
studies owing to its ability to reduce toxicity associated with DOX (Imondi et al., 1996; 
Speyer et al., 1988; Swain et al., 1997). Hasinoff (1997) proposed that DXZ inhibits free 
radical formation through iron-chelation, and in this manner prevents the formation of DOX-
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iron adducts. Speyer and colleagues (1992) previously demonstrated that when DXZ is 
administrated to woman with advanced breast cancer 15 – 30 minutes prior to treatment with 
DOX, that this did not hinder DOX distribution or its antitumor function. This study further 
indicated that the incidence of cardiotoxicity was reduced and therefore patients who 
received DXZ could be treated with higher, cumulative doses of DOX.  
 
Over the last few years however there has been a reconsideration of DXZ’s pharmacological 
and clinical cardioprotective properties. In addition to its iron-chelative effects, DXZ has 
been identified as an important anticancer agent itself (Hasinoff et al., 1997). Numerous 
studies have indicated that DXZ functions as an inhibitor of topoisomerase II, in a manner 
similar to DOX (Hasinoff et al., 1997; Langer et al., 2000). This has sparked new interest in 
using this agent as an antineoplastic drug, either as a single agent or in combination with 
DOX (Tetef et al., 2001). However since the mechanisms and underlying interactions 
between DXZ and DOX have not been clinically evaluated, some studies have expressed 
concern that DXZ might in fact compete against DOX within the cell and therefore reduce 
DOX’s anticancer capabilities (Minotti et al., 2004).  
 
Flavonoids are believed to also act as free radical scavengers as well as iron-chelators 
(Haenen et al., 1993; Van Acker et al., 1995). Quercetin is one of the most commonly studied 
flavonoids (Hertog et al., 1993; Jacobs et al., 2010). A semi-synthetic flavonoid, 7-mono-O-
(β-hydroxyethyl)-rutoside (monoHER), which closely resembles the chemical structure of 
Quecetin has been shown to provide protection against chronic DOX-induced cardiotoxicity 
in vivo (Van Acker et al., 1995; Van Acker et al., 1997). However due to monoHER’s 
negative effects on the glutathione (GSH) antioxidant defense system in the heart, researchers 
have been unable to replicate or reproduce these results in the clinical setting (Bruynzeel et 
al., 2007a; Bruynzeel et al., 2007b). The majority of free radical scavengers, like 
dexrazoxane and flavonoids, are utilized as protectants against DOX-induced cardiotoxicity, 
but many of them have failed to provide long-term protection against chronic cardiotoxicity 
(Yang et al., 2014). This suggests that alternate mechanisms, other than the production of 
free radicals, may be involved in the progression of cardiotoxicity.  
 
The administration of antioxidants in conjunction with DOX treatment has been successful in 
vivo in reducing oxidative stress and cardiotoxicity (Saleem et al., 2014; Wergeland et al., 
2011), but again results have been unsuccessful in clinical trials (Bjelogrlic et al., 2005; 
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Dresdale et al., 1982; Vejpongsa and Yeh, 2014). Yagmurca (2003) demonstrated that 
Erdosteine, an antioxidant agent, protected against chronic DOX cardiotoxicity in vivo, but 
reduced DOX’s antitumor effects. Vitamin E (α-tocopherol), another important antioxidant, 
was found to be effective in ameliorating acute DOX toxicity in vivo (Mimnaugh et al., 
1979), while offering no protection in the chronic setting (Breed et al., 1980; Legha et al., 
1982; Van Vleet et al., 1980). Administration with other antioxidant compounds such as 
vitamin C (ascorbic acid) (Tavares et al., 1998), vitamin A (Shimpo et al., 1991) and 
coenzyme Q (Greenlee et al., 2012) also found to be ineffective in reducing or inhibiting 
chronic DOX cardiotoxicity.  Evidence from the literature suggests that antioxidants may 
only assist in delaying the onset of DOX’s toxic effects, rather than completely preventing 
cardiomyopathy. Although it is clear that oxidative stress plays a major role in mediating 
DOX-induced cardiotoxicity, the failure of antioxidants to reduce chronic toxicity implies 
that other cellular mechanisms are involved.  DOX-activated apoptotic signaling, which has 
previously been linked to the formation of ROS, is another mechanism thought to contribute 
to DOX-mediated cardiomyopathy (Nitobe et al., 2003; Wang et al., 2004).   
1.4.3 Apoptosis 
 
It is long been understood that ANTs induce cardiotoxicity by mechanisms other than those 
initiated in mediating its antineoplastic efficacy. Until a few years ago, apoptosis was 
overlooked as a possible mechanism for DOX-induced cardiotoxicity and CHF. Since then, it 
has been shown extensively in the literature that DOX mediates both intrinsic and extrinsic 
apoptotic pathways, as shown in Figure 1.6 (Liu et al., 2007; Wang et al., 1998; Yamaoka et 
al., 2000). 
 
Initially it was thought that DOX initiated apoptosis indirectly via the generation of ROS 
only (Wang et al., 2002; Nitobe et al., 2003), but it has recently been shown that DOX can 
directly regulate cardiomyocyte apoptosis, bypassing ROS involvement (Papadopoulou et al., 
1999; Liu et al., 2007). DOX directly induces intrinsic (mitochondrial) apoptosis by 
promoting the leakage of cytochrome C from the mitochondria, formation of the apoptosome 
complex and activation of caspase 3 (Kim et al., 2006; Zhang et al., 2012). The manner in 
which this occurs is possibly a result of DOX’s binding to the mitochondria, which causes the 
collapse of the mitochondrial membrane potential. This leads to the opening of the 
mitochondrial permeability transition pore (mPTP), mitochondrial swelling, rupture the 
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mitochondrial outer membrane and leakage of cytochrome C (Camello-Almaraz et al., 2006; 
Deniuad et al., 2008). While this is happening, there is an upregulation of Bax (Bcl-2-
associated X-protein, a pro-apoptotic protein) and downregulation of Bcl-XL (an anti-
apoptotic protein). In this scenario, Bcl-XL would usually play a critical role inhibiting the 
effects of cytochrome C function, however due to its downregulation, apoptosis is the 
ultimate event (Figure 1.6) (Kim et al., 2006; Minotti et al., 2004). Indirectly, DOX-mediated 
intrinsic apoptosis may also be promoted not only by DOX-associated ROS production but 
also ceramide production (Armstrong, 2004; Parra et al., 2008) and p53 phosphorylation (Liu 
et al., 2008).  
 
The Fas/Fas ligand  (Fas/FasL) system is an important regulator of the extrinsic pathway of 
apoptosis signaling in various organisms. Fas, a member of the tumor necrosis factor (TNF)-
receptor family, is a type I membrane protein, expressed in a wide variety of tissues (Nagata, 
1997; Yonehara, 1989). FasL on the other hand, is a member of the TNF family, and a type II 
membrane protein (Suda et al., 1993; Nagata, 1997). The binding of Fas ligand to its receptor 
Fas on the target cell results in the activation of the caspase cascade.  
 
This cascade proteolytically cleaves important proteins and cellular DNA and thereby 
induces cell death (Nagata, 1997; Enari et al., 1998). Yamaoka and colleagues (2000) 
confirmed this in a study and demonstrated that resting cardiomyocytes treated with DOX 
were sensitized to Fas/FasL induced apoptosis. Recently Ren et al. (2012) found that the 
overexpression of angiopoietin-1 (ang-1), an important growth factor protein, protected 
cardiomyocytes against DOX-induced apoptosis by attenuating both intrinsic and extrinsic 
apoptosis, which suggests that both apoptotic pathways are important in mediating DOX 
toxicity. Although there is no indication in the literature as to which of the two pathways is 
dominant or whether both pathways are stimulated concurrently, it is evident that DOX can 
induce apoptotic cell death.  
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Figure 1.6: Intrinsic and extrinsic apoptotic pathways activated in the myocardium 
following Doxorubicin treatment. DOX induces intrinsic apoptosis (indicated with the black 
arrows) via the mitochondria by promoting mPTP opening and cytochrome c leakage. DOX 
mediates extrinsic apoptosis (indicated with the orange arrows) via activation of the 
Fas/FasL system. Abbreviations - Bax: apoptotic regulator, Bcl: B-cell lymphoma, Bcl-X1: Bcl 
associated X protein, DOX: Doxorubicin, FADD: Fas associated protein with death domain, 
FasL: Fas Ligand, mPTP: mitochondrial permeability transition pore.   
 
1.4.4 Intracellular Calcium Dysregulation 
 
Research indicates that treatment with DOX induces an increase in intracellular calcium 
levels, which identifies another mechanism whereby DOX-induced cardiotoxicity may arise. 
Supporting this hypothesis, a study compiled in 1974 by Olson et al. described an 
incremental increase in calcium accumulation in both the ventricular myocardium and the 
mitochondria of rabbit hearts following DOX infusion. Other studies have shown that DOX 
alters the transitional sacrolemmal calcium influx, otherwise known as activator calcium 
(Rossini et al., 1986), due to DOX’s effects on the Na+/K+ -ATPase and Na+/Ca2+exchanger 
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pumps (Gosálves et al., 1979; Caroni et al., 1981; Boucek, 1997b). Under normal conditions, 
activator calcium forms an integral part of the electrical excitation within the sarcoplasmic 
reticulum (Rossini et al., 1986) and is regulated by the activity of these ion channels and 
exchanger pumps (Carafoli, 1985; De Beer et al., 2001). Activator calcium initiates the 
interaction between actin and myosin, ultimately determining the force of cardiac contraction 
(Rossini et al., 1986).  Thus continuous disruption in the calcium flux can lead to contractile 
dysfunctions, and thereby contribute to the development of CHF.  
 
The augmentation of intracellular calcium levels could be the cause or consequence of 
oxidative stress.  DOX-induced ROS can directly disrupt sarcoplasmic reticulum function, 
leading to alterations in calcium homeostasis (Octavia et al., 2012). Studies by numerous 
authors show that oxidative stress, in particular hydrogen peroxide (Arai et al., 2000), inhibits 
the activity of the sarcoplasmic Ca2+ -ATPase pump, and causes impaired calcium handling 
(Boucek et al., 1987; Ondrias et al., 1990; Dodd et al., 1993; De Beer et al., 2001), in 
addition to indirectly activating the ryanodine calcium-release (RyR) channels (Holmberg 
and Williams, 1990; Boucek, 1999). Under normal conditions RyR channels represent the 
primary pathway responsible for calcium release during the excitation-contraction coupling 
process. These unique channels are found on calcium storage/release organelles, like the 
sarcoplasmic/endoplasmic reticulum. Regular sacrolemmal/endoplasmic calcium influx 
activates the RyR channels, but under DOX-induced calcium distress, these channels remain 
open (Boucek, 1999; Fill and Copello, 2002).  It is possible that DOX binds to one of the 
many sites on the channel, and in this manner directly influences RyR channel opening 
(Saeki et al., 2002). Taking all this into consideration, together with other reviews (Boucek, 
1999; Octavia et al., 2012), dysregulation in sarcolemmal calcium loading and release is a 
major factor in the pathogenesis of DOX-induced chronic-cardiotoxicity. 
 
To further emphasize the damaging role of DOX-induced oxidative stress, Kalivendi et al. 
(2005) illustrated that when intracellular calcium accumulation occurs, NFAT (nuclear factor 
of activated T-cells) is activated and Fas/FasL apoptosis is stimulated. Calineurin, a calcium-
dependent phosphatase, dephosphorylates and activates NFAT in response to a sustained 
elevation of intracellular calcium (Baksh and Burakoff, 2000; Hogan et al., 2003). 
Dephosphorylated NFAT in the cardiac cell then translocates to the nucleus where it initiates 
hypertrophic gene expression and cardiac hypertrophy (Schulz et al., 2004) as well as the 
activation FasL and extrinsic apoptosis (Latinis et al., 1997) (Figure 1.7). Thus, the 
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calcineurin/NFAT pathway under pathological conditions can induce both cardiac 
hypertrophy and cell death, contributing to DOX-induced contractile dysfunction and 
toxicity. Additionally DOX-induced oxidative stress can also result in calcium ‘leakage’ from 
the sarcoplasmic reticulum (Solem et al., 1996). Prolonged conditions of increased 
intracellular calcium can lead to the activation of the calcium-dependent proteolytic enzyme, 
Calpain (Campos et al., 2011; Octavia et al., 2012). Calpain activation can induce the 
cleavage of caspase 12 (usually seen under conditions of endoplasmic/sarcoplasmic reticulum 
stress) and activation of apoptotic pathways (Figure 1.7) (Nakagawa et al., 2000). In support 
of this theory, Jang et al. (2004) demonstrated that DOX-induced calpain activation is one of 
the mechanisms involved in progression towards cardiomyopathy and heart failure, in both 
male and female rats. Additionally, it is known that DOX-induced cardiotoxicity is associated 
with myofibrillar deterioration (Sawyer et al., 2002) and it is thought that calpain activation 
mediates this effect. Considering that myofibrillar proteins (e.g. titin) are essential 
components involved in maintaining myocardial contraction and cardiac integrity, 
uncontrolled degradation could result in detrimental consequences for the myocardium 
(Danialou et al., 2001; Lapidos et al., 2004; Tidball and Wehling-Henricks, 2007).  
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Figure 1.7: Intracellular Calcium Dysregulation and cell signaling induced by 
Doxorubicin treatment. DOX increases intracellular calcium levels. Calineurin 
dephosphorylates and activates NFAT in response to a sustained elevation of intracellular 
calcium and results in cardiac hypertrophy and activation of FasL (pathway indicated in 
blue). An increase in FasL expression activates Fas/FasL apoptosis (pathway indicated in 
orange). Elevated intracellular calcium results in calpain activation, which leads to contractile 
dysfunction and apoptosis (pathway indicated in purple).  Abbreviations - DOX: Doxorubicin, 
FADD: Fas associated protein with death domain, FasL: Fas Ligand, NFAT: nuclear factor of 
activated T-lymphocytes, P: Phosphate.  
 
1.5 Endoplasmic Reticulum Stress  
 
The endoplasmic reticulum (ER) forms part of an extension of the nuclear envelope within a 
mammalian cell, and is the major organelle responsible for the synthesis, post-translational 
modification and folding of proteins (Xu et al., 2005; Malhi and Kaufman, 2011; Grim, 
2012). The ER is involved in various cellular processes, such as the maintenance of calcium 
homeostasis and lipid biosynthesis (Ron and Walter, 2007; Kaufman, 2002). Under 
conditions of oxidative stress, calcium dysregulation or a decrease in ATP levels (adenosine 
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triphosphate), the ER becomes overwhelmed and cannot function efficiently. This leads to 
the accumulation of misfolded proteins within the ER lumen and when this occurs, a 
phenomenon termed ER stress is stimulated (Stutzmann and Mattson, 2011). Special 
receptors or transmembrane sensors detect the build up of these proteins within the lumen 
and initiate the unfolded protein response (UPR) in order to try and overcome the resulting 
ER stress (Minamino et al., 2010; Wang et al., 2014). However, in order to elucidate the role 
the ER plays in the pathophysiological progression of DOX-induced cardiotoxicity, a deeper 
understanding of ER stress and the UPR is required.  
1.5.1 Understanding the Unfolded Protein Response 
 
The UPR is stimulated when ER transmembrane sensors detect signals of ER stress. These 
sensors include protein kinase RNA-like endoplasmic reticulum kinase (PERK), inositol-
requiring enzymes 1α (IRE1α) and activating transcription factor 6 (ATF6) (Shamu and 
Walter, 1996; Haze et al., 1999; Harding et al., 2000).  Under normal homeostatic conditions 
PERK, IRE1α and ATF6 form complexes with the ER binding immunoglobulin protein 
(BiP/GRP78), which inhibits their activity (Kozutsumi et al., 1988; Bertolotti et al., 2000; 
Hetz, 2012). When misfolded or damaged proteins accumulate in the ER lumen, they bind to 
BiP competitively, causing its dissociation from the BiP transmembrane receptors and 
thereby inducing their activation (Figure 1.8) (Bertolotti et al., 2000; Hampton, 2000; Hetz, 
2012).  
 
PERK is a serine-threonine kinase. These particular types of kinases are generally responsible 
for regulating cell proliferation, cell death signaling and cellular differentiation (Avivar-
Valderas et al., 2011) Following the onset of ER stress and subsequent activation, PERK 
phosphorylates and inactivates eIF2α (eukaryotic translation initiation factor 2α). The now 
inactive eIF2α inhibits mRNA translation resulting in a reduction protein synthesis and ER 
protein load. IRE1α, also a serine-threonine kinase, has been termed the most fundamental 
ER stress sensor in the cell (Minamino et al., 2010). Upon its activation, IRE1α stimulates 
specific endoribonuclease cleavage of mRNA encoding for the protein XBP1 (transcriptional 
factor X-box binding protein 1). XBP1 activates an adaptive transcriptional response focused 
on inducing normal ER homeostasis. Interestingly IRE1α appears to stimulate c -dependent 
signaling pathways, as described by Ogata et al. (2006), and later by Green and colleagues 
(2011). This activation regulates autophagy, and thus identified a potential cross-link or 
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pairing between the UPR and autophagy, which was unknown before. It is important to note 
that activation of c-JUN has also been implicated with an increase in tumor invasiveness 
implying that the activation of IRE1α could have a potentially negative impact in the cell, 
rather than just trying to alleviate ER stress (Ogata et al., 2006; Green et al., 2011; Yang et 
al., 2014). 
 
ER stress also induces the release of BiP from ATF6, thereby unmasking ATF6’s Golgi-
apparatus signal (Minamino et al., 2010). This permits ATF6 translocation from the nucleus 
to the Golgi- apparatus, where is it proteolytically cleaved. Cleaved ATF6 acts as a 
transcription factor, and induces the transcription of XPB1 and ERAD (Endoplasmic-
reticulum-associated protein degradation proteins (Yoshida et al., 2000; Minamino et al., 
2010; Wang et al., 2014). Upregulation of ERAD proteins directly increases activity through 
the ERAD pathway, which mediates the translocation of misfolded proteins to the 26S 
proteasome, a process known as retrotranslation (Kaufman, 2002; Ron and Walter, 2007). 
Therefore based on the above, the UPR does not work alone in the process of alleviating ER 
stress. It elicits the help of the cell’s major degradation pathways, autophagy and the 
ubiquitin-proteasome pathway (UPP) in an effort to try and bring the cell back to 
homeostasis. However, should ER stress not be resolved, apoptosis can be induced 
(Benbrook and Long, 2012).  
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Figure 1.8: The Unfolded Protein Response. Misfolded or damaged proteins accumulate, 
which bind to BiP, which releases BiP inhibitory effects on the ER’s transmembrane sensors 
PERK, ATF6 and IRE1. Through a serious of downstream activities, the UPR is initiated in 
order to try and decrease the ER protein load. Abbreviations - ATF6: activating transcription 
factor 6, BiP: ER binding immunoglobulin protein, ER: endoplasmic reticulum, ERAD: 
Endoplasmic reticulum associated protein degradation, IRE1: inositol-requiring enzymes 1 
alpha, PERK: endoplasmic reticulum kinase, PTN: protein, UPP: the ubiquitin proteasome 
pathway, XBP1: transcriptional factor X-box binding protein 1.  
1.5.2 Calcium Dysregulation During ER Stress 
 
It is only natural that there be a high calcium concentration in the lumen. Since the ER is 
responsible for the storage and maintenance of calcium homeostasis, elevated calcium 
concentrations and a low oxidative environment within the lumen creates the optimal 
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environment that the ER requires for synthesizing and folding proteins into their proper 
conformation (Lam and Galione, 2013). When ER stress occurs, calcium from the ER is 
released causing an increase in free intracellular calcium (Doroudgar et al., 2013). 
Considering that the ER is in close proximity to the mitochondria, the mitochondrial will 
likely take up the calcium via the calcium uniporter until a certain threshold is reached 
(Trenker et al., 2007; Brookes et al., 2008). Once this threshold is reached, the mitochondrial 
membrane potential collapses, the mPTP opens, cytochrome c leaks and apoptosis is induced 
(Williams et al., 2013). DOX appears to have an affinity for the ER, as demonstrated by Sishi 
et al. (2013b), potentially demonstrating a mechanism whereby DOX can directly initiate ER 
stress. Considering this study made use of an acute cellular model of DOX-induced 
cardiotoxicity, it remains to be elucidated whether this phenomenon is also present in the 
chronic scenario of this condition. Not only is the ER sensitive to changes in calcium 
homeostasis; it is just as sensitive to condition of elevated oxidative stress. It is therefore not 
surprising that ER stress is detected in conditions such a cardiotoxicity and other 
cardiovascular diseases caused by proteasome inhibition or ERAD overload (Minamino and 
Kitakaze, 2010).  
 
Many studies have shown coordinated calcium signaling between the mitochondria and ER 
(Chami et al., 2008; Pizzo and Pozzan, 2007), and in order to stimulate oxidative 
phosphorylation, calcium is required (Brookes et al., 2004; Dedkova and Blatter, 2013; 
Duchen, 2000). Since the ER is the major source of calcium within the cell, and the 
mitochondrial rely on calcium for various functions, proper communication between these 
two organelles is essential (Brookes et al., 2004). In the presence of DOX however this is not 
the case, as both organelles become dysfunctional and induce cell death mechanisms 
(Paradies et al., 2009; Solem et al., 1994).   
 
1.6 DOX-induced Cardiotoxicity and the Mitochondria 
 
Research indicates that the mitochondria are the most extensively and progressively damaged 
organelles during DOX-induced cardiotoxicity (Octavia et al., 2012). DOX directly affects 
mitochondrial respiration, induces oxidative stress and disrupts mitochondrial membrane 
potential, by either binding directly to the mitochondria or by other indirect mechanisms 
(Childs et al., 2002; Tokarska-Schlattner et al., 2007). Literature has also demonstrated the 
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involvement of the mitochondria in the activation of the cell death pathways, apoptosis and 
necrosis (Berthiaume and Wallace, 2007; Parra et al., 2008). Considering that clinical 
therapeutic interventions involving the use of antioxidants has been widely unsuccessful in 
treating the chronic side effects of DOX, novel investigations into new adjuvant therapies 
targeting mitochondria are focused on preventing their damage by DOX.  
 
One of the main reasons why the mitochondria may be so extensively damaged and prone to 
abnormal morphological features in the presence of DOX is due to DOX’s ability to form 
complexes with cardiolipin present in inner mitochondrial membrane (Schlame et al., 2000; 
Schlame and Hostetler, 1992). Once bound, DOX can be retained within the mitochondria 
and interrupt important cardiolipin-protein complexes (Goormaghtigh et al., 1990; Schlame 
et al., 2000). Cardiolipin is a phospholipid bio-synthesized in the mitochondrial matrix 
(Daum, 1985; Schlame et al., 2000; Schlame and Hostetler, 1992). It plays an integral role in 
mitochondrial oxidative phosphorylation and in maintaining the structural integrity of the 
mitochondrial membranes (Zhong et al., 2014), thus any alterations in its activity or 
compositions can induce mitochondrial dysfunction (Petrosillo et al., 2003; Lesnefsky 
Hoppel, 2008; Pope et al., 2008).  One of the critical functions of cardiolipin is that proteins 
of the electron-transport chain require cardiolipin binding to function effectively 
(Goormaghtigh et al., 1990). Once this balance is disturbed by the formation of DOX-
cardiolipin complexes, superoxide is instead produced (Schlame et al., 2000). This prevents 
normal mitochondria from performing critical cellular functions such as ATP production. 
Bearing all of the above in mind, an important aspect that needs serious consideration is 
mitochondrial morphology. Since mitochondrial morphology governs many biological 
functions including cell survival and cell death, it is important to investigate the effects of 
DOX on mitochondrial dynamics. 
 
1.6.1 Mitochondrial Dynamics 
 
The mitochondrion has long been considered as the “energy powerhouse” of the cell, which 
works consistently, and tirelessly to provide the energy, in the form of ATP, that is required 
for biological functioning (McBride et al., 2006). Recent studies have however demonstrated 
that the maintenance of the mitochondria’s bioenergetic demand relies heavily on the 
morphological plasticity of the organelle (Galloway et al., 2012b). The steady state of the 
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mitochondrial morphology is regulated by the two dynamic events; mitochondrial fission and 
mitochondrial fusion.  
 
Mitochondrial fusion is a mechanism whereby neighboring mitochondria fuse together 
creating elongated, interconnected mitochondrial tubules. Conversely, mitochondrial fission 
is involved in the fragmentation of the tubular interconnected mitochondria into smaller, 
discontinuous ones (Dimmer and Scorrano, 2006; Ong et al., 2010). Mitochondrial fusion 
involves fusion of both the outer and inner mitochondrial membranes in order to form a 
functional mitochondrion (Hammerling and Gustafsson, 2014). Fusion of the outer 
mitochondrial membranes (OMM) is regulated by the two mitochondrial fusion proteins 
mitofusin 1 (Mfn1) and mitofusin 2 (Mfn2), whereas inner mitochondrial membrane (IMM) 
fusion is dependent on the optic atrophy protein 1 (Opa1) (Chen et al., 2013; Chen et al., 
2011b) (Figure 1.9a). Two proteins that mediate Mitochondrial fission are dynamin-related 
protein 1 (Drp1/DLP1) and mitochondrial fission protein 1 (hFis1/TTC11) (Mozdy et al., 
2000; Yoon et al., 2003). Cytosolic Drp1 translocates to the OMM, through its interaction 
with the hFis1, and forms a ring around the mitochondrion, pinching it into two daughter 
mitochondria (Lee et al., 2007; Smirnova et al., 2001) (Figure 1.9b). Disruption of fine 
balance of mitochondrial dynamics has been linked to the cell’s regulation of apoptosis, as 
well as many cardiac diseases, including cardiac hypertrophy, dilated cardiomyopathy and 
heart failure (Dorn, 2013; Zungu et al., 2011). 
 
Mitochondrial fission has previously been shown to be induced by oxidative stress, a 
mechanism proposed by Frank et al. (2001). In conditions where oxidative stress levels are 
high, Drp1 translocates from the cytosol into the mitochondria, where mitochondrial division 
is initiated. Drp1 hydrolyses GTP (Guanosine-5'-triphosphate), which in turn dysregulates the 
fine balance between mitochondrial fission and fusion, tipping the scale towards fission 
(Karbowski and Youle, 2003; Chen and Chan, 2009; Ong and Hausenloy, 2010). This fission, 
under pathological conditions, can stimulate the release of cytochrome C from the 
mitochondria, activate caspases and ultimately apoptosis (Green and Reed, 1998; Frank et al., 
2001). In the context of DOX cardiotoxicity, it is highly possible that the ER stress and 
calcium dysregulation that occurs triggers mitochondrial fission and contributes to the 
pathological consequences of DOX toxicity (Brookes et al., 2004; Iglewski et al., 2010).  
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Figure 1.9: Mitochondrial morphology regulated by mitochondrial fusion and fission 
events. (A) Mitochondrial Fusion; OMM fusion is mediated by the mitofusin proteins Mfn1 
and Mfn2, whereas IMM is controlled by Opa1. (B) Mitochondrial Fission; Fission of the 
mitochondria is regulated by both Drp1 and hFis. Abbreviations - Drp1: Dynamin-related 
protein 1, hFis1; mitochondrial fission protein 1, IMM: inner mitochondrial membrane, Mfn: 
mitofusin protein, OMM: outer mitochondrial membrane, Opa1: optic atrophy protein 1. 
Powers et al., 2012.  
 
In support of the above, studies by Parra et al. (2008) and Ong et al. (2010) identified that 
inhibition of mitochondrial fission with mitochondrial division inhibitor 1 (mdivi-1) 
protected the heart against DOX-induced cardiac injury. This suggests that inhibition of 
mitochondrial fission could be cardioprotective. Mdivi-1 is described to provide 
cardioprotection through the elimination of left ventricular dysfunction and the promotion of 
angiogenesis (Givvimani et al., 2012). Co-administration of mdivi-1 with DOX treatment 
significantly reduced DOX-associated cardiac dysfunction in vitro, while mdivi-1 had no 
effects on DOX’s antineoplastic properties (Gharanei et al., 2013). Interestingly, low doses of 
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cyclosporin (CsA), a known mPTP inhibitor, prevented mitochondrial fragmentation and 
consequently lead to a significant attenuation of DOX-induced cardiac dysfunction (Marechal 
et al., 2011). Disruption of mitochondrial dynamics, through the upregulation of 
mitochondrial fission in the heart may play a critical role in mediating DOX cardiotoxicity 
(Marechal et al., 2011; Galloway et al., 2012a). Mitochondrial dynamics are however not 
only responsible for maintaining mitochondrial integrity and function, but also plays an 
important role in regulating mitochondrial quality control (QC) (Hammerling and Gustafsson, 
2014). Therefore DOX may have detrimental effects not only on fission and fusion events, 
but could also disrupt mechanisms involved in mitochondrial QC.   
 
1.6.2 Mitochondrial Quality Control  
 
Since the mitochondria proteins are prone to cumulative oxidative damage, especially in the 
presence of DOX, cells have developed QC mechanisms to safeguard against mitochondrial 
dysfunction (Lionaki and Travernarakis, 2013). Since the cardiomyocytes require a 
continuous supply of ATP, they have high mitochondria density compared to other tissues 
(Iglewski et al., 2010). Therefore it is essential that mitochondrial QC systems are in place in 
order to maintain both cardiac and mitochondrial function as well as tissue homeostasis (Seo 
et al., 2010; Youle and van der Bliek, 2012). Mitochondrial QC is regulated by the balance 
between the synthesis of new mitochondria and degradation of the dysfunctional ones (Ikeda 
et al., 2014; Lionaki and Travernarakis, 2013). Coordination between these two processes 
maintains both the quantity and quality of the mitochondria (Palikaras and Tavernarakis, 
2014)  
  
Mitochondrial biogenesis is the process whereby pre-existing mitochondria grow and divide, 
creating new healthy mitochondria (François and Gerald, 2010) and is controlled by the 
synthesis of mitochondrial proteins encoded by the nuclear genome (Baker et al., 2007). The 
coordinated transcription of both mitochondrial and nuclear genomes is directed by 
peroxisome proliferator-activated receptor-ϒ-coactivator-1α (PGC-1α), the main regulator of 
mitochondrial biogenesis (Puigserver et al., 1998; Ventura-Clapier et al., 2008). Various in 
vivo studies have demonstrated that disruption of mitochondrial biogenesis, via decreased 
PGC-1α expression, contributed to the development of heart failure, and subsequent reversal 
of which resulted in cardioprotection (Faerber et al., 2011; Garnier et al., 2003; Sebastiani et 
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al., 2007; Witt et al., 2008). Bouitbir et al. (2012) revealed that DOX’s cardiotoxic effects 
was inhibited via the pharmacological induction of mitochondrial biogenesis. These results 
not only suggest that DOX may have inhibitory effects on mitochondrial biogenetics, but also 
potentially implicates PGC-1α as a therapeutic target in DOX-induced cardiotoxicity. 
However, considering that major controversy about the role PGC-1α in human failing heart 
still exists, it is not surprising that it’s role in mediating DOX cardiotoxicity remains to be 
fully elucidated (Bayeva et al., 2013). 
 
The degradation of dysfunctional and redundant mitochondria is initiated by an increase in 
oxidative stress and mitochondrial fission (Papanicolaou et al., 2012; Youle and Narendra, 
2011). An important proteolytic QC system, which promotes the degradation of the damaged, 
misfolded or oxidized OMM proteins, is the ubiquitin-proteasome pathway (UPP) (Campello 
et al., 2014; Heo and Rutter, 2011). Autophagy, another QC pathway, is the main mechanism 
utilized by the cell to ensure the degradation of both the dysfunctional organelles and proteins 
(Levine and Yuan, 2005). The accumulation of fragmented mitochondria, the opening of the 
mPTP and the loss of mitochondria membrane potential results in severely damaged 
mitochondria, which promotes a selective form mitochondrial autophagy, termed mitophagy 
(Tolkovsky, 2009; Twig et al., 2008). Mitophagy specifically targets the dysfunctional 
mitochondria for lysosomal degradation in an attempt to restore homeostasis (Campello et 
al., 2014).  
The degradation of the mitochondria and its proteins has been termed mitochondrial 
proteaostasis, and each proteolytic pathway involved in this process will be discussed in 
detail in the following section (Campello et al., 2014).  
1.7 The Proteolytic Pathways 
1.7.1 The Ubiquitin-Proteasome Pathway 
 
The UPP is one of the major proteolytic pathways responsible for selective degradation of 
short-lived proteins (Marques et al., 2009). It forms a critical component of the cell cycle and 
inflammatory response, but also regulates mitochondrial quality control (Wilkinson, 1999; 
Neutzner et al., 2012). Targeted proteins are tagged with the small protein, ubiquitin (Ub) via 
a cascade of enzymatic reactions and identified for degradation by 26S proteasome (Marques 
et al., 2009; Korolchuk et al., 2010).  Three types of enzymes are involved in this process; an 
Ub-activating enzyme (E1) activates free Ub in an ATP dependent manner and carries it to 
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the second enzyme, Ub-conjugating enzyme (E2). E2 is a carrier protein and presents the 
activated Ub to the enzyme, Ub-protein ligase (E3). E3 ligase binds to a specific lysine 
residue of the targeted protein, and covalently attaches Ub to it. This process, termed the 
‘tagging hypothesis’ (Hasselgren and Fischer, 1997), is repeated until a polyubiquitin chain 
has been formed and tagged to the protein (Figure 1.10). Considering that there are different 
types of Ub configurations, in order for these “tagged” proteins to be degraded specifically by 
the 26S proteasome, the polyUb chain has to be attached to the lysine-48 residue (Adams, 
2003; Marques et al., 2009). So far only one E1 enzyme (UBE1 - human ubiquitin-activating 
enzyme) has been identified, ± twenty E2 enzymes and hundred’s of E3 ligases have been 
identified (Adams, 2003). This noticeable hierarchy of available E1, E2 and E3 enzymes 
ensures that the UPP remains highly regulated and controlled in order to prevent excessive 
protein degradation and cell death (Adams, 2003). The variety of E3 ligases availability 
however may also indicate that the UPP is a highly inducible process.  
 
Recently several mitochondrial E3 ubiquitin ligases have been identified (Kotiadis et al., 
2014; Livnat-Levanon and Glickman, 2011). Mitochondrial ubiquitin ligase 
(MARCH5/MITOL) is localized on the cytosolic side of the OMM and is essential for the 
regulation of mitochondrial fission (Karbowski et al., 2007; Kotiadis et al., 2014). MARCH5 
ubiqitinates hFis1, Mfn1 and Mfn2, three of the essential proteins involved in regulating 
mitochondrial dynamics, and tags them for proteasomal degradation (Karbowski et al., 2007; 
Park et al., 2010; Nakamura et al., 2006). Additionally, Karbowski et al. (2007) 
demonstrated that MARCH5 promoted the translocation of cytosolic Drp1 to the OMM, 
mediating Drp1-dependent mitochondrial fission. Another specific mitochondrial E3 ligase, 
named mitochondrial ubiquitin ligase activated of NF- κB (MULAN/MAPL), was also found 
to facilitate mitochondrial fission via the ubiquitination and degradation of Mfn2 (Livnat-
Levanon and Glickman, 2011; Lokireddy et al., 2012). Other cytosolic E3 ligases, such as 
Parkin and myelin leukemia cell differentiation protein 1(Mcl-1)- ubiquitin ligase E3 
(MULE/ARF-BP1) also mediate the degradation of the Mfn proteins, confirming the role of 
the UPP in regulating mitochondrial dynamics (Geisler et al., 2010; Wang et al., 2011). 
However, both Parkin and MULE are known to induce mitophagy, suggesting the UPP is 
also an important regulator of mitochondrial quality control (Hammerling and Gustafsson, 
2014; Wang et al., 2011). Acute DOX treatment is known to induce activation of the UPP 
and upregulation of specific E3 ligase expression in the heart, and is thought to be a potential 
mechanism whereby UPP dysfunction contributes to DOX cardiotoxicity (da Silva et al., 
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2012; Ranek and Wang, 2009; Sishi et al., 2013b). However, DOX’s effect in the chronic 
setting, specifically on mitochondrial E3 ligase expression has not been reported in the 
literature. 
 
 
Figure 1.10: The Ubiquitin-proteasome pathway.  Ubiquitin is activated by ATP and E1 
and carried by E2 enzyme to the E3 ligase. The E3 ligase tags ubiquitin to the targeted 
protein. This process is repeated until a polyUb chain is attached to the targeted protein. 
This allows the protein to be recognized by the 26S proteasome and subsequently 
degraded. Following degradation the Ub proteins are free and can be recycled and reused to 
degrade other short-lived, redundant proteins. Abbreviations - E1: ubiquitin-activating 
enzyme, E2: ubiquitin-conjugating enzyme, E3: ubiquitin-protein ligase, polyUb: polyubiquitin 
Ub: ubiquitin 
 
1.7.2 The 26S Proteasome and its Role in DOX cardiotoxicity 
 
The main component of the UPP responsible for the degradation of poly-ubiquitinated 
proteins into small peptide fragments is the 26S proteasome. It is a multi-protein complex, 
composed of a 20S core and two 19S regulatory caps  (Figure 1.11) (Adams, 2003). The 19S 
regulatory caps recognize the tagged poly-ubiquitinated proteins. Recognition and cleaves the 
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poly-ubiquitin chain from the protein upon binding. Once bound the protein begins to unfold 
and the substrate pass through the hollow core of the 19S cap to the 20S catalytic core 
(Adams, 2003; Kisselev et al., 1999). 
 
The 20S catalytic core comprises of four rings: two outer α-rings and two inner β-rings 
(Adams, 2003; Kisselev et al., 1999).  Each α-ring is composed of seven α-subunits that form 
a ‘sandwich’ around the two β-rings.  The amino-terminal tails of the α-rings form a gate, 
which monitors the entry of the unfolded proteins into the catalytic complex of the β-rings. If 
a protein has not been unfolded correctly, the α-ring is able to ‘close the gate’ and restrict 
protein entry into the core thus inhibiting proteolysis. Similarly, the two inner β-rings also 
contain seven subunits each, however they differ from the α-rings, as they contain three 
specific proteolytic or ‘active’ sites that degrade proteins according to their residues (Figure 
1.11). These catalytic sites include the caspase-like (post-glutamyl peptide hydrolase-
like/PGPH), trypsin-like and chymotrypsin-like, and are named in accordance with enzymes 
that possess the same proteolytic activity (Adams, 2003).  
 
It was in 1996 when Figueired-Pereira and colleagues illustrated that the ANT aclacinomycin 
A, inhibited proteasome activity. Since then Kiyomiya et al. (2001, 2002) eloquently 
demonstrated that DOX has a high affinity with the proteasome and that DOX uses the 
proteasome to gain entry into the nucleus. In doing so, proteasome activity is compromised, 
particularly the chymotrypsin-like site (Kiyomiya et al., 2002). Therefore, if the proteasome 
is being “hijacked” into performing functions, other than protein degradation, it is plausible 
to speculate that proteins meant to be degraded by this pathway are not, and either protein 
aggregations occurs, or these proteins are being degraded by another proteolytic pathways, 
such as autophagy (Dirks-Naylor, 2013).  
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Figure 1.11: The 26S Proteasome. The proteasome is comprised of two 19S caps and a 
20S core particle. The 20S core contains 4 rings: two inner alpha-rings and two out beta-
rings. The alpha-rings house the catalytic site of the proteasome, responsible for degrading 
various types of proteins.   
 
1.7.3 Autophagy  
 
Autophagy is a process that degrades expired or faulty components of a cell. This form of 
degradation is mediated by the formation of an autophagosome, which, upon fusion with the 
lysosome, breaks down long-lived proteins and organelles (Loos et al., 2011). Autophagic 
flux is constant within the cell as it is a process essential for clearing cellular damage as well 
as maintenance of homeostasis. However, autophagic flux is dependent on cell activity and 
can be upregulated in situations of metabolic stress (Loos et al., 2011). For example, under 
conditions of starvation autophagy is utilized to breakdown cellular components and 
organelles in order to provide nutrients for the cell. Macro-autophagy (Figure 1.12), hereafter 
referred to as autophagy, is the major inducible pathway within the cytoplasm of all cells and 
will be the main focus in further discussion (Klionsky and Emr, 2000).   
 
The process of autophagy involves various stages. Firstly autophagy is initiated by the 
formation of the phagophore, which requires the presence of two protein complexes; the 
U1k1 (Unc-51 like kinase)-Atg13-FIP200 (RB1CC1; focal adhesion kinase family interacting 
protein) complex and PI3 kinase (phosphatidylinositol 3)-Beclin 1-Atg14 complex (Class III 
PI3 complex).  Next the formation of the Atg16L (autophagy-related protein 16-L) complex 
mediates phagophore elongation and sequestration of redundant cellular components. Once 
the cellular components have been selected, LC3-I is lipidated into LC3-II. LC3 lipidatation 
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is followed by membrane fusion and formation of the autophagosome (Glick et al 2010). 
Lastly the newly formed autophagosome fuses with the lysosome, which releases acidic 
hydrolases into the autophagosome and degrades its components (Glick et al., 2010; Dirks-
Naylor, 2013) (Figure 1.12).    
 
Autophagy has duel functions within the cells. Under normal conditions it is crucial in 
promoting normal cell function and cell survival, but in pathophysiological conditions 
autophagy can initially be upregulated to protect against cellular stressors, as well as 
contribute to cellular demise (Dirks-Naylor, 2013).  It has recently been proposed that the 
dysregulation of autophagic activity may be an underlying mechanism contributing to the 
development of DOX-induced cardiotoxicity (Lu et al., 2009; Kawaguchi et al., 2012).  
 
Figure 1.12: The Stages of Autophagy. The initiation of autophagy and formation of the 
phagomore is regulated by two important complexes; the UIk1-Atg13-FIP200 complex and the 
PI3 kinase complex. Phagophore elongation and sequestration is regulated by the Atg16L 
complex and LC3-II lipidation. Atg7 and Atg10 are involved in the binding of Atg5 to Atg12, 
forming the Atg16L complex. Atg4, Atg 3 and Atg7 catalyze the two-step LC3-II lipidiation 
process. The autophagosome fuses with the lysosome, forming an autolysosome and 
redundant cytosolic material is degraded. DOX has been shown to have various regulatory (+) 
and inhibitory (-) effects on the autophagic pathway. Abbreviations - Atg: Autophagy-related 
proteins, Bcl-2: B-cell lymphoma 2, FIP200: 200 kDa focal adhesion kinase family protein, LC3: 
microtubule-associated protein light chain 3, UIk1: Unc-51 like kinase. Image adapted from 
Dirks-Naylor, 2013.   
Stellenbosch University  https://scholar.sun.ac.za
 33
1.7.4 Mitophagy 
 
It is often thought that autophagy is a non-selective process responsible for the bulk 
degradation of cytosolic proteins and organelles (Svenning and Johansen, 2013). However, 
over the last decade it has become increasingly clear that specific autophagic substrates, such 
as the ER or the mitochondria, are selectively targeted for destruction rather than being 
randomly taken up with redundant cytoplasmic constituents (Korolchuk et al., 2010; 
Svenning and Johansen, 2013). Ubiquitination, similar to its role in the UPP, acts as a signal 
for triggering selective autophagy, suggesting that the E3 ligases and ubiquitin coordinate 
proteolysis via both the UPP and autophagy (Hammerling and Gustafsson, 2014; Korolchuk 
et al., 2010; Kraft et al., 2010). 
 
In 2005 Lemasters officially proposed the term Mitophagy as a selective form mitochondrial 
degradation by autophagy, which is essential for the maintenance of mitochondrial function 
and survival. Although many studies have reported the selective degradation of the ER 
(Szegezdi et al., 2009), peroxisomes (Dunn et al., 2005) and ribosomes (Beau et al., 2008) by 
autophagy, mitophagy appears to be the most important (Twig and Shirihai, 2011).  Since the 
mitochondria are the main source of ROS and the build up of dysfunctional mitochondria can 
result in ROS overproduction and apoptotic signaling, mitophagy is an essential process 
required to maintain cellular homeostasis (Crompton, 1999; Grivennikova et al., 2010). 
Mitochondrial fission and loss of mitochondrial membrane potential regulate mitophagy 
through the mitochondrial PTEN-induced kinase 1 (PINK1)/Parkin pathway.  
 
PINK1 is activated on OMM in response to mitochondrial damage, and recruits the E3 
ubiquitin ligase, Parkin, resulting in mitochondrial fragmentation. Parkin ubiquitinates the 
mitofusin proteins, Mfn1 and Mfn2, but also associates with the sequestosome 1 
(p62/SQSTM1) (Geisler et al., 2010; Kirkin et al., 2009; Tanaka et al., 2010). P62 is an 
ubiquitin-binding protein that colocalizes with ubiquitinated proteins and interacts with LC3 
(Bjørkøy et al., 2009), promoting the formation of the autophagosome and removal of the 
damaged mitochondria by mitophagy (Lee et al., 2010a; Lee et al., 2010b; Vives-Bauza et 
al., 2010) (Figure 1.13). Taken together, these results suggest that the UPP is not only 
responsible for the regulation of mitochondrial dynamics, but it is also required for Parkin-
mediated mitophagy (Heo and Rutter, 2011).  
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Figure 1.13: The E3 ubiquitin ligase, Parkin mediates mitophagy. Parkin is recruited to 
the dysfunctional mitochondria by PINK1. Once on the OMM, Parkin interacts with p62, 
initiating phagophore formation and mitophagy resulting in the degradation of the 
dysfunctional mitochondria. Image adapted from Hammerling and Gustaffson, 2014.  
Abbreviations - LC3: microtubule-associated protein light chain 3, PINK1: PTEN-induced 
kinase 1, p62: sequestersome 1, ub: ubiquitin.     
 
1.7.5 The Role of Autophagy in DOX Cardiotoxicity 
 
Autophagy is triggered by various pathophysiological stimuli, such as ER stress, ROS 
production, intracellular calcium dysregulation and apoptosis, and as such has been largely 
associated with various cardiomyopathies (Margariti et al., 2013; Muller et al., 2011; Xu et 
al., 2013). Considering these stimuli are known side effects associated with DOX, it has 
recently been suggested that autophagic dysregulation may contribute to DOX-induced 
cardiotoxicity (Lu et al., 2009; Kawaguchi et al., 2012). However the relationship between 
autophagy and DOX treatment has thus far been contradictory (Dirks-Naylor, 2013).  
 
Kawaguchi et al. (2012) demonstrated that treatment with acute DOX inhibited AMPK 
(AMP activated protein kinase), a regulator of cellular metabolism and autophagy (Kim et 
al., 2011), and thereby suppressed autophagic activity. Similarly, Sishi et al. (2013a) found 
that acute DOX treatment induced suppression of autophagy in vivo. However in contrast, 
Kobayashi et al. (2010) demonstrated elevated autophagy in vitro in the presence of DOX. 
Stellenbosch University  https://scholar.sun.ac.za
 35
This is said to occur via the inhibition of GATA4, a transcription factor highly expressed in 
the myocardium, which regulates Bcl-2, an inhibitor of autophagy. Xu and colleagues (2012) 
also found that DOX upregulated autophagy in vitro. Other studies have proposed that DOX-
induced autophagy could be as a result of upregulation of Atg genes (ATG-4, -5, -7 and -12) 
and Bad (Kusama et al., 2009; Smuder et al., 2013). However one comparable finding 
between these studies is that inhibiting DOX’s induced effect on autophagy, whatever it may 
be, via pharmacological manipulation of autophagic activity was found to be beneficial 
against DOX cardiotoxicity (Dirks-Naylor, 2013).  
 
Until recently the effect of DOX on mitophagy had not been described in the literature, 
although DOX has been shown to induce both oxidative stress and mitochondrial 
dysfunction, physiological mediators of mitophagy. Dirks-Naylor and others (2014a) initially 
demonstrated that acute DOX altered mitochondrial dynamics and promoted mitophagy in 
the liver of treated rats. Later Dirks-Naylor et al. (2014b) demonstrated similar results in 
skeletal muscle, although DOX was found to have varying effects on mitophagy amongst the 
different skeletal muscle types. These are the first two studies that have investigated the 
effects of DOX on mitophagic activity. However the effect of DOX on mitophagy in the 
chronic setting and in the heart remains to be investigated.  
 
1.8 Motivation for Current Study 
 
DOX-induced cardiotoxicity is an important public health concern. Acute and chronic DOX 
treatment not only leads to irreversible heart damage but also to the development of heart 
failure, which may only be detected in its advanced stage and thus makes DOX-induced 
cardiotoxicity a life-long burden. This review highlights the numerous detrimental effects of 
DOX in the heart and proposes new mechanisms by which DOX mediates cardiotoxicity in 
vitro. The prevention of DOX-induced cardiotoxicity will allow for both high dose and 
effective treatment of advanced stage malignancies, as well as controlling the onset of CHF.   
 
DOX treatment is known to induce cardiotoxicity via the production of ROS. Since the 
1980’s researchers have made use of free radical scavengers and antioxidants to reduce the 
oxidative stress associated with DOX and therefore also cardiotoxicity (Davies and 
Doroshow, 1986; Minotti et al., 2004; Granger, 2006). Although results appeared promising 
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at first, researchers have been unable to reproduce positive results in the clinical setting. This 
observation suggests that oxidative stress is not the only mechanism involved in the 
pathogenesis DOX-induced cardiotoxicity, but rather a secondary downstream consequence 
of DOX-induced cellular damage (Simůnek et al., 2009). Therefore, it is worth exploring the 
effects of DOX on ROS-producing organelles such as the mitochondria, rather than the 
oxidative stress hypothesis itself. 
 
Oxidative stress, apoptosis, ER stress and calcium dysregulation may contribute to DOX-
induced cardiotoxicity by inducing mitochondrial damage. Under normal conditions, 
mitochondrial dynamics and mitochondrial QC systems help to maintain a healthy 
mitochondrial population and cellular homeostasis in response cellular stresses (Brookes et 
al., 2004; Iglewski et al., 2010). Since the mitochondria are so extensively damaged by DOX, 
it is thought that DOX-induced cardiotoxicity may be facilitated by an imbalance between 
mitochondrial fission and fusion as well as the impairment of mitochondrial QC (Gharanei et 
al., 2013).  
 
Previous studies that investigated the effects of DOX in the liver, skeletal muscle and the 
heart demonstrated an increase in mitochondrial fragmentation (Dirks-Naylor et al., 2014a; 
Gharanei et al., 2013; Givvimani et al., 2012). Although these studies have been performed 
both in vitro (Gharanei et al., 2013; Givvimani et al., 2012; Parra et al., 2008) and in vivo 
(Dirks-Naylor et al., 2014a; Dirks-Naylor et al., 2014b), only acute models of cardiotoxicity 
or non-cardiac models have been used. Considering that the molecular mechanisms involved 
in the pathogenesis of chronic DOX-induced cardiotoxicity are still controversial, it is 
important to investigate the effects of DOX on mitochondrial dynamics in the chronic setting. 
Furthermore, since mitochondrial fission precedes mitophagy, it is likely that DOX treatment 
may indirectly trigger mitophagic activity and thereby disrupt mitochondrial QC.   
 
The mitochondrial E3 ubiquitin ligases, MARCH5 and Parkin, play an important role in 
regulating mitochondrial dynamics and mitophagy through the ubiquitination and subsequent 
proteasomal degradation of the mitochondrial fusion proteins, Mfn1 and Mfn2. This suggests 
that even though mitochondrial fission is required for mitophagy, so is the activation of the 
UPP. DOX is known to up-regulate cardiac E3 ligases, MuRF-1 and MAFbx, however its 
effect on mitochondrial E3 ligase expression remains to be elucidated. It is therefore 
important to establish the role of the UPP during chronic DOX-induced cardiotoxicity. 
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DOX-induced cardiotoxicity is indeed an extremely complex condition that is associated with 
high mortality rates, yet DOX still remains one of the most effective and widely used ANTs 
utilized in the fight against cancer today. It is clear that at this stage the problem does not lie 
with identifying new chemotherapeutic regimes, but rather with identifying ways to diminish 
the chronic side effects associated with DOX. Unveiling the mechanisms involved in DOX-
induced mitochondrial damage will help us better understand the pathogenesis involved in 
the development of cardiotoxicity. This study therefore investigated the effects of cumulative, 
chronic DOX treatment in two in vitro cardiac cell models. In light of this it was 
hypothesized that chronic DOX treatment will disrupt mitochondrial dynamics, favoring 
mitochondrial fission, resulting in increased mitophagy and unopposed cell death. 
Mitochondrial fragmentation and disruption of mitochondrial quality control will therefore 
ultimately contribute to the pathogenesis of DOX-induced cardiotoxicity and heart failure.  
 
1.9 Research Aims 
 
This study therefore aims to investigate the effects of chronic DOX treatment on: 
 
(i) Mitochondrial fission and fusion events  
(ii) E3 ligase expression and the activity of the UPP  
(iii) Mitophagy 
(iv) Mitochondrial biogenesis 
(v) ER stress and calcium homeostasis 
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Chapter 2 - Materials and Methods 
2.1 Cell Culture 
 
H9C2 rat cardiomyoblasts (European Collection of Cell Cultures), which is an in vitro cell 
model commonly used to assess DOX-induced cardiotoxicity (Branco et al., 2012; Kaiserová 
et al., 2007; Sardão et al., 2009), and human-derived Girardi heart cells (kindly donated by 
Tazneem Adams - UCT), another widely used cardiac cell line (Carroll and Yellon, 2000; 
Dutta, 1981; Minners et al., 2001), were cultured for this study. Both cell lines were initially 
seeded and cultured in Dulbecco’s Modified Eagle’s Medium (DMEM) (41965-062, 
Invitrogen Gibco) containing glucose supplemented with 10% heat-inactivated Fetal Bovine 
Serum (FBS) (BC/50615-HI, Biochrom) and 1% Antibiotic-Antimycotic (15240-062, 
Invitrogen Gibco). Cells were incubated at 37 ˚C in a humidified atmosphere of 5% CO2 and 
95% O2, and cell growth was monitored daily using an inverted phase contrast microscope 
(Olympus CKX4SF; Tokyo, Japan). Growth medium was refreshed every 48 hours (hrs.) 
after washing the monolayer of cells with warm, sterile Phosphate Buffered Saline (PBS) 
solution. Once the desired confluency was established (70 – 80%), cells were again rinsed 
with PBS, trypsinized (25050, Invitrogen Gibco), and re-seeded at the desired density for 
each experiment according to Table 1. Refer to Appendix B, protocol 1 – 2 (pg. 167-170) for 
a detailed protocol of the H9C2 and Girardi cell culture.  
 
 
Table 1: Amount of Cells Seeded for Each Experiment 
Experiment Flask/plate Density 
MTT assay 24 well plate ±250 000 
Caspase-Glo Assay 96 well plate ±30 000 
Flow Cytometry 25cm2 flask ±350 000 
Fluorescence Microscopy 8-chamber slide ±20 000 
Superresolution Structured Illumination 
Microscopy  
8-chamber slide ±20 000 
ORAC/TBARS/GSH assay  6 well plate ±250 000 
Proteasome-Glo Assay 96 well plate ±30 000 
Western Blotting 6 well plate ±250 000 
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Abbreviations – MTT:  3-(4,5-dimethythiazol-2-yl)-2, 5-diphenyle terazolium bromide, 
ORAC: Oxygen radical absorbance capacity, TBARS: Thiobarbituric acid reactive 
substances, GSH: Glutathione.   
2.2 Pilot Study  
 
Since this study aimed to establish a chronic, cumulative cell model of DOX-induced 
cardiotoxicity, a dose and time response study was done in order to determine a suitable, but 
clinically relevant DOX concentration and treatment duration for the main study.  
 
2.2.1 Doxorubicin Treatment 
 
A 3.4 mM stock solution of DOX (D1515, Sigma-Aldrich) was prepared using growth 
medium as the solvent (Refer to Appendix B, protocol 3, pg. 165). DOX was diluted in 
growth medium to a final concentration of 0.2, 0.4, 0.6, 0.8 and 1.0 µM. Once cells had 
reached desired confluency they were treated daily with DOX with the above concentrations 
for 72, 96 and 120 hrs.  
 
2.2.2 Cell Viability  
 
Following treatment H9C2 and Girardi cell viability was determined by the MTT (3-(4,5-
dimethythiazol-2-yl)-2, 5-diphenyle terazolium bromide) assay. The MTT viability assay 
(M2003, Sigma-Aldrich) is a common technique used to determine the percentage of 
metabolically viable cells present in a population. The principle of the MTT assay is based on 
the ability of the cells’ mitochondrial enzymes to reduce the water-soluble yellowish MTT 
(tetrazolium dye) to purple/blue formazan pigments (Berridge et al., 2005). The absorbance 
of the formazan crystals can be detected spectrophotometrically and the amount of crystals 
formed is directly proportional to the number of metabolically viable cells present. This study 
used the MTT assay to determine H9C2 and Girardi viability following incubation with 
various concentrations of DOX. Cell viability was analyzed directly post-treatment. 
 
H9C2 cardiomyoblasts and Girardi’s were randomly divided into experimental groups and 
seeded into 24-well plates at a density in accordance to table 1. Following the experimental 
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procedure, the medium was decanted and 1% MTT (0.01 g/ml) solution was gently added to 
each well. Thereafter culture plates were maintained in the dark and incubated for 2 hours at 
37 ˚C in a humidified 5% CO2 atmosphere. Following incubation, the supernatant was 
discarded and a 50:1 solution of 1% Isopropanol (1% HCl in Isopropanol): 0.1% Triton (0.1 
ml Triton-X-100 in 100 ml distilled water) was added to each well and the plates were 
covered with foil and placed on a “Belly Dancer” for 5 minutes to ensure that the formazan 
crystals were completely dissolved. Optical density was determined using a microtiter plate 
reader measuring at an absorbency of 540 nm and acidified isopropanol: triton-x mixture 
represented the blank. The values obtained are expressed as percentages of the control values. 
Refer to Appendix B, Protocol 4 (pg. 171) for the full experimental protocol.   
 
2.2.3 Apoptosis 
 
In order to evaluate apoptosis, caspase-3/7 activity was measured in both cell lines utilizing 
the Caspase-Glo® 3/7 assay (G8091, Promega). This is a luminescent cell based assay where 
following caspase-cleavage, a substrate for luciferase is released which results in the 
luciferase reaction and subsequent production of light. H9C2s and Girardi’s were cultured 
and treated as previously described in 96-well illuminometer plates. Following treatment, the 
Caspase-Glo® 3/7 reagent was prepared according to the manufacturer’s instructions and 100 
µl was added to each well, and left to incubate for 30 minutes at room temperature. 
Luminescence was measured in a luminometer (GloMax® 96 microplate Illuminometer - 
E6510, Promega). The data obtained is expressed as a percentage of the control values. Refer 
to Appendix B, protocol 5 (pg. 172) for the full experimental protocol.   
 
2.3 Main Study 
 
Based on the above assay, treatment of cells with 0.2 and 1 µM DOX for 96 and 120 hrs were 
deemed appropriate for the duration of this study. This is because this study aimed to 
investigate the cumulative and chronic changes associated with DOX cardiotoxicity relevant 
to the clinical setting. Refer to Appendix B, protocol 6 (pg. 172) for detailed treatment 
procedure.  
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2.3.1 Flow Cytometry 
 
2.3.1.1 Mitochondrial and Endoplasmic Reticulum Load 
 
Flow cytometry with the MitoTracker® Green dye (M7514, Molecular Probes) is used to 
determine mitochondrial load, which is used as an indicator of mitochondrial number. This is 
a cell-permeant, fluorescence probe that contains a mildly thio-reactive chloromethyl moiety, 
which is specific for detecting mitochondria. The ER-TrackerTM Blue-White DPX dye 
(E12353, Molecular Probes) is used to determine ER load, a marker of ER mass. ER-
TrackerTM is a photostable, fluorescence probe that is highly selective for labeling the ER. 
For this technique both H9C2s and Girardi cells were grown and treated as previously 
described in T25 cm2 flasks. Following treatment, cells were briefly washed with sterile PBS, 
trypsinized, and resuspended in 500 µl warm PBS. 25 nM MitoTracker® Green and 100 nM 
ER-TrackerTM blue were added directly to the cells and incubated for 15 minutes. Thereafter 
minimum of 10 000 cells were immediately analyzed on the flow cytometer (BD FACSAria 
I) utilizing the 488 nm and 407 nm Coherent Sapphire solid-state laser (13 – 20 mW) and the 
430 nm and 640 nm emission filters. Fluorescence intensity signal was measured using the 
geometric mean on the intensity histogram. It is important to note that DOX naturally emits 
its own intrinsic fluorescence (excitation; 480 nm, emission; 580 nm). Therefore the 
fluorescence intensity of DOX was also measured.  Refer to Appendix B, protocol 7 (pg. 
173-174) for the full experimental protocol. 
 
2.3.1.2 Intracellular Calcium Measurements 
 
The Calcium GreenTM -5N AM (C-3739, Molecular Probes) fluorescence probe is used as an 
indicator for intracellular calcium. Upon binding to calcium, Calcium GreenTM exhibits an 
increase in fluorescence emission intensity, which directly correlates to the amount of 
intracellular calcium present in the cell. Following treatment cells were prepared as 
previously described, and 5 µM Calcium GreenTM was directly added to the cells and left to 
incubate for 20 minutes at room temperature. Analysis followed on the flow cytometer and a 
minimum on 10 000 cells were collected using the 488 nm laser (13 – 20 mW) and the 530 
emission filter. Mean fluorescence intensity was measured using the geometric mean on the 
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intensity histogram. Refer to Appendix B, protocol 8 (pg. 174) for the full experimental 
protocol.   
2.3.2 Fluorescence Microscopy 
 
Girardi and H9C2 cells were grown and treated as previously stated in NuncTM Lab-TekTM 8-
chamber slides (154534, Thermo Scientific). Following treatment cells were washed with 
warm PBS and incubated with MitoTracker GreenTM and ER-Tracker for 15 minutes at room 
temperature. Using an Olympus PlanApo N60x/1.4 oil objective, with a 60X magnification, 
structural alterations of mitochondrial and ER morphology could then be determined.  Since 
DOX is autofluorescent, this study additionally wanted to determine DOX localization within 
the cells as well as whether DOX binds to the mitochondria and/or the ER. This was done by 
co-localization analysis using specific settings on the Olympus Cell^R system. Images were 
acquired through multi-colour z-stacks with the DAPI, FITC and PE-TexasRed emission 
filters, performed with an Olympus Cell^R System attached to an IX 81 inverted fluorescence 
microscope equipped with a F-view-II cooled CCD camera (Soft Imaging Systems) using 
Xenon-Arc burner (Olympus Biosystems GMBH) as a light source. The top and bottom focus 
position parameters for the z-stacks were selected, indicating the upper and lower dimensions 
of the sample to be acquired after single-frame imaging. Images were processed and 
sharpened with the Cell^R software, and presented as the maximum intensity projection. 
Refer to Appendix B, protocol 9 (pg. 175) for the full experimental protocol.   
 
2.3.3 Superresolution Structured Illumination Microscopy (SR-SIM) 
 
Cells were grown and treated as previously described in NuncTM Lab-TekTM 8-chamber 
slides. Following treatment cells were loaded with 4 µM Rhod-2 AM (R-1244, Molecular 
Probes) and 5 µM Calcium Green dye respectively, in order to visualize calcium distribution 
with the cells. Rhod-2 is a rhodamine-based fluorescence probe used to detect mitochondrial 
calcium. After 20 minutes of incubation, cells were imaged at room temperature on the Carl 
Zeiss Laser Scanning Microscope (LSM 780) using the Plan-Apochromat 63X/1.3 Oil 
DICM27 objective. Mitochondrial specific calcium was detected with the 561 nm laser, and 
fluorescence was emitted between the 575 nm – 635 nm, while free cytosolic calcium was 
determined using the excitation of the 488 nm laser and measured fluorescence emitted 
between 534 nm – 569 nm. Images were processed using Zen 2011 Software (Zeiss). While 
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intracellular calcium could be quantified with flow cytometry, mitochondrial calcium could 
not. Since Rhod-2 and DOX fluoresce on the same emission spectrum, and the flow 
cytometer is not equipped with the correct lasers, these two fluorescence probes could not be 
detected simultaneously. Therefore mitochondrial calcium fluorescence was quantified in 
relative fluorescence units (RFU) using the Zen 2011 Software. Refer to Appendix B, 
protocol 10 and 11 (pg. 175-176) for the full experimental protocol.   
 
2.3.4 Oxidative Stress and Antioxidant Capacity  
 
The following experiments were conducted at the Oxidative Stress Research Center of Cape 
Peninsula University of Technology (CPUT). 
2.3.4.1 ORAC Assay 
 
Using trolox, a water-soluble analog of vitamin E, as a reference antioxidant, the antioxidant 
capacity of both cell lines following treatment was determined with the ORAC (Oxygen 
Radical Antioxidant Capacity) assay. This assay is based on the oxidation of the fluorescence 
probe by peroxyl radicals. If antioxidants are present, they will inhibit oxidation and peroxyl 
radicals will destroy the probe. Therefore antioxidant capacity directly correlates to 
fluorescence decay (Ou et al., 2001).  After treatment the cells were washed with ice cold 
PBS, detached from plate surface with a cell scraper and transferred into corresponding, 
chilled eppendorf tubes. Cells were then sonnicated and centrifuged at 10 000 g for 10 
minutes at 4 °C. Supernatant was allocated into new eppendorf tubes and kept on ice. The 
fluorescence probe, fluorescein (F6377, Sigma-Aldrich) and the peroxyl radical, AAPH (2,2'-
azobis(2-amidino-propane) dihydrochloride) (440914, Sigma-Aldrich) were used to 
determine the ORAC value as per the method described by the Oxidative Stress Research 
Center (CPUT). Fluorescence was immediately measured using the Fluoroskan Ascent plate 
reader (Thermo Electron Corporation, USA) at excitation/emission of 485 nm/530 nm. Each 
sample was read in increments of 5 minutes for a total for 2 hrs. Fluorescence decay is 
represented as the area under the curve (AUC), which was thereby used to quantify the total 
antioxidant capacity. These results are then compared to the antioxidant standard curve of 
TroloxTM (238813, Sigma-Aldrich). Results from the assay are expressed as µmol TroloxTM 
equivalents (TE) per L of sample. Refer to Appendix B, protocol 12 (pg. 177) for the full 
experimental protocol.   
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2.3.4.2 TBARS Assay 
 
Lipid peroxidation is a well-defined mechanism whereby lipids are oxidatively degraded 
thereby resulting in cellular damage. Malondialdehyde (MDA), which is a natural by-product 
of lipid peroxidation, is used as a marker for oxidative stress. The Thiobarbituric Acid 
Reactive Substances (TBARS) assay is utilized in screening and monitoring lipid 
peroxidation. MDA reacts with thiobarbituric acid (TBA) to form a single MDA-TBA 
adduct, which can measured colorimetrically or fluorometrically, thereby allowing for direct 
quantitative measurement of the oxidative stress by-products (Devasagayum et al., 2003). 
Samples were prepared as previously described, and 4 mM Butylated hydroxytroluene (BHT) 
(B1378, Sigma-Aldrich) was added to each sample, to prevent any further oxidation and 
immediately sonnicated. No centrifuge or allocation was required as whole cell homogenate 
is utilized in the assay. Reagent preparation was performed in accordance with the Oxidative 
Stress Research Center’s (CPUT) protocol. A volume of 50 µl supernatant was added to 6.25 
µl TBA reagent and incubated at 90 °C for 45 minutes. Absorbance was measured 532 nm in 
a 96-well flat bottom plate with the Multiskan Spectrum (Thermo Electron Corporation, 
USA). The concentration of TBARs per sample was determined using the MDA (820756, 
Merck) equivalence standard and expressed as µmol of MDA. Absorbance is directly 
proportional to amount of oxidative stress by-products present in the cells. Refer to Appendix 
B, protocol 13 (pg. 179) for the full experimental protocol.   
 
2.3.4.3 GSH Redox Assay  
 
Reduced glutathione (GSH) is an important antioxidant present in high levels in all living 
cells. It has numerous cellular functions, but most importantly it plays a role in protecting the 
cells against oxidative damage. To protect against oxidative stress, GSH is converted to its 
oxidized form, oxidized glutathione (GSSG). Therefore the ratio of GSH to GSSG within the 
cells can be used as a good indicator for oxidative stress (Asensi et al., 1999; Zitka et al., 
2012). A decrease in this ratio can be indicative of significantly decreased GSH levels or of 
high amounts of GSSG present in the cells. The total glutathione (tGSH) and GSSG 
concentrations were measured using the method described by Asensi et al. (1999). The 
concentration of GSH was calculated according to the equation indicated below: 
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				 =  − 2, 
 
where after the ratio of GSH to GSSG (GSH/GSSG) was determined. Following treatment, 
samples were prepared as previously described. 50 µl 0.3 mM DTNB (5 5'-dithiobis(2-
nitrobenzoic acid)) (D8130, Sigma-Aldrich), 16 µl glutathione reductase (G3664, Sigma-
Aldrich) and 50 µl of sample for GSH, or 50 µl sample with 50 µl 30 mM M2VP (1-methyl-
2-vinylpyridinium) (69701, Sigma-Aldrich) for GSSG were added into clear 96-well flat 
bottomed plates and incubated for 5 minutes at 25 °C in a preheated BioTek plate reader. 
Following incubation, 50 µl 1 mM NADPH (β-nictinamide adenine dinucleotide phosphate 
reduced tetrasodium salt) (N7505, Sigma-Aldrich) was quickly added to each well. 
Absorbance was measured at 412 nm every 30 seconds for 3 minutes, and the concentration 
of total glutathione, GSH and GSSG were determined with GSH as standard. Refer to 
Appendix B, protocol 14 (pg. 180) for the full experimental protocol.   
 
2.3.5 Proteasomal Activity 
 
The Proteasome-GloTM Assay (G8531, Promega) contains three separate bioluminescent 
assays that detect the different protease activities of the 20S proteasome catalytic sites. The 
luminogenic substrates: Suc-LLVY-aminoluciferin, Z-LRR-aminoluciferin and Z-LPnLD-
aminoluciferin, were used to detect chymotrypsin-like, trypsin-like and caspase-like catalytic 
activities within the proteasome respectively. The luminescent signal produced is directly 
proportional to the amount of proteasomal activity present within the cells. Both cell lines 
were cultured and treated as previously described. After the treatment protocol the 
Proteasome-GloTM assay was carried out according to the specifications and standards of the 
protocol supplied by manufacturer. Luminescence of the individual protease activities were 
detected with the GloMax® 96-well Microplate Luminometer (E6501, Promega). Refer to 
Appendix B, protocol 15 (pg. 182) for the full experimental protocol.   
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2.3.6 Western Blot Analysis 
 
2.3.6.2 Protein Extraction 
 
After treatment with DOX, cell were then rinsed with PBS where after 30 μl of lysis buffer, 
pH 7.4, containing: Benzamidine 1 mM, dithiothreitol 1mM, EDTA (Ethylenediaminetetra-
acetic acid) 1 mM, 10 mg/ml of leupeptin, 0.5% Na-Deoxychlorate, NaF (Sodium Fluoride) 
50 mM, 1%, NP40, PMSF (phenylmethylsulfonyle fluoride) 0.1 mM, 4 mg/ml of SBTI 
(soybean trypsin inhibitor), 0.1% SDS (Sodium dodecyle sulphate) and Tris (tri-(hydroxyl-
methyl)-aminomethane)-HCl 2.5 mM, was added to each well and kept on ice for 5 minutes. 
Cells were scraped lose from the bottom of the wells using a sterile cell scraper and 
transferred into chilled eppendorf tubes. Cardiomyoblasts were sonnicated at 15% amplitude 
for 10 seconds with the Misonic Ultrasonic Liquid Processor (Qsonica, USA) to ensure the 
breakdown of the cell membranes and release of cellular proteins. Cell lysates were then 
centrifuged at -4 ˚C for 10 minutes at 8000 rpm and the supernatant was transferred into new, 
chilled eppendorf tubes. Protein content was then determined by the Bradford technique 
described below. Refer to Appendix B, protocol 16 (pg. 184) for the full experimental 
protocol.   
 
2.3.6.3 Bradford Protein Determination and Sample Preparation 
 
Protein content was quantified using the Bradford protein determination method. In order to 
determine how much protein is contained in each sample a standard curve was established; 
where a sequence of protein dilutions were set up in eppendorf tubes.  10 μl, 20 μl, 40	μl, 
60	μl, 80 μl and 100	μl of 1 mg/ml BSA (albumin bovine serum dissolved in PBS) was added 
to distilled water (dH2O). 900 μl of the Bradford Reagent was thereafter added to each 
eppendorf, contributing to a final volume of 1000 μl. Sample protein concentrations were 
subsequently determined by pipetting 5 μl of protein sample into 900 μl Bradford Reagent 
and 95-µl dH2O. All eppendorf tubes were vortexed and absorbance was measured at 595 nm 
against the reagent blank with a spectrophotometer (Cecil 2000, type CE 2021 UV/VIS). The 
weight of protein in μg/ml was determined and subsequent protein concentrations (50 μg/ml) 
were made up using Laemmli sample buffer. Prepared samples were boiled at 95.5˚C for 5 
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minutes and stored at −80˚C until required. Refer to Appendix B, protocol 16 (pg. 184) for 
the full experimental protocol.  
 
2.3.6.4 Sodium-dodecyl-sulfate-polyacrylamide Gel Electrophoresis (SDS-PAGE) and 
Electrotransfer 
 
Proteins weighing between 30 – 90 kDA were separated with a 12% polyacrylamide gel, 
whereas lower molecular weight proteins (≤ 30 kDA) a 15% polyacrylamide gel was used.  
Previously prepared protein samples were thawed and boiled at a temperature of 95.5˚C for 5 
minutes before being briefly centrifuged. Equal protein concentrations (50 	μg/ml) were 
loaded into each gel. In order to determine protein molecular weight and gel orientation, 
BLUeye pre-stained protein ladder (PM007-0500, GeneDirex) was loaded into the first left 
well of each gel. Proteins separated by SDS-PAGE (Mini-PROTEAN® Tetra cell, Biorad) at 
a constant voltage of 100 V and current of 400 mA (Biorad Power Pac 1000) for 10 minutes, 
and thereafter at constant voltage of 200 V for 50 minutes. The separated proteins were 
transferred to PVDF (polyvinylidine fluoride) membranes (Trans-Turbo® mini transfer pack, 
170-4156, Bio-Rad) using Trans-Blot Turbo System (170-4155, Bio-Rad) at a voltage of 12V 
and constant current of 12A for 12 minutes. Membranes were routinely stained with Ponceau 
Red to ensure protein transfer and equal loading. Refer to Appendix B, protocol 16 (pg. 185) 
for the full experimental protocol. 
2.3.6.5 Immuno-dectection 
 
Non-specific binding sites on membranes were blocked for 2 hours in 5% fat-free powered 
milk in TBS-T (TRIS-buffered saline-Tween Solution), after which membranes were 
incubated overnight at 4 °C in specific primary antibody solutions. The protein of interest 
was detected using manufacturers recommended dilutions of the following primary 
antibodies; ATF-4 (11815, Cell Signaling), BiP (3177, Cell Signaling), Cleaved Caspase 3 
(9661, Cell Signaling), Drp1 (ab56788, Abcam), hFis1 (ab71498, Abcam), GAPDH (2118, 
Cell Signaling), K48-Ubiquitin (8081, Cell Signaling), LC3-II (2775, Cell Signaling), 
MARCH5 (Ab77585, Abcam), Mitofusion 1 (ab129154, Abcam), Mitofusion 2 (ab124773, 
Abcam), p62 (5114, Cell Signaling), Parkin (2132, Cell Signaling), PGC-1α (2178, Cell 
Signaling) and Tomm20 (ab56783, Abcam). Following overnight incubation, membranes 
were washed three times with 1X TBS-T solution where after they were incubated with their 
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corresponding secondary antibodies at room temperature for 1 hour. The secondary 
antibodies; HRP-linked anti-Rabbit secondary antibody (7074, Cell Signaling), Goat anti-
Rabbit IgG H&L (HRP) secondary antibody (ab97069, Abcam) and Goat anti-Mouse IgG 
H&L (HRP) secondary antibody (ab97040, Abcam) were utilized. To eliminate background, 
all goat secondary antibodies were made up in 5% w/v milk blocking solution.  After 
washing membranes with TBS-T, they were incubated with ClarityTM Western ECL Substrate 
(170-5061, Bio-rad) and exposed with the ChemiDocTM XRS+ System. Lane profile analysis 
was performed with the Image LabTM Software (Bio-Rad). Refer to Appendix B, protocol 16 
(pg. 181) for the full experimental protocol. 
 
2.3.7 Statistical Analysis 
 
Data from at least three independent experiments, of which each was conducted in triplicate, 
were analyzed. All values are presented as a percentage of the control (100%). Comparison 
between the groups was achieved using one-way analysis variance (ANOVA) followed by 
Bonferroni’s post-hoc test. All data are presented as the means ± SEM. A p-value < 0.05 
was considered statistically significant. All statistical analysis was carried out on the 
computer program, GraphPad Prism (GraphPad Inc., version 5.0). 
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Chapter 3 –Results 
3.1 Pilot Study: Cell Viability 
  
In order to determine an appropriate DOX treatment regime over a long period of time, the 
MTT bio-reductive assay was employed to establish a dose- and time-response graph. Cell 
viability of the H9C2 cells became significantly reduced as the treatment concentration 
increased compared to the control group (Figure 3.1). This occurred across all times points 
analyzed where cell viability was at its lowest after 96 hours. Although no statistical 
significance was observed, there was a modest improvement in cell viability following 120 
hours versus 96 hours at all DOX concentrations except 0.6 µM. Similarly the Girardi’s cell 
viability was significantly reduced over time as the concentration of DOX was increased 
(Figure 3.2). Interestingly the Girardi’s behaved very differently to the H9C2 cells at the 0.2 
µM concentration group, where a statistical increase in viability occurred following 72 and 96 
hours.  
 
 
Figure 3.1: The effect of increasing, cumulative doses of doxorubicin on H9C2 cell 
viability. H9C2 cardiomyoblasts were incubated with 0.2, 0.4, 0.6, 0.8 and 1.0 µM of 
DOX for 72, 96 and 120 hours. Values are expressed as a percentage of the control 
(100%). Results presented as mean ± SEM (n=4). *P < 0.05, **P < 0.01 and ***P < 0.001 
vs. Control. Abbreviations – C: control, DOX: doxorubicin, hr: hour, vs: versus.  
Stellenbosch University  https://scholar.sun.ac.za
 50
This study also wanted to assess the activities of caspase 3 and 7 under these conditions. As 
shown in Figure 3.3, H9C2’s apoptotic activity was significantly elevated when compared to 
the control. Interestingly after 120 hours of DOX treatment, apoptotic activity declines 
despite remaining above baseline values. Treatment with the highest concentration of DOX 
(1 µM) for 96 and 120 hours resulted in a decrease in apoptosis compared to the 72 hour 
group. Analysis of Girardi cell apoptosis demonstrated a significant increase in apoptotic 
activity at most of the concentration groups, however similar to the H9C2 cells, a decrease in 
activity was observed at the 1.0 µM group following 96 and 120 hours of treatment (Figure 
3.4).  
 
As this study aimed to investigate the cumulative and chronic changes associated with DOX 
cardiotoxicity relevant to the clinical setting, the remainder of the data will be presented with 
the 0.2 µM and 1.0 µM DOX treatment over 96 and 120 hours only. Since the Girardi cells 
appeared more sensitive to DOX compared to the H9C2 cells, the following results will only 
represent experiments performed on the H9C2 cell line. Please refer to Appendix A for the 
Girardi cell’s results.   
Figure 3.2: The effect of increasing, cumulative doses of doxorubicin on Girardi cell 
viability. Girardi cells were incubated with 0.2, 0.4, 0.6, 0.8 and 1.0 µM of DOX for 72, 96 
and 120 hours. Values are expressed as a percentage of the control (100%). Results 
presented as mean ± SEM (n=4). *P < 0.05, **P < 0.01 and ***P < 0.001 vs. Control.
Abbreviations: - C: control, DOX: doxorubicin, hr:  hour, vs = versus. 
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Figure 3.3: The effect of increasing, cumulative doses of doxorubicin on H9C2 
caspase 3/7 luminescence. H9C2 cells were incubated with 0.2, 0.4, 0.6, 0.8 and 1.0 µM of 
DOX for 72, 96 and 120 hours. Values are expressed as a percentage of the control (100%). 
Results presented as mean ± SEM (n=3). **P < 0.01 and ***P < 0.001 vs. Control. 
Abbreviations – C: control, DOX: doxorubicin, hr:  hour, vs: versus. 
 
Figure 3.4: The effect of increasing, cumulative doses of doxorubicin on Girardi 
caspase 3/7 luminescence. Girardi cells were incubated with 0.2, 0.4, 0.6, 0.8 and 1.0 µM 
Stellenbosch University  https://scholar.sun.ac.za
 52
of DOX for 72, 96 and 120 hours. Values are expressed as a percentage of the control 
(100%). Results presented as mean ± SEM (n=3). **P < 0.01 and ***P < 0.001 vs. Control. 
Abbreviations – C: control, DOX: doxorubicin, hr: hour, vs: versus. 
3.2 The Effect of Chronic DOX Treatment Regimes on Mitochondrial Dynamics  
 
Mitochondria are the “heart” of the cell as they are responsible for energy production. These 
organelles have previously been shown to be extensively damaged during DOX 
cardiotoxicity (Octavia, 2012), but the extent of the damage is relatively unknown. As the 
mitochondria are constantly undergoing regulated fission and fusion events, this study aimed 
to determine whether the balance of mitochondrial dynamic would be disturbed following 
chronic treatment with DOX. 
3.2.1 Evaluation of Mitochondrial Fission  
 
Drp1 and hFis1 are two essential promoters of mitochondrial fragmentation. In order to 
establish the effect of chronic DOX treatment regimes on mitochondrial fission, western 
blotting assessed the expression of both these proteins. Drp1 expression was modestly 
unregulated after 96 hours of treatment and significance was obtained with the higher 
concentration of DOX [116.70 ± 2.86%, (p < 0.01)] when compared to the control (100%) 
(Figure 3.5). Following 120 hours of exposure, DOX induced an even greater increase in 
Drp1 expression across both treatment groups relative to the control. Hfis1, a recruiter of 
Drp1, elicited a similar response although not in the same magnitude (Figure 3.6). Both the 
low [122.60 ± 0.33%, (p < 0.01)] and high [117.70 ± 4.97%, (p < 0.05)] concentrations of 
DOX significantly elevated hFis1 expression following 120 hours of treatment. Given the 
crucial role that both these proteins play in regulation of mitochondrial fragmentation, these 
results demonstrate that chronic DOX treatment increases mitochondrial fission in a time- 
and dose-dependent manner.  
3.2.2 Evaluation of Mitochondrial Fusion  
 
In order to fully understand the impact of chronic DOX treatment on mitochondrial dynamics 
in these cardiomyocytes, mitochondrial fusion proteins (Mfn1 and Mfn2) were also assessed. 
In contrast to the elevated Drp1 and hFis1 expression, Mfn1 was significantly reduced in 
response to 96 hours [0.2 µM: 73.74 ± 6.24%, (p < 0.05) and 1.0 µM: 22.07 ± 3.61%, (p < 
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0.001)] and 120 hours [0.2 µM: 52.52 ± 4.75%, (p < 0.001) and 1.0 µM: 29.33 ± 4.93%, (p < 
0.001)] of chronic DOX treatment relative to the control (100%) (Figure 3.7). What was 
interesting to note in these results was the substantial difference within the group and 
between groups, suggesting that repeated administration as well as cumulative DOX 
concentration negatively affects expression of Mfn1. Analysis of Mfn2 results also indicated 
significantly reduced protein expression in a dose and time dependent manner when 
compared to the control (Figure 3.8). Therefore, the overall reduction in mitochondrial fusion 
proteins and the concomitant rise in fission factors throughout the treatment duration 
highlights the imbalance between mitochondrial dynamics. These results further substantiate 
the occurrence of mitochondrial fragmentation in DOX treated cardiomyoblasts.  
 
 
Figure 3.5: The effect of chronic doxorubicin treatment regimes on Drp1 expression in 
H9C2 cardiomyoblasts. (A) Lane profile analysis of Drp1. (B) Representative immunoblot 
of Drp1. TOMM20 served as the loading control. H9C2 cardiomyoblasts were treated daily 
with 0.2 and 1.0 µM DOX for 96 and 120 hours. Results are presented as mean ± SEM 
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(n=3). **P < 0.01 and ***P< 0.001 vs. Control. $$$P < 0.001 96 hr vs. 120 hr. Abbreviations – 
C: control, DOX: doxorubicin, Drp1: dynamin-related protein 1, hr: hour, vs: versus. 
 
 
Figure 3.6: The effect of chronic doxorubicin treatment regimes on hFis1 expression 
in H9C2 cardiomyoblasts. (A) Lane profile analysis of hFis1. (B) Representative 
immunoblot of hFis1. TOMM20 served as the loading control. H9C2 cardiomyoblasts were 
treated daily with 0.2 and 1.0 µM DOX for 96 and 120 hours. Results are presented as mean 
± SEM (n=3). *P < 0.05 and **P < 0.01 vs. Control. $$P < 0.01 96 hr vs. 120 hr. 
Abbreviations – C: control, DOX: doxorubicin, hFis1: mitochondrial fission factor 1, hr: hour, 
vs: versus 
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Figure 3.7: The effect of chronic doxorubicin treatment regimes on Mitofusin 1 
expression in H9C2 cardiomyoblasts. (A) Lane profile analysis of Mitofusin 1. (B) 
Representative immunoblot of Mitofusin 1 TOMM20 served as the loading control. H9C2 
cardiomyoblasts were treated daily with 0.2 and 1.0 µM DOX for 96 and 120 hours. Results 
are presented as mean ± SEM (n=3). *P < 0.05 and  ***P< 0.001 vs. Control. $P < 0.05 96 hr 
vs. 120 hr. #P < 0.05 and ###P < 0.001 0.2 µM vs. 1.0 µM. Abbreviations – C: control, DOX: 
doxorubicin, hr: hour,  vs: versus. 
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Figure 3.8: The effect of chronic doxorubicin treatment regimes on Mitofusin 2 
expression in H9C2 cardiomyoblasts. (A) Lane profile analysis of Mitofusin 2. (B) 
Representative immunoblot of Mitofusin 2. TOMM20 served as the loading control. H9C2 
cardiomyoblasts were treated daily with 0.2 µM and 1.0 µM DOX for 96 and 120 hours. 
Results are presented as mean ± SEM (n=3). *P < 0.05  and ***P< 0.001 vs. Control. 
Abbreviations – C: control, DOX: doxorubicin, hr: hour, vs: versus. 
 
3.2.3  Evaluation of Mitochondrial Morphology  
 
Mitochondrial morphology has been defined as the balance between fission and fusion 
(Rolland, 2014). Therefore, in order to establish whether chronic DOX treatment induced any 
changes in mitochondrial morphology, cells where stained with MitoTracker green and 
visualized with fluorescence microscopy (Figure 3.9).  This data indicates that the control 
group displays a dense, interconnected mitochondrial network, with elongated and tubular 
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mitochondria. Then as the concentration of DOX increased over time, the mitochondrial 
network progressively appeared to dissociate and separate, as the mitochondria themselves 
displayed a shorter and fragmented morphology. Mitochondrial load, which is used to 
quantify the number of mitochondria present in the cells, was also determined in the context 
of chronic DOX-induced cardiotoxicity (Figure 3.10). Cells were again stained with 
MitoTracker green and analyzed by flow cytometry. Only treatment with 1.0 µM DOX 
resulted in a significant increase in fluorescence at the 96 hour [145.50 ± 14.74%, (p < 0.05)] 
and 120 hour [162.30 ± 4.88%, (p < 0.001)] time points in comparison to the control (100%). 
Therefore as the mitochondria become more fragmented, mitochondrial load increases.   
 
Additionally, the intercellular localization of DOX was assessed following treatment. It is 
difficult to visualize the location of DOX, since the low concentration did not exhibit a high 
fluorescence. However we can determine that following 120 hours of treatment, DOX 
appears to be dispersed throughout the cell in the 0.2 µM DOX group, showing strong, 
significant localization with the mitochondria. This was confirmed by colocalization analysis 
(Figure 3.11). As can be seen in the images, treatment with the high dose of DOX, also 
resulted in a significant increase in area of colocalization following 96 hours [13.06 ± 0.47%, 
(p < 0.001)] and 120 hours [5.10 ± 0.50%, (p < 0.001)] compared to the 0.2 µM DOX group 
respectively.  
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Figure 3.9: The effect of chronic doxorubicin treatment regimes on mitochondrial morphology and DOX localization in H9C2 cardiomyoblasts. Cells
were treated daily with 0.2 and 1.0 µM DOX for 96 and 120 hours. Only 120 hour represented in image. Following treatment cells were stained MitoTracker 
Green (green) and visualized using fluorescence microscopy (n=3). Red indicates DOX and grey indicates area of colocalization Abbreviations – DOX: 
doxorubicin, hr: hour. Magnification = 60X. Scale Bar = 20 µm. Selected regions where magnified two-fold, and displayed in corresponding insets. 
DOX MitoTracker Colocalization 
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Figure 3.10: The effect of chronic doxorubicin treatment regimes on mitochondrial 
load in H9C2 cardiomyoblasts. H9C2 cells were treated daily with 0.2 and 1.0 µM DOX for 
96 and 120 hours, followed by staining with MitoTracker Green and assessed using flow 
cytometry (n=3). *P < 0.05 and ***P< 0.001 vs. Control. #P < 0.05 and ###P < 0.001 0.2 µM 
vs. 1.0 µM. Abbreviations – C: control,  DOX: doxorubicin,  hr: hour., vs: versus. 
 
 
 
 
 
 
 
 
 
 
Figure 3.11: Area of doxorubicin and mitochondria colocalization. H9C2 
cardiomyoblasts were treated daily with 0.2 and 1.0 µM DOX for 96 and 120 hours, followed 
by staining with MitoTracker Green (green) and DOX (Red) and visualized with fluorescence 
microscopy (n=3). Area of colocalization was determined using the Cell^R analysis software. 
***P< 0.001 vs. Control. $$P < 0.01 and $$$P < 0.001 96 hr vs. 120 hr.  ##P < 0.01 and ###P < 
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0.001 0.2 µM vs. 1.0 µM. Abbreviations – AU: arbitrary units, C: control,  DOX: doxorubicin,  
hr: hour., vs: versus. 
 
3.3 The Effect of Chronic DOX Treatment Regimes on the Ubiquitin Proteasome 
Pathway 
 
The UPP is a lysosomal-independent proteolytic system responsible for proteasomal 
degradation of misfolded, aggregated and oxidized proteins (Powell, 2006). It can be 
activated under cellular stress, and is highly associated with regulating mitochondrial QC as 
well as the UPR. In order to establish the effects of chronic DOX-induced cardiotoxicity on 
the UPP, some of the components involved in this pathway were assessed.   
3.3.1 Evaluation of E3 ligase expression  
 
Membrane-associated RING finger 5 (MARCH5/MARCH-V/MITOL) is an E3 ubiquitin 
ligase, which plays an essential role in controlling mitochondrial dynamics and morphology 
by regulating mitochondrial fission (Karbowski et al., 2007; Sugiura et al., 2011). This study 
used western blotting to examine MARCH5 expression in cardiomyoblasts following chronic 
DOX treatment (Figure 3.12). No significant change in MARCH5 activity was observed in 
the 0.2 µM DOX group after 96 hours of treatment [128.00 ± 3.3%] compared to control 
(100%). However, following 120 hours with 0.2 µM of DOX [148.70 ± 4.18%, (p < 0.001)], 
results showed that expression was increased significantly in relation to the control.  
MARCH5 expression remained considerably elevated at 96 hour [238.80 ± 11.32, (p < 
0.001)] and 120 hour [154.60 ± 5.67%, (p < 0.001)] time points when treated with 1.0 µM 
DOX in comparison to the control.   
 
The accumulation of fragmented mitochondrial in the cell triggers mitophagy, a select form 
of autophagy, to remove the damaged mitochondria. Since mitochondrial fission was 
elevated, this study investigated whether mitophagy was initiated under conditions of chronic 
DOX-induced cardiotoxicity. The expression of the E3 ubiquitin ligase, Parkin, which 
mediates mitophagy, was assessed with western blotting (Park et al., 2014a) (Figure 3.13). 
Results showed that treatment with 0.2 µM of DOX caused a significant increase in Parkin 
expression following 96 hours [141.10 ± 3.19%, (p < 0.001)] and 120 hours [137.60 ± 5.37%, 
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(p < 0.001)] when compared to the control (100%). Parkin remained elevated significantly 
after 96 hours of treatment with 1.0 µM of DOX [153.5 ± 1.95%, (p < 0.001 vs. Control)]. 
However following 120 hours the 1.0 µM DOX group returned to baseline values. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.12: The effect of chronic doxorubicin treatment regimes on MARCH5 
expression in H9C2 cardiomyoblasts. (A) Lane profile analysis of MARCH5. (B) 
Representative immunoblot of MARCH5. GAPDH served as the loading control. H9C2 
cardiomyoblasts were treated daily with 0.2 µM and 1.0 µM DOX for 96 and 120 hours. 
Results are presented as mean ± SEM (n=3). ***P< 0.001 vs Control. $$P < 0.01 and $$$P < 
0.001 96 hr vs 120 hr. ###P < 0.001 0.2 µM vs 1.0 µM.  Abbreviations – C: control, DOX: 
Doxorubicin, hr: hour, MARCH5: membrane-associated RING finger 5, vs: versus.  
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Figure 3.13: The effect of chronic doxorubicin treatment regimes on Parkin 
expression in H9C2 cardiomyoblasts. (A) Lane profile analysis of Parkin. (B) 
Representative immunoblot of Parkin. GAPDH served as the loading control. H9C2 
cardiomyoblasts were treated daily with 0.2 µM and 1.0 µM DOX for 96 and 120 hours. 
Results are presented as mean ± SEM (n=3). ***P< 0.001 vs Control. $$$P < 0.001 96 hr vs 
120 hr. ###P < 0.001 0.2 µM vs 1.0 µM. Abbreviations – C: control, DOX: Doxorubicin, hr: 
hour, vs: versus.  
3.3.2 Evaluation of K48 Protein Ubiquitination 
 
The K48 ubiquitin antibody detects polyubiquitin chains formed directly by the Lys48 
residue of ubiquitin. These polyubiquitin chains are commonly tagged by E3 ligases to 
proteins targeted for protein degradation specifically by the 26S proteasome (Komander, 
2009). K48 ubiquitination was significantly augmented at the 0.2 µM concentration group 
following 120 hours of treatment [357.10 ± 3.73%, (p < 0.001)] versus the control group 
(100%) (Figure 3.14). No significance was observed following 96 hours of treatment with 
this low dose of DOX. However, treatment with 1.0 µM of DOX resulted in elevated 
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ubiquitination after 96 hours [163.20 ± 10.13%, (p < 0.001)] and 120 hours [439.10 ± 4.32%, 
(p < 0.001)] in comparison to the control. Additionally, as seen in the representative 
immunoblot image (Figure 3.14b), a difference in protein tagging was observed across the 
two concentration groups. Low concentrations of DOX resulted intense tagging of proteins 
with a molecular weight range of 50 – 85 kDa. Whereas treatment with the higher 
concentration of DOX resulted in ubiquitination of proteins with a relatively higher 
molecular weight range, suggestive of myofibrillar protein targeting.   
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Figure 3.14:  The effect of chronic doxorubicin treatment regimes on K48 
ubiquitination in H9C2 cardiomyoblasts. (A) Lane profile analysis of K48 Ubiquitin. (B) 
Representative immunoblot of K48 ubiquitination. GAPDH served as the loading control. 
H9C2 cardiomyoblasts were treated daily with 0.2 µM and 1.0 µM DOX for 96 and 120 
hours. Results are presented as mean ± SEM (n=3). ***P< 0.001 vs Control. $$$P < 0.001 96 
hr vs 120 hr. ###P < 0.001 0.2 µM vs 1.0 µM Abbreviations – C: control, DOX: doxorubicin, 
hr: hour, vs: versus.  
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3.3.3 Evaluation of the 26S Proteasome    
 
The 26S proteasome is a multi-protein complex, which contains two 19S caps and a 20S core 
particle. The 20S core contains three different catalytic sites, the chymotrypsin-like, trypsin-
like and caspase-like sites, which are responsible for degrading proteins into small peptide 
fragments. In order to fully elucidate the effect of chronic DOX treatment on the entire 20S 
core particle, all three catalytic moieties were evaluated.  
 
Findings from this study demonstrate that both the chymotrypsin-like (Figure 3.15) and 
trypsin-like (Figure 3.16) catalytic activity was significantly and progressively reduced over 
time as the concentration of DOX increased relative to their controls (100%). However 
chymotrypsin-like activity was more sensitive to the 1.0 µM DOX treatment [96 hour: 31.45 
± 0.88%, (p < 0.001) and 120 hour: 21.25 ± 0.83%, (p < 0.001)] compared to trypsin-like 
activity in the same concentration group [96 hour: 64 ± 3.63%, (p < 0.001) and 120 hour: 
54.47 ± 3.02%, (p < 0.001)].  On the other hand, treatment with 0.2 µM DOX resulted in no 
significant reduction in chymotrypsin-like activity following 96 hours, whereas a significant 
decrease in the activity of the trypsin-like site was observed [80.01 ± 4.17%, (p < 0.05)].  
Both sites however, elicited a similar ±30% reduction in activity following 120 hours of 
treatment with the low dose of DOX. 
 
The activity of the catalytic-site, displayed a decreasing trend, comparable to that of its 
counterparts (Figure 3.17). Yet, treatment with the lower dose of DOX resulted in an increase 
in activity, with significance attained only following 96 hours [137.40 ± 6.15%, (p < 0.01 vs. 
Control)]. Although a significant reduction in catalysis was observed after 120 hours, at the 
1.0 µM concentration group [45.54 ± 7.46%, (p < 0.01)] compared to the control. 
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Figure 3.15: The effect of chronic doxorubicin treatment regimes on chymotrypsin-
like catalytic activity in H9C2 cardiomyoblasts. Cells were treated daily with 0.2 µM and 
1.0 µM DOX for 96 and 120 hours. Results are presented as mean ± SEM (n=3). ***P< 
0.001 vs Control. $$$P < 0.001 96 hr vs 120 hr. ##P < 0.01 and ###P < 0.001 0.2 µM vs 1.0 
µM. Abbreviations – C: control, DOX: doxorubicin, hr: hour, vs: versus.  
 
Figure 3.16: The effect of chronic doxorubicin treatment regimes on trypsin-like 
catalytic activity in H9C2 cardiomyoblasts. Cells were treated daily with 0.2 µM and 1.0 
µM DOX for 96 and 120 hours. Results are presented as mean ± SEM (n=3). *P < 0.05 and 
***P< 0.001 vs Control. $$$P < 0.001 96 hr vs 120 hr. ##P < 0.01 and ###P < 0.001 0.2 µM vs 
1.0 µM. Abbreviations: C: control, DOX: doxorubicin, hr: hour., vs.: versus. 
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Figure 3.17: The effect of chronic doxorubicin treatment regimes on caspase-like 
catalytic activity in H9C2 cardiomyoblasts. Cells were treated daily with 0.2 µM and 1.0 
µM DOX for 96 and 120 hours. Results are presented as mean ± SEM (n=3). **P < 0.01 vs 
Control. $$P < 0.01 and $$$P < 0.001 96 hr vs 120 hr. ###P < 0.001 0.2 µM vs 1.0 µM. 
Abbreviations – C: control, DOX: doxorubicin, hr: hour, vs: versus.  
 
3.4 The Effect of Chronic DOX Treatment Regimes on Autophagy 
 
Autophagy, a lysosomal-dependent proteolytic pathway, is upregulated under various 
conditions such as oxidative or ER stress. It is responsible for degradation of protein 
aggregates and redundant organelles, like the mitochondria, and is therefore an important 
process associated with mitochondrial QC (Marchi et al., 2014). In order to effectively 
evaluate autophagic activity following chronic DOX treatment, two specific biomarkers for 
the autophagic pathway, LC-3 and p62/SQSTM1, were assessed by western blotting.  
 
The lipidation of the cytosolic form of the microtubule-associated protein light chain (LC3-I) 
to its autophagosome-associated form (LC3-II) is used to assess the autophagic activity and 
formation of autophagosomes (Kadowaki et al., 2009). There are many accepted methods in 
which LC3 expression can be interpreted. This study chose to analyze the LC3-II/LC3-I ratio 
since it is an accurate determinant for autophagic activity (Kabeya et al., 2000) (Figure 3.18). 
These results demonstrate that at both the lowest and the highest dose of DOX, autophagic 
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activity was significantly increased following 96 hours [0.2 µM: 144.60 ± 4.56% and 1.0 µM: 
159.10 ± 1.34%, (p < 0.001)] and 120 hours (0.2 µM: 165.00 ± 5.46% and 1 µM: 193.90 ± 
8.43%, (p < 0.001)] of treatment in comparison to the control (100%). Additionally, 
statistical differences were also obtained between concentration groups (p < 0.001), 
suggesting that increases in autophagic activity are not only dependent on the duration of 
treatment, but also on the concentration. However, the analysis of LC3-II/LC3-I ratio does 
not represent autophagic flux, since the accumulation of LC3-II, as indicated in the 
immunoblot image (Figure 3.18b), only correlates to the extent of autophagosome formation 
and not to its degradation (Kabeya et al., 2000).  
 
Sequestosome, or p62 (SQSTM1) has been identified as an ubiquitin-binding protein 
(Vadlamudi et al., 1996). In the mediation of autophagy and mitophagy, p62 promotes the 
formation of protein aggregates, and directs them to the autophagosome through its 
interactions with LC3. P62, along with the targeted and defective cargo are engulfed and 
subsequently degraded by the autophagolysosome (Ichimura et al., 2008). DOX treatment 
resulted in a significant reduction in p62 expression at both concentrations following 96 
hours [0.2 µM: 51.39 ± 5.14% and 1.0 µM: 42.11 ± 1.98%, (p < 0.001)] and 120 hours [0.2 
µM: 59.29± 3.02% and 1.0 µM: 61.4 ± 0.95%, (p < 0.001)] compared to their respective 
controls (Figure 3.19). Therefore, since p62 is selectively degraded by autophagy, our results 
demonstrate that autophagic flux increases in response to both the duration and the 
concentration of DOX treatment.  
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Figure 3.18: The effect of chronic doxorubicin treatment regimes on LC3 expression 
in H9C2 cardiomyoblasts. (A) Lane profile analysis of LC3-II/LC3-Ratio. (B) 
Representative immunoblot of LC3-I and LC3-II. GAPDH served as the loading control. 
H9C2 cardiomyoblasts were treated daily with 0.2 µM and 1.0 µM DOX for 96 and 120 
hours. Results are presented as mean ± SEM (n=3). ***P < 0.01 vs Control. $$P < 0.01 and 
$$$P < 0.001 96 hr vs 120 hr. #P < 0.05 0.2 µM vs 1.0 µM. Abbreviations – C: control, DOX: 
doxorubicin, hr: hour, LC3: microtubule –associated protein light chain 3, vs.: versus. 
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Figure 3.19:  The effect of chronic doxorubicin treatment regimes on p62 expression 
in H9C2 cardiomyoblasts. (A) Lane profile analysis of p62. (B) Representative immunoblot 
of p62. GAPDH served as the loading control. H9C2 cardiomyoblasts were treated daily with 
0.2 µM and 1.0 µM DOX for 96 and 120 hours. Results are presented as mean ± SEM (n=3). 
***P < 0.001 vs Control. $$$P < 0.001 96 hr vs 120 hr. Abbreviations – C: control, DOX: 
doxorubicin, hr: hour, vs.: versus.   
 
3.5 The Effect of Chronic DOX Treatment Regimes on Mitochondrial Biogenesis  
 
Since the coordination and cross-talk between the proteolytic systems, specifically 
mitophagy, and mitochondrial biogenesis is essential for maintaining mitochondrial 
homeostasis (Palikaras and Tavernarakis, 2014), this study wanted to assess whether these 
H9C2 cells have the ability to “make new” mitochondria, considering the amount of fission 
observed. Western blotting was used to assess the transcription factor, PGC-1α (peroxisome 
proliferator-activated receptor gammer co-activator 1-alpha), an important protein involved 
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in regulating mitochondrial biogenesis. PGC-1α controls the synthesis of new mitochondrial 
by coordinating the transcription of both the mitochondrial and nuclear genomes (Baker et 
al., 2007; Puigserver et al., 1998). Compared to the control group (100%), these results 
demonstrated that PGC-1α levels were significantly attenuated over time following treatment 
with 0.2 µM DOX [96 hours: 78.68 ± 4.02% and 120 hours: 66.45 ± 5.12%, (p < 0.01)] and 
1.0 µM DOX [96 hours: 50.56 ± 2.62% and 120 hours: 43.63 ± 6.16%, (p < 0.001)] (Figure 
3.20).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.20: The effect of chronic doxorubicin treatment regimes on PGC-1α 
expression in H9C2 cardiomyoblasts. (A) Lane profile analysis of PGC-1α. (B) 
Representative immunoblot of PGC-1α. GAPDH served as the loading control. H9C2 
cardiomyoblasts were treated daily with 0.2 µM and 1.0 µM DOX for 96 and 120 hours. 
Results are presented as mean ± SEM (n=3). **P < 0.01 ***P < 0.001 vs Control. #P < 0.05 
and ##P < 0.01 0.2 µM vs 1.0 µM. Abbreviations – C: control, DOX: Doxorubicin, hr: hour, 
PGC-1α: peroxisome proliferator-activated receptor gamma co-activator 1-alpha, vs: versus.   
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3.6 The Effect of Chronic DOX Treatment Regimes on Apoptosis 
 
In order to further validate the results obtained from the Caspase-Glo 3/7 Assay, the 
expression of cleaved-caspase 3 was analyzed with immunoblotting. As seen in the Caspase-
Glo assay, caspase 3 cleavage was significantly higher in both the 0.2 µM [261.60 ± 18.38%, 
(p < 0.001)] and 1.0 µM [204.60 ± 9.94%, (p < 0.01)] DOX concentration groups following 
96 hours of treatment compared to the control (100%). Expression of cleaved-caspase after 
120 hours of treatment further corresponded to results obtained from the Caspase-Glo assay. 
Comparison between groups revealed that although treatment with 0.2 µM DOX significantly 
increased caspase cleavage compared to the control, a significant reduction a cleavage was 
observed over time [133.50 ± 6.00%, (p < 0.01 0.2 µM vs. 1.0 µM)]. Similarly, apoptosis was 
significantly downregulated at the higher concentration of DOX accumulated over 120 hours 
[65.44 ± 4.06%, (p < 0.001 0.2 µM vs. 1.0 µM)]. These results demonstrate that apoptosis is 
downregulated in both a time- and dose-dependent manner by chronic DOX treatment 
regimes.  
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Figure 3.21: The effect of chronic doxorubicin treatment regimes on apoptosis in 
H9C2 cardiomyoblasts. Cells were treated daily with 0.2 µM and 1.0 µM DOX for 96 and 
120 hours. Results are presented as mean ± SEM (n=3). **P < 0.01 and ***P < 0.001 vs. 
Control. $$$P < 0.001 96 hr vs 120 hr. P < 0.05 and ###P < 0.001 0.2 µM vs 1.0 
µM.Abbreviations: C = control, DOX = doxorubicin, hr = hour. 
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3.7 The Effect of Chronic DOX Treatment Regimes on Oxidative Stress  
 
It has been shown extensively in the literature that dyregulation of the mitochondrial 
dynamics can result in the overproduction of ROS, and induce oxidative stress within the 
cells (Frank et al., 2012; Yu et al., 2006). Furthermore, oxidative stress is a well-known 
consequence of DOX-induced cardiotoxicity. With this in mind this study employed the 
ORAC, TBARS and GSH assay to assess the antioxidant capacity, oxidative damage and the 
redox status respectively following chronic DOX treatment.   
 
3.7.1 Evaluation of Antioxidant Capacity (ORAC assay)  
 
Results from the ORAC assay indicated that the antioxidant capacity significantly increased 
following 0.2 µM DOX treatment for 96 hours [550.0 ± 5.52 µmol TE/L, (p < 0.001)] and 
120 hours [553.40 ± 1.87 µmol TE/L, (p < 0.001)] compared to the control [465.30 ± 11.47 
µmol TE/L] respectively (Figure 3.22). Antioxidant capacity remained significantly increased 
in the 1.0 µM DOX group, at both the 96 hour [543.7 ± 2.41 µmol TE/L, (p < 0.001)] and 120 
hour [500.80 ± 8.42 µmol TE/L] time points versus the control. Interestingly, a significant (p 
< 0.01) reduction in H9C2 antioxidant capacity occurred in the highest concentration group 
(1.0 µM DOX) after 120 hours of treatment compared to the same concentration group after 
96 hours of exposure. These results indicate that the cells initially try to survive under these 
harsh environmental conditions, however as the concentration of DOX increases over time 
the antioxidant capacity is reduced. This suggests that cumulative and chronic doses of DOX 
impair the cells ability to cope under conditions of oxidative stress.  
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Figure 3.22: The effect of chronic doxorubicin treatment regimes on antioxidant 
capacity in H9C2 cardiomyoblasts. Cells were treated daily with 0.2 µM and 1.0 µM DOX 
for 96 and 120 hours. Following treatment the oxygen radical absorbance capacity (ORAC) 
of each treatment group was determined with a fluorometric assay (n=3). *P < 0.05 ***P < 
0.001 vs Control. $$$P < 0.001 96 hr vs 120 hr. ###P < 0.001 0.2 µM vs 1.0 µM. Abbreviations 
– C: control, DOX: doxorubicin,  hr: hour, TE/L: Trolox equivalent per litre, vs: versus. 
3.7.2 Evaluation of Oxidative Damage (TBARS assay)  
 
MDA (Malondialdehyde) is a natural by-product of lipid peroxidation, and is used as an 
indicator for oxidative damage. Daily treatment with lower dose of DOX for 96 hours [0.20 ± 
0.014 µmol/L, (p < 0.001)] and 120 hours [0.30 ± 0.015 µmol /L, (p < 0.001)] significantly 
elevated lipid peroxidation compared to the control [0.12 ± 0.030 µmol/L] (Figure 3.23). 
Similarly, treatment with the high DOX also induced a significant increase in lipid 
peroxidation at both time points [96 hours: 0.19 ± 0.03 µmol/L, (p < 0.001) and 120 hour: 
0.13 ± 0.02 µmol/L, (p < 0.01)] compared to the control group. These results suggest that 
high cumulative dose and chronic treatment induce incremental lipid oxidative damage in a 
time and dose dependent manner.  
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Figure 3.23: The effect of chronic doxorubicin treatment regimes on lipid peroxidation 
in H9C2 cardiomyoblasts. Cells were treated daily with 0.2 µM and 1.0 µM DOX for 96 and 
120 hours. Following treatment the concentration of thiobarbituric acid reacting substance 
(TBARS) per sample was determined (n=3). ***P < 0.001 vs Control. $P < 0.05 96 hr vs 120 
hr. ###P < 0.001 0.2 µM vs 1.0 µM Abbreviations – C: control, DOX: doxorubicin,  hr: hour, 
MDA: Malondialdehyde, vs.: versus.  
 
3.7.3 Evaluation of Oxidative Status (GSH assay)  
 
Determination of reduced glutathione (GSH) to oxidized glutathione (GSSG) was assessed 
using the GSH:GSSG ratio. GSH is an important antioxidant that helps maintain the redox 
state within the cells. As indicated in Table 2, as the concentration of DOX increased over 
time [96 hour: (p < 0.001), 120 hour: (p < 0.05)], GSH levels were significantly decreased 
versus the control group [6.73 ± 0.35]. However the concentration of GSSG was statistically 
elevated following 96 hours [p < 0.001, 0.2 µM vs. 1.0] and 120 hours [p < 0.001, 0.2 µM vs. 
1.0 µM] of treatment as the dose increased, but no change in GSSG was observed at either 
time point following 1.0 µM of treatment versus the GSSG control group (Table 2). No 
changes in the GSH:GSSG ratio was observed following 96 hours of treatment with 0.2 µM 
[52.59 ± 1.14], whereas after 120 hours the ratio was significantly decreased at the 0.2 uM 
group [44.35 ± 1.78, (p < 0.01)] compared to the control [52.59 ± 1.14] (Figure 3.24). Given 
that GSH levels were reduced and no significant difference in GSSG occurred at either of the 
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1.0 µM treatment groups, the ratio was substantially reduced following 96 hours [41.81 ± 
2.02, (p < 0.01)] and 120 hours [39.99 ± 0.94, (p < 0.001)] of treatment with 1.0 µM DOX 
compared to the control. Overall, GSH:GSSH ratio progressively declined indicating an 
elevation in oxidative stress occurs in both a time- and dose- dependent manner following 
chronic treatment with DOX.  
 
Table 2: The effect of chronic DOX treatment on GSH, GSSG and the GSH/GSSG ratio 
Groups GSH (µmol/L) GSSG (µmol/L) GSH/GSSG 
Ratio 
Control  6.72 ± 0.35 0.13 ± 0.01 53.68 ± 2.31 
96 hr: 0.2 µM DOX 5.43 ± 0.12 0.10 ± 0.02 52.59 ± 1.14 
96 hr: 1.0 µM DOX 5.31 ± 0.16 0.13 ± 0.02 41.81 ± 2.02 
120 hr: 0.2 µM DOX 5.52 ± 0.26 0.11 ± 0.01 44.35 ± 1.78 
120 hr: 1.0 µM DOX  5.52 ± 0.19 0.14 ± 0.03 39.99 ± 0.94 
Abbreviations – DOX: Doxorubicin, GSH: reduced glutathione, GSSG: oxidized glutathione.  
 
 
 
 
 
 
 
 
 
Figure 3.24: The effect of chronic doxorubicin treatment regimes on GSH:GSSG ratio 
in H9C2 cardiomyoblasts. Cells were treated daily with 0.2 µM and 1.0 µM DOX for 96 and 
120 hours. Following treatment the GSH and GSSG content was determined, and the 
GSH:GSSG ratio was calculated (n=3). **P < 0.01 and ***P < 0.001 vs Control. ##P < 0.01 
0.2 µM vs 1.0 µM. $$$P < 0.001 96 hr vs 120 hr. Abbreviations – C: control, DOX: 
doxorubicin, GSH: reduced glutathione, GSSG: oxidized glutathione,  hr: hour, vs: versus  
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3.8 The Effect of Chronic DOX Treatment Regimes on the Endoplasmic Reticulum  
 
It has been established that altered mitochondrial function as well as oxidative injury, 
disrupts ER homeostasis and results in ER stress and activation of the UPR (Verfaillie et al., 
2013). Given the role that DOX plays in mediating both mitochondrial dysfunction and 
oxidative stress, it is thought that chronic DOX treatment may also induce ER stress and UPR 
activation. 
3.8.1 Evaluation of BiP Expression  
 
BiP (GRP78/Gp78), an ER-associated E3 ubiquitin ligase, is activated under conditions of 
ER Stress and regulates UPR signaling (Minamino et al., 2010). The effect of chronic DOX 
treatment on BiP expression was evaluated with western blotting (Figure 3.25). Following 0.2 
µM DOX treatment, a significant increase in BiP activity was only observed following 120 
hours [151.60 ± 6.50%, (p < 0.01)] of exposure when compared to the control (100%).  
However analysis of the 1.0 µM DOX group showed a substantial elevation in BiP 
expression following 96 hours [177.80 ± 11.32%, (p < 0.01)] and 120 hours [277.20 ± 8.34%, 
(p < 0.001)] of treatment in comparison to the control. This data demonstrates that BiP 
expression significantly increased in both a time- and dose-dependent manner.  
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Figure 3.25: The effect of chronic doxorubicin treatment regimes on BiP expression in 
H9C2 cardiomyoblasts. (A) Lane profile analysis of BiP. (B) Representative immunoblot of 
BiP. GAPDH served as the loading control. Cells were treated daily with 0.2 µM and 1.0 µM 
DOX for 96 and 120 hours (n=3). *P < 0.05, **P < 0.01 and ***P < 0.001 vs Control. ###P < 
0.001 0.2 µM vs 1.0 µM. $$$P < 0.001 96 hr vs 120 hr. Abbreviations – BiP: binding 
immunoglobulin protein,  C: control, DOX: doxorubicin, hr: hour, vs: versus.  
 
3.8.2 Evaluation of ATF4 Expression  
 
ATF4 is a UPR protein translated under conditions of mild ER Stress (Verfaillie et al., 2013). 
To examine whether chronic DOX-induced cardiotoxicity influenced ATF4 expression by 
ER stress, western blotting analysis was performed (Figure 3.26). Compared to the control 
(100%), ATF4 expression was significantly downregulated after 96 hours at both 0.2 µM 
DOX [50.82 ± 3.64%, (p < 0.001)] and 1.0 µM DOX [43.45 ± 4.77%, (p < 0.001)] 
concentration groups. Treatment for 120 hours produced no change in ATF4 expression at 
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the 0.2 µM DOX group, yet at the 1.0 µM group [76.81 ± 2.72%, (p < 0.01)] a significant 
reduction in ATF4 occurred compared to the control group.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.26: The effect of chronic doxorubicin treatment regimes on ATF4 expression 
in H9C2 cardiomyoblasts. (A) Lane profile analysis of ATF4. (B) Representative 
immunoblot of ATF4. GAPDH served as the loading control. Cells were treated daily with 0.2 
µM and 1.0 µM DOX for 96 and 120 hours (n=3). **P < 0.01 and ***P < 0.001 vs Control. #P 
< 0.05 0.2 µM vs 1.0 µM. $$P < 0.01 and $$$P < 0.001 96 hr vs 120 hr. Abbreviations – ATF4: 
activating transcription factor 4, C: control, DOX: doxorubicin, hr: hour, vs: versus. 
3.8.3 Evaluation of ER Load and DOX Localization  
 
It has previously been shown that the under conditions of ER stress and UPR activated that 
the ER expands (Minotti et al., 2004; Wang and Kaufman, 2014). Therefore ER load, an 
indicator for ER expansion, was used as an additional marker to evaluate ER stress. Results 
from flow cytometry analysis demonstrate that ER load was significantly increased after 96 
hours of treatment with 0.2 µM DOX [159.30 ± 16.53%, (p < 0.05)] and 1.0 µM DOX 
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[216.70 ± 6.74%, (p <0.001)] when compared to the control (100%) (Figure 3.27). Treatment 
with both the low dose [149.00 ± 2.81%, (p < 0.001)] and high dose [212.4 ± 7.52, (p < 
0.001)] of DOX for 120 hours also significantly increased ER load. Fluorescence imaging of 
the ER also indicates an increase in ER fluorescence in a time and dose dependent manner. 
An increase in ER mass and distribution were visualized in following DOX treatment 
compared to the normal ER observed in the control (Figure 3.28). Additionally, analysis of 
ER and DOX colocalization demonstrated that DOX is highly localized to the ER (Figure 
3.28), and area of localization continued to significantly increase over time, as the 
concentration of DOX increased (Figure 3.28 and Figure 3.29).  
 
 
 
 
 
 
 
 
 
 
Figure 3.27: The effect of chronic doxorubicin treatment regimes on ER load H9C2 
cardiomyoblasts. Cells were treated daily with 0.2 µM and 1.0 µM DOX for 96 and 120 
hours. Following treatment cell were stained with ER-tracker and mean fluorescence 
intensity was measured by flow cytometry (n=3). *P < 0.05 and ***P < 0.001 vs Control. #P < 
0.05 and ###P < 0.001 0.2 µM vs 1.0 µM. Abbreviations – C: control, DOX: doxorubicin, ER: 
endoplasmic reticulum, hr: hour, vs: versus 
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Figure 3.28: The effect of chronic doxorubicin treatment regimes on ER morphology and DOX localization in H9C2 cardiomyoblasts. Cells were 
treated daily with 0.2 and 1.0 µM DOX for 96 and 120 hours. Only 120 hour represented in image. Following treatment cells were stained ER-tracker blue and 
visualized using fluorescence microscopy (n=3). Red indicates DOX and purple indicates area of colocalization Abbreviations – DOX; doxorubicin, hr;  hour. 
Magnification = 60X. Scale Bar = 20 µm.  
DOX ER-Tracker Colocalization 
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Figure 3.29: Area of Doxorubicin and ER colocalization. H9C2 cardiomyoblasts were 
treated daily with 0.2 and 1.0 µM DOX for 96 and 120 hours, followed by staining with ER-
tracker (blue) and DOX (Red) and visualized with fluorescence microscopy (n=3). Area of 
colocalization was determined using the Cell^R analysis software. ***P< 0.001 vs. Control. 
$$$P < 0.001 96 hr vs. 120 hr. ###P < 0.001 0.2 µM vs. 1.0 µM. Abbreviations – AU: arbitrary 
units, C: control,  DOX: doxorubicin,  hr: hour., vs: versus. 
 
3.9 The Effect of Chronic DOX Treatment Regimes on Intracellular and Mitochondrial 
Calcium Levels  
 
It has been known for decades that mitochondria and the ER are tightly associated with one 
another, and both play an important role in maintaining calcium homeostasis (Marchi et al., 
2014; Grimm, 2012). Calcium is an essential component of the excitation-contraction 
coupling process, and a disruption of intracellular calcium levels has previously been 
associated with contractile dysfunction and the pathogenesis of heart failure (Rossini et al., 
1986).  Given the role ER stress, oxidative stress and mitochondrial dysfunction play in 
disrupting calcium homeostasis this study chose to investigate the effects of chronic DOX 
cardiotoxicity on calcium activity within the cells.  
 
First, this study established the effects of DOX treatment on intracellular calcium levels 
located in the cytosol using flow cytometry (Figure 3.30). Results showed that after 96 and 
Stellenbosch University  https://scholar.sun.ac.za
 84
120 hours, calcium levels were significantly upregulated in both the low [96 hour: 151.50 ± 
2.00%, (p < 0.001) and 120 hour: 197.70 ± 1.43%, (p < 0.001)] and high [96 hour: 197.70 ± 
0.50%, (p<0.001) and 120 hour: 212 ± 6.20%, (p < 0.001)] concentration groups compared to 
the control group (100%). These results were confirmed with SR-SIM, where little calcium 
was observed in the control group and an increase in intracellular calcium was visualized in 
the DOX treated groups (Figure 3.31). Furthermore, significant differences between 
concentration groups were also observed, indicating that elevated cytosolic calcium is not 
only highly dependent on duration of DOX treatment, but also on the concentration of DOX 
administrated.  
 
Since the mitochondria take up calcium when intracellular calcium levels rise in an effort to 
maintain homeostasis (Hom et al., 2007), this study next stained cells with Rhod-2 and 
assessed mitochondrial-specific calcium with SR-SIM in response to chronic DOX treatment 
(Figure 3.32). The mitochondrial calcium profile was similar to that of cytosolic, showing a 
significant increase in calcium levels over time, after treatment with 0.2 µM [96 hour: 34.69 
± 1.44 RFU, (p < 0.001) and 120 hour: 49.16 ± 3.10 RFU, (p < 0.001)] and 1.0 µM  [96 hour: 
50.90 ± 7.84 RFU, (p < 0.001) and 120 hour: 96.56 ± 6.04 RFU, (p < 0.001)] concentrations 
of DOX compared to the control [11.50 ± 0.49 RFU]. Additional evaluation showed a 
statistical difference between the treatment groups, suggesting an increase in mitochondrial 
calcium occurs also in a time- and dose-dependent manner.  
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Figure 3.30: The effect of chronic doxorubicin treatment regimes on intracellular 
calcium in H9C2 cardiomyoblasts. Cells were treated daily with 0.2 µM and 1.0 µM DOX 
for 96 and 120 hours. Following treatment H9C2 cardiomyoblasts were stained with the 
specific intracellular calcium dye, Calcium Green and mean fluorescence intensity was 
measured using flow cytometry (n=3). ***P < 0.001 vs Control. $$P < 0.01 96 hr vs 120 hr.  
###P < 0.001 0.2 µM vs 1.0 µM. Abbreviations – C: control, DOX: doxorubicin, hr: hour.  
 
Figure 3.31: Visualization of intracellular calcium following chronic DOX treatment. 
Cells were treated daily with 0.2 µM and 1.0 µM DOX for 96 and 120 hours. Following 
treatment H9C2 cardiomyoblasts were stained with the specific intracellular calcium dye, 
Calcium green and visualized with SR-SIM (n=3). Abbreviations – DOX: Doxorubicin, hr: 
hour, SR-SIM: Superresolution structured illumination microscopy, vs: versus. Magnification 
= 60X. Scale bar = 20 µm.  
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Figure 3.32: The effect of chronic doxorubicin treatment regimes on mitochondrial 
calcium in H9C2 cardiomyoblasts. Cells were treated daily with 0.2 µM and 1.0 µM DOX 
for 96 and 120 hours. Following treatment H9C2 cardiomyoblasts were stained with the 
specific mitochondrial calcium dye, Rhod-2AM and (A) Quantified and (B) Visualized using 
SR-SIM (n=3). . ***P < 0.001 vs Control. $$$P < 0.001 96 hr vs 120 hr. #P < 0.05 and ##P < 
0.01 0.2 µM vs 1.0 µM. Abbreviations -  C: control, DOX: Doxorubicin, hr: hour, SR-SIM: 
Superresolution structured illumination microscopy, vs: versus.  Magnification = 60X. Scale 
bar = 0.2 µm. 
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Chapter 4 – Discussion  
 
It has been well established that the clinical utility of DOX is compromised by its induced, 
cumulative and dose-dependent cardiotoxicity. However, given the fact that DOX remains 
one of the most effective antineoplastic agents used in oncologic practice today, the search 
for effective cardioprotective therapies is becoming increasingly relevant. Considering that 
the mitochondria are the most extensively damaged organelles under conditions of DOX-
mediated cardiomyopathy, they have become the main focus of novel therapeutic 
interventions (Doroshow, 1983; Gharanei et al., 2013; Gilliam et al., 2013). Although DOX 
is known to activate the mitochondrial death pathways by initiating apoptosis and necrosis 
(Berthiaume and Wallace, 2007; Parra et al., 2008), it is not understood why the heart’s 
response to progressive mitochondrial dysfunction is limited. Bearing in mind that the 
myocardium normally has highly effective mitochondrial quality control systems in place 
regulating mitochondrial turnover (Fischer et al., 2012), it is thought that DOX may interfere 
with the efficiency of these systems (Gharanei et al., 2013; Suliman et al., 2007). It is in light 
of these speculations that the aim of this study was to analyze the effects of chronic DOX-
induced cardiotoxicity on mitochondrial quality control, with special focus on mitochondrial 
dynamics and mitochondrial biogenesis. Additionally, since the mitochondria and ER are two 
interconnected organelles, and both play a role in maintaining calcium homeostasis, this 
study also assessed the effects of chronic DOX treatment on ER function and calcium status.  
 
Chronic DOX treatment mediates mitochondrial fragmentation through the 
downregulation of fusion proteins 
 
The tight regulation of mitochondrial dynamics through fission and fusion processes 
facilitates the maintenance of mitochondrial function, and thus are essential components of 
mitochondria quality control (Fischer et al., 2012; Westermann, 2010). Many studies have 
demonstrated that changes in mitochondrial morphology, due to an imbalance between the 
fission and fusion events within the myocardium, mediates the pathophysiology of heart 
failure (Chen and Chang, 2009; Kuzmicic et al., 2011; Marín-García et al., 2013; 
Papanicolaou et al., 2012). In addition, literature has indicated that elevated ROS production 
and oxidative stress, a known side effect of DOX treatment, regulates fission of mitochondria 
(Dagda et al., 2009; Frank et al., 2012; Minotti et al., 2004). These findings lead to the 
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hypothesis that dysregulation of mitochondrial dynamics is associated with DOX-induced 
cardiotoxicity. This study demonstrated that chronic DOX treatment induces a significant 
upregulation of DRP1 and hFis1 expression, mediators of mitochondrial fission, in a time- 
and dose-dependent manner. These results have also been observed in acute studies which 
may suggest that mitochondrial fission occurs irrespective of the treatment duration, but 
rather as a recurring effect in response to DOX treatment (Gharanei et al., 2013; Parra et al., 
2008). Furthermore the upregulation of mitochondrial fission described is consistent with the 
abnormal mitochondrial morphology observed in this study.  
 
Changes in mitochondrial morphology are regulated by fission and fusion events. Under 
normal homeostatic conditions, when the balance between mitochondrial dynamics is 
maintained, the mitochondria display a highly dense and interconnected mitochondrial 
network. However, dysregulated and unopposed mitochondrial fission results in shortened 
mitochondria and a dispersed mitochondrial network (Ong et al., 2010), which was observed 
in the DOX-treated groups of this study.  The relative increase in fragmented mitochondria 
observed correlates with the significant elevation of mitochondrial load. Taken together, 
these findings are in line with previous studies showing that elevated DRP1 and hFis1 
activity induces similar morphological changes and fragmentation of mitochondria (Frank et 
al., 2001). However to further validate the effect of DOX on mitochondrial dynamics, this 
study additionally investigated the effects of chronic DOX treatment on fusion protein 
expression.     
 
Outer mitochondrial membrane (OMM) fusion is regulated by two mitofusin proteins, Mfn 1 
and Mfn 2. Many studies conducted on Mfn1/2 knockout models have highlighted the 
importance of these two proteins in maintaining normal mitochondrial morphology and 
function. Papanicolaou and others (2012) showed that specific double knockout out of both 
mitofusins in mice resulted in the accumulation of abnormal mitochondria in the myocytes. 
While Chen and colleagues (2011b) demonstrated that cardiac specific deletion of either Mfn 
1 or Mft 2 lead to mitochondrial dysfunction and lethal dilated cardiomyopathy. Therefore, 
from the above it can be deduced that inhibition of either of these fusion proteins can have 
detrimental consequences in the myocardium. This study demonstrated a significant 
downregulation of both Mft 1 and Mft 2, which was observed throughout the duration of 
treatment with both the low (0.2 µM) and high (1.0 µM) concentration of DOX, thus 
indicating that chronic DOX treatment inhibits mitochondrial fusion in vitro. These results 
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suggest that chronic treatment with DOX disrupts the balance between fission and fusion 
events, resulting in unopposed mitochondrial fragmentation. However, the exact mechanisms 
involved in DOX-induced mitochondrial fission remains to be fully elucidated. It is thought 
that DOX may regulate nuclear transcription of pro-fission mediators, such as MARCH5.  
 
Chronic DOX treatment promotes mitochondrial fragmentation and mitophagy via the 
upregulation of mitochondrial E3 ligases 
 
MARCH5, a mitochondrial E3 ubiquitin ligase, is an important OMM protein required for the 
maintenance of mitochondrial dynamics (Nagashima et al., 2014; Yonashiro et al., 2006). 
Numerous studies have demonstrated MARCH5’s role in the regulation of mitochondrial 
morphology through its ubiquitination of hFis1, Mft 1 and Mft 2 (Karbowski et al., 2007; 
Park et al., 2010; Park et al., 2014b; Nakamura et al., 2006). Additionally, MARCH5 also 
interacts with DRP1 and is an essential component required for DRP1-mediated 
mitochondrial fragmentation (Karbowski et al., 2007). A recent study by Park and colleagues 
(2014b) demonstrated that mitochondrial stress induced MARCH5-dependent Mft 
ubiquitination and degradation, and thereby inhibited mitochondrial fusion in an attempt to 
maintain homeostasis. Given that the mitochondria are so extensively damaged by DOX, it is 
thought that MARCH5 may be involved in mediating mitochondrial fission, as indicated in 
this study. The significant decrease in both Mft1 and Mft2 expression following DOX 
treatment appears to directly correlate to the significant increase in MARCH5 expression 
observed in the same treatment groups. This is most likely due to MARCH5’s ability to 
directly bind to the mitofusins and reduce their expression levels through intensive 
ubiquitination (Park et al., 2014b). Furthermore, considering that MARCH5 also tags hFis1 
with ubiquitin moieties specific for proteasomal degradation, it is not surprising that no 
significant increase in hFis1 expression occurred following 96 hours of treatment with 1.0 
µM DOX, when MARCH5 was most prevalent. Similar to results observed by Karbowski et 
al. (2006), MARCH5 expression also appeared to correlate to the elevated DRP1 expression. 
These findings suggest that DOX not only mediates DRP1-dependent fission through 
upregulation of MARCH5, but also regulates MARCH5-dependent degradation of the 
mitofusin proteins.  
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At the organelle level, the regulation of mitochondrial dynamics is only the first line of 
defense activated to minimize mitochondrial dysfunction. Additionally, terminally damaged 
and impaired mitochondria can be selectively degraded by a specific quality control pathway, 
termed mitophagy (Frank et al., 2012; Fischer et al., 2012). Parkin is an E3 ubiquitin ligase, 
which upon translocation from the cytosol to the OMM, initiates mitophagy. There is 
mounting evidence highlighting a functional link between the regulation of both 
mitochondrial dynamics and mitophagy (Tanaka et al., 2010; Westermann, 2010). This was 
confirmed by Gegg and colleagues (2011), who recently described that PINK/Parkin-
dependent mitophagy regulates mitochondrial dynamics by rapid ubiquitination of Mfn 1 and 
Mfn 2, which was also indicated in this study. It has been hypothesized that the ubiquitination 
of the mitofusins helps promote fragmentation of damaged mitochondria for Parkin-mediated 
mitophagy (Gegg et al., 2011; Fischer et al., 2012), as does the overexpression of the pro-
fission proteins, DRP1 and hFis1 (Gomes and Scorrano, 2008; Kanki et al., 2009). Similarly 
in this study, elevated expression of DRP1 and hFis1 significantly upregulated Parkin 
expression following chronic DOX treatment with the lowest concentration of DOX. These 
levels remained elevated following 96 hours of treatment with 1.0 µM of DOX, however after 
120 hours of treatment with the highest concentration of DOX elicited no changes in Parkin 
activity. This may be brought on by the significant cell death that occurred following the 
most chronic treatment with DOX, resulting in little or no cells left to degrade. However, a 
very recent study by Morán and colleagues (2014) observed that under conditions of severe 
mitochondrial damage and oxidative stress, bulk macroautophagy was upregulated, rather 
than Parkin-mediated mitophagy, which is also consistent with the findings in this study. 
Nonetheless, mitophagy is initially upregulated in response to mitochondrial fission in order 
to assist with the removal of the damaged mitochondria induced by chronic DOX treatment.   
 
Chronic DOX treatment induces protein ubiquitination, but inhibits proteasome 
function 
 
The UPP is an important proteolytic pathway responsible for the degradation of misfolded 
protein aggregates, and as such is critical for protein turnover. A recent review by Day (2013) 
showed that dysfunction of the UPP is fast becoming associated with the pathogenesis of 
cardiac diseases, including CHF. DOX has previously been shown to disrupt normal UPP 
activity through the overactivation or inhibition of various components involved in this 
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pathway.  However, considering that contradictory evidence exists in the literature, the effect 
of chronic DOX treatment on UPP activity remains to be fully elucidated (Ito et al., 2007; 
Kiyomiya et al., 2002; Lui et al., 2008). Other than the elevated activity of the two ubiquitin 
E3 ligases already discussed, K48 ubiquitination was also significantly increased following 
chronic DOX administration, in a time- and dose- dependent manner. These results are in 
agreement with other studies who have also reported significant increases in DOX-mediated 
protein ubiquitination following treatment with the same clinically relevant doses utilized in 
this study, although different cellular models of DOX-induced cardiotoxicity were employed 
(Chen et al., 2013; Dimitrakis et al., 2012; Liu et al., 2008; Sishi et al., 2013b). Therefore 
this study confirmed that chronic DOX treatment induces an increase in polyubiquitination 
and UPP activity.  
 
Results from this study further indicate that over time different types of proteins have been 
marked for proteasomal degradation. 96 hours of treatment with DOX resulted in proteins 
with a molecular weight range of ± 50 – 130 kDa being tagged with ubiquitin molecules for 
proteasomal degradation. After 120 hours however, proteins with a relatively higher 
molecular weight range (± 100 – 245 kDa) were targeted. Given that the molecular weight of 
both mitofusin proteins (Mfn 1 and Mfn 2) and the regulator of mitochondrial biogenesis, 
PGC-1α range between 80 – 130 kDA, and MARCH5 is upregulated, which specifically tags 
these proteins, it possible that DOX induces K48 ubiquitination and subsequent degradation 
of these proteins following treatment. However, after 120 hours the ubiquitination of these 
proteins is decreased, which is most likely due to the significant reduction in their expression 
at this same time point as well as DOX’s inhibition of protein synthesis (Momparler et al., 
1976). In addition, since the molecular weights of some cardiac myofibrillar proteins, such as 
myosin and cardiac myosin binding protein-C (cMyBP-C), are known to have very high 
molecular weight (Fritz et al., 1989), the observations discussed above further imply that 
these proteins are specifically targeted for degradation during chronic treatment with DOX. 
Although this current study did not investigate the expression of MAFbx (Muscle Atrophy F-
box/Antrogin-1) and MuRF1 (Muscle RING Finger-1), the E3 ligases responsible for tagging 
myofibrillar proteins for degradation, it has been well established in the literature that DOX 
upregulates the expression of both these proteins (da Silva et al., 2012; Ranek and Wang, 
2009; Sishi et al., 2013b; Yamamoto et al., 2008). Ultimately the destruction of these 
myofibrillar proteins suggests that DOX mediates the development of myocardial remodeling 
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and cardiac dysfunction associated with chronic DOX-induced cardiotoxicity by upregulating 
the components of the UPP.  
 
Evaluation of the 26S proteasome revealed that chronic DOX treatment inhibits the activity 
of all three catalytic sites throughout duration of the study, with potent inhibition occurring 
following 1.0 µM DOX treatment. It has previously been shown that DOX binds directly to 
the proteasome in order to gain access into the nucleus, and as such high concentrations of 
DOX inhibit proteasomal activity (Kiyomiya et al., 1998; Sishi et al., 2013b). Although Liu 
and others (2008) found that clinically relevant concentrations of DOX (0.1 – 2.5 µM) 
administrated over shorter, acute time periods elevated 20S core’s catalytic activity, this was 
not the case following this study’s longer, chronic treatment times. Therefore clinically 
relevant concentrations DOX administrated chronically, strongly inhibits proteasomal protein 
degradation, blocking the flow through the UPP. Although inhibition of the proteasome 
blocks proteasomal degradation via the UPP, it does not necessarily imply that protein 
degradation is completely inhibited within the cell. Instead it suggests that the proteins 
marked for UPP degradation may be degraded by another proteolytic pathway, such as 
autophagy. 
 
Chronic DOX treatment upregulates autophagy 
 
Autophagy is another proteolytic pathway that is functionally linked to the UPP (Ding et al., 
2007). Under normal conditions the two pathways are responsible for degrading different 
types of proteins, however under conditions of cellular stress and UPP inhibition, autophagy 
has been shown to assist with the clearance and degradation of polyubiquitinated protein 
aggregates (Wang and Wang, 2014). Additionally, several studies have demonstrated that 
autophagy is activated as consequence to induced proteasome inhibition and thus aims to 
compensate for the reduced proteasomal activity (Ding et al., 2007; Dong et al., 2013; Keller 
et al., 2004; Zheng et al., 2011). Recently Kyrychenko and others (2014) showed that 
inhibition of the caspase-like catalytic activity paired together with an elevation of ER stress, 
as seen in this study, induced autophagy. Dirks-Naylor (2013) recently reviewed the effect of 
DOX treatment on regulating autophagy, and showed that DOX has been implicated in 
increasing and decreasing autophagic activity, depending on the cell model and concentration 
of DOX used. However it appears that autophagy upregulation is dependent on the 
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cumulative concentration of DOX used, rather than the duration of treatment. For example, 
results from in vitro and in vivo studies demonstrated that DOX elicited the same effect on 
autophagy after administration with a single high dose for 24 hours and multiple low doses 
over two weeks (Smuder et al., 2013; Lu et al., 2009). This study showed that chronic 
treatment with DOX induced LC3 lipidation and p62 degradation resulting in a significant 
increase autophagic activity over time. These results are similar to initial findings by Lu et al. 
(2009), who together with other researchers (Chen et al., 2011; Kobayashi et al., 2010; Xu et 
al., 2012), reported that DOX stimulated autophagy both in vitro and in vivo. Therefore this 
study confirmed that autophagy is indeed upregulated in vitro by chronic DOX 
administration.  
 
Chronic DOX treatment inhibits mitochondrial biogenesis by downregulating PGC-1α 
expression  
 
Under conditions of oxidative stress and nutrient deprivation, mitochondrial bioenergetic 
mechanisms are important for generating new mitochondria and preserving mitochondrial 
function. Mitochondrial biogenesis is tightly associated with mitophagy since these two 
processes work together in regulating cellular adaption to stress and maintaining 
mitochondrial homeostasis. The balanced interplay between these two processes is essential 
for ensuring the production of healthy mitochondria (Palikaras and Tavernarakis, 2014). 
Excessive mitophagy, as shown in this study, together with inhibited mitochondrial 
biogenesis, has previously been shown to impair mitochondrial function and contribute to 
unsolicited cell death via the activation of apoptosis (Dagda et al., 2009; Yan et al., 2012; 
Zhu et al., 2012). Since PGC-1α is a transcriptional co-activator that is essential in 
orchestrating the activity of various transcription factors associated with mitochondrial 
proliferation (Dominy et al., 2010), it is described as the “master regulator” of mitochondrial 
biogenesis (Palikaras and Tavernarakis, 2014). It is important to note that the downregulation 
of PGC-1α is not only associated with the progression of heart failure (Arany et al., 2008) but 
has also previously been shown to be exacerbated by mitochondrial dysfunction (Patten and 
Arany, 2012), oxidative stress and the loss of mitochondrial membrane potential (Sihag et al., 
2009). Since each of these characteristics are mediated by chronic DOX treatment, it is 
thought that DOX may inhibit PGC-1α expression and mitochondrial biogenesis. This study 
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showed that chronic DOX treatment progressively decreased PGC-1α expression throughout 
the duration of treatment in this in vitro model. In light of these results, and also considering 
that mitophagy and autophagy were significantly upregulated in this study, inhibition of 
mitochondrial biogenesis is most likely involved in the pathogenesis of chronic DOX-
induced cardiotoxicity.   
 
Chronic DOX treatment induces apoptotic toxicity in cardiomyoblasts 
 
Apoptosis of cardiac cells has been defined an essential process in the pathogensis of DOX-
induced cardiotoxicity (Lai et al., 2010). Similar to findings by Ueno and colleagues (2006), 
results from this study show that DOX administration induces a significant upregulation in 
cleaved caspase-3 expression, a popular marker for apoptotic cell death. However, a 
moderate decline in cleaved caspase-3 was observed following treatment with 1.0 µM of 
DOX for 120 hours. Considering that at this same time point and concentration cell viability 
remains significantly reduced compared to the control groups, could suggest that although 
caspase activity is donwregulated, caspase-independent apoptosis may be involved. p53 is a 
transcription factor that can activate apoptosis independently of the caspase cascade, via the 
activation of the pro-apoptotic factors, Bax and endonuclease G (endo G) (Amaral et al., 
2010; Li et al., 2001). Although this study did not investigate p53 activity, it has previously 
been shown that DOX induces mitochondrial apoptosis in the heart via p53 upregulation (Lai 
et al., 2010; Wang et al., 2004). It has been generally accepted that DOX-induced oxidative 
stress activates apoptotic signaling resulting in consequential cardiomyocyte apoptosis 
(Nitobe et al., 2003; Octavia et al., 2012).   
 
Chronic DOX treatment induces oxidative stress  
 
The generation of superoxide from redox cycling of DOX’s quinone moiety is known to 
initiate a series of oxidative chain reactions in the myocardium, which mediates acute and 
chronic DOX cardiotoxicity (Luo et al., 1999; Minotti et al., 2004; Xiong et al., 2006). DOX-
induced ROS production disturbs the myocardiums already low, antioxidant defenses 
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resulting in increased lipid peroxidation and compromised enzymatic defenses (Dalloz et al., 
1999; Kasapović et al., 2010; Nowak et al., 1995).  
 
DOX also induces the formation of hydrogen peroxide, which can subsequently lead to the 
formation of hydroxyl radicals. These ROS have been shown to react with lipid, protein and 
nucleic acids resulting in oxidative damage to the cardiac mitochondria (Minotti et al., 1999; 
Singal et al., 2000). Results from this study indicate that chronic DOX treatment induces 
significant lipid peroxidation, as indicated by elevated MDA levels, corresponding to results 
reported by Lai et al  (2010) and Luo et al (1999), in vivo. It is important to note that while 
lipid peroxidation is a complex process with a range of products formed in various amounts, 
the current TBARS method used has been critizied in the literature for its low specificity. 
Although it is still widely used because of the ease in performing the assay, it is 
recommended that for future studies high performance liquid chormatography (HPLC) is 
used to validate the specific MDA-TBA chromagin that is formed using the TBARS 
technique.  
 
The mitochondria have adaptive responses in place to deal with the increase in ROS 
production, although these are not sufficient as demonstrated in this study. The ORAC assay 
utilized in this study demonstrates a significant increase in H9C2’s antioxidant capacity, 
which could be a compensatory mechanism in place to protect the myoblasts against 
oxidative stress. However, despite this compensatory increase in antioxidant capacity, the 
GSH assay showed that DOX significantly reduces GSH levels, as represented by the 
decreased GSH:GSSG ratio. Significantly diminished GSH levels have also been observed in 
the brains of DOX-treated mice (Cardoso et al., 2008; Valko et al., 2007). Given that GSH is 
a crucial intracellular antioxidant and plays an important role in maintaining the redox state 
of the cells (Cardoso et al., 2008), a decrease in GSH can dyregulate GSH turnover and 
increase oxidative stress (Brechbuhl et al., 2012; Estrela et al., 2006; Jordan et al., 1987). 
This study confirms the effect of DOX on the generation of oxidative stress in the heart, as 
shown by the increased MDA levels, lipid peroxidation and inhibition of the important 
antioxidant, GSH. Oxidative stress not only alters mitochondrial function, but also disrupts 
ER homeostasis, which can have detrimental effects with the cells (Malhotra and Kaufman, 
2007).   
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Chronic DOX treatment induces ER stress and activation of the UPR 
 
The ER is responsible for the synthesis and major folding of proteins. However, ER function 
is highly sensitive to stressors that disrupt calcium homeostasis and alter intracellular 
oxidative status (Minamino et al., 2010), both of which are associated with DOX 
cardiotoxicity (Octavia et al., 2012). Perturbations in ER function result in ER stress, 
diminished protein folding capacity and subsequent accumulation of misfolded proteins. The 
UPR is thus activated in response to ER stress in order to clear unfolded/misfolded proteins 
in an attempt to restore ER homeostasis (Sano and Reed, 2013). Marked increases in BiP 
expression has been observed in patients with heart failure, suggesting that unresolved ER 
stress is most likely involved in the pathophysiology of this cardiomyopathy (Dally et al., 
2009; Minamino et al., 2010; Okada et al., 2004). Previously research by Lai et al. (2010) 
found that chronic DOX induces an increase in two ER-stress proteins, BiP and CHOP in 
vivo. In relation to these results, this study demonstrated that chronic DOX induces a 
progressive increase in BiP expression in both a time- and dose-dependent manner, 
suggesting that DOX induces ER stress and thus possibly contributes to the development 
cardiotoxicity.  BiP is also defined as an ER E3 ubiquitin ligase, which is important in 
mediating ER-associated degradation (ERAD) of misfolded proteins via the UPP. However, 
Fu et al. (2013) recently demonstrated that upon translocation to the mitochondrial 
membrane, BiP also plays a role in mediating Parkin-independent mitophagy. BiP promotes 
mitochondrial fragmentation by targeting the mitofusins for degradation.  Therefore, DOX 
not only appears to mediate mitochondrial fragmentation directly, but its effect on ER could 
promote fission via a BiP second-messenger system.  
 
The accumulation of unfolded proteins in the ER lumen ruptures BiP’s association with the 
ER stress sensors; PERK, IRE1 and ATF6. Once activated, these three transmembrane 
proteins initiate a series of downstream signaling cascades that mediate the UPR. The PERK-
elF2α-ATF4 axis regulates the transcription of proteins involved in maintaining ER 
homeostasis. These results show that DOX treatment significantly reduces ATF4 expression 
in the cardiomyoblasts. Similarly, Kim and co-workers (2005) demonstrated that DOX 
administration directly downregulated ATF4 transcription in MCF7 human breast carcinoma 
cells, interfering with the UPR. DOX has previously been shown to directly inhibit specific 
gene expression in heart cells (Ito et al., 1990), and these results confirm that DOX inhibits 
ATF4 expression.  Although this study did not investigate other UPR proteins, there is 
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evidence in the literature to suggest that during chronic DOX cardiotoxicity that gene 
transcription is inhibited 
 
One of the ultrastructural features of DOX-induced chronic cardiotoxicity is 
sacro/endoplasmic reticulum dilation (Minotti et al., 2004).  Pronounced ER dilation, also 
represented as ER load, is another marker for ER stress (Schönthal, 2012). Mammalian and 
yeast cells have shown to expand their ER volume up to 5-fold under conditions of ER stress 
and UPR activation (Bernales et al., 2006; Hartley et al., 2010; Welihinda et al., 1999). Upon 
visualization, drastic expansion of the ER was noted in the DOX treated groups, which was 
confirmed with flow cytometry analysis of ER load. These results together with the elevated 
BiP levels, confirm that chronic DOX induces ER stress and activation of the UPR. 
 
Chronic DOX treatment impairs ER and mitochondrial calcium handling, disrupting 
calcium homeostasis 
 
It has been well established in the literature that the cross talk between the mitochondria and 
ER are involved in maintaining calcium homeostasis (Dorn and Maack, 2013; Marchi et al., 
2014). Considering that the ER is the main source of intracellular calcium, and the 
mitochondria require calcium in order to modulate various physiological responses, it is 
essential that the ER-mitochondrial interface be maintained (Brookes et al., 2004; Marchi et 
al., 2014). However, under conditions of DOX-induced cardiotoxicity, calcium homeostasis 
is disrupted (Octavia et al., 2012; Saeki et al., 2002).  In this current study, chronic DOX 
administration resulted in progressive elevation in both intracellular and mitochondrial 
calcium over time. Chronic DOX treatment has been known to elicit similar effects on 
calcium levels in the heart before, however these results were demonstrated in vivo (Lebrecht 
et al., 2010; Saeki et al., 2002). Furthermore, colocalization analysis from this study revealed 
that DOX has a high affinity with the ER, compared to that of the mitochondria. This is most 
likely due to DOX interactions with the cardiac ER RyR channels. DOX binds to and 
prevents closing of the RyR channels and as result, calcium leaks uncontrollably from the ER 
lumen into the cytosol causing elevated intracellular calcium and ER stress (Pessah et al., 
1990; Saeki et al., 2002). As consequence the mitochondria increase their calcium uptake in 
an attempt to restore homeostasis, overwhelming the mitochondrial matrix. Excessive 
calcium within the mitochondria is followed by mitochondrial fragmentation, ROS 
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production and apoptosis (Marchi et al., 2014; Dorn, 2013; Hom et al., 2010). Disruption of 
calcium signaling within the myocardium can also have serious implications on cardiac 
contraction considering calcium is a vital component of excitation-contraction coupling 
(ECC) (Dedkova and Blatter, 2013).  
 
Conclusion 
 
The results from the present study demonstrate that chronic DOX treatment disrupts the 
balance of mitochondrial dynamics, resulting in unopposed mitochondrial fission and 
fragmented mitochondrial networks. Since unregulated mitochondrial fission is a hallmark 
associated with heart failure, these results suggest that DOX mediates mitochondrial 
dysfunction and cardiotoxicity by stimulating fission. Furthermore this study identified that 
the observed degradation of the mitochondrial fusion proteins, Mfn 1 and Mfn 2, was 
mediated by the activation of the mitochondrial E3 ligases, MARCH5 and Parkin. These 
results, together with the elevated K48-specific ubiquitination, suggest that chronic DOX 
treatment mediates mitochondrial fission through the UPP.  However, DOX inhibited 26S 
proteasomal activity, proposing that ubiquitin-tagged proteins targeted for proteasomal 
degradation were redirected and degraded by autophagy, which was significantly upregulated 
following chronic DOX treatment.  
 
Mitophagy is a select form of mitochondrial autophagy and regulated by Parkin. Therefore 
the UPP not only plays a role in regulating mitochondrial fission following DOX treatment, 
but also mitophagy. Mitophagy activation helps maintain a healthy mitochondrial population 
and as such, is an important component required for mitochondrial QC. However, excessive 
mitophagy in the absence of mitochondrial biogenesis, which was evident following chronic 
DOX administration, is known to contribute to mitochondrial dysfunction and cell death, and 
has also been implicated in the pathogenesis of many cardiovascular diseases (Kubli and 
Gustafsson, 2012; Marechal et al., 2011; Palikaras and Tavernarakis, 2014). Therefore 
chronic DOX treatment not only mediates mitochondrial fission and mitophagy, it also 
inhibits mitochondrial biogenesis.  
 
Results from this study further indicate that chronic DOX induces oxidative stress and this 
condition may have played a critical role in the augmentation of intracellular calcium levels. 
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It has been well-established in the literature that the ER is extremely sensitive to changes in 
redox status and cytosolic calcium dysregulation, and it is therefore not surprising that during 
chronic DOX treatment ER stress is induced and as a consequence to this, the UPR is 
activated. Moreover, the elevated cytosolic calcium levels appear to prompt the 
mitochondria, which are in close proximity to the ER, to take up the excess calcium in an 
attempt to restore calcium homeostasis. This resulted in a significant increase in 
mitochondrial calcium, which was observed following treatment. However it has been 
previously shown that excessive uptake of calcium by mitochondrial disrupts the 
mitochondrial membrane potential, which triggers mitochondrial fission and apoptosis (Otera 
and Mikara; 2012; Pletjushkina et al., 2006), both of which were increased following 
treatment.  
 
Although DOX is known to induce oxidative damage within the cells, treatment with 
antioxidant agents in an attempt to reduce ROS production have been unsuccessful in the 
clinical setting. This suggests that intervention therapies should focus instead on the 
molecular and cellular mechanisms which mediate DOX-induced ROS production and 
mitochondrial damage. For the first time, results from this study demonstrate that the chronic 
administration of DOX mediates mitochondria fission via the activation of the mitochondrial 
E3 ligases (MARCH5 and Parkin), and therefore provides fundamental insight into the 
molecular mechanisms involved in regulating the mitochondrial dysfunction associated with 
chronic DOX-induced cardiotoxicity. A unifying image of this study’s findings is provided in 
Figure 4.1. Therapeutic agents directed towards inhibiting mitochondrial fission, through the 
regulation of mitochondrial E3 ligases activity, and restoration to ER function and calcium 
homeostasis, in an attempt to restore mitochondrial dynamics may provide cardioprotection 
against chronic DOX-induced cardiotoxicity. These findings warrant further investigations in 
the relevant animal models before specific intervention therapies can be explored. 
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Figure 4.1: A unifying image of the molecular mechanisms involved in regulating 
mitochondrial dysfunction associated with chronic DOX-induced cardiotoxicity. (1) DOX 
activates the E3 ligases, Parkin & MARCH5, ultimately disrupting the balance of mitochondrial 
dynamics, resulting in unopposed mitochondrial fission & mitophagy. (2) DOX-induced oxidative 
stress triggering ER stress & increases intracellular calcium. Calcium is taken up by the 
mitochondria, further contributing mitochondrial fission. (3) DOX inhibits PGC-1α expression 
thereby impairing mitochondrial biogenesis. All these effects cumulate resulting in mitochondrial 
dysfunction which contributes to  the progression of cardiotoxicity. Abbreviations – ↑: Increase,  ↓: 
decrease,  DOX: doxorubicin, Drp1: dynamin-related protein 1, E3: ubiquitin ligase protein, ER: 
endoplasmic reticulum; hFis1: mitochondrial fission protein 1, MARCH5: mitochondrial ubiquitin 
ligase, Mfn 1/2: mitofusin 1/2 protein, PGC-1α: peroxisome proliferator-activated receptor gamma 
coactivator 1-alpha 
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APPENDIX A – Supplementary  Data  
 
The following results were obtained from experiments conducted on the second, in vitro 
cardiac cell line; the human-derived Girardi heart cells.  
 
The Effect of Chronic DOX Treatment Regimes on Mitochondrial Dynamics  
 
Evaluation of Mitochondrial Fission   
 
In order to establish the effect of chronic DOX treatment regimes on mitochondrial fission in 
human-derived Girardi heart cells, western blotting assessed the expression Drp1 and hFis1. 
No significant increase in Drp1 expression was observed following treatment with the lowest 
concentration of DOX after 96 hours. However treatment with the highest dose of DOX 
induced a significant increase in Drp1 expression [181.30 ± 10.51%, (p < 0.01)] when 
compared to the control (100%) (Figure 5.1). Following 120 hours of exposure, DOX 
induced an even greater incremental increase in Drp1 at both the 0.2 µM [171.40 ± 12.21%, 
(p < 0.05)] and 1.0 µM [246.70 ± 14,17%, (p < 0.01)]. No significant change in hFis1 
expression was observed in the Girardi cells following treatment (Figure 5.2). These results 
demonstrate that chronic DOX treatment increases Drp1-mediated mitochondrial fission in a 
time- and dose-dependent manner. 
Evaluation of Mitochondrial Fusion  
 
In contrast to results obtained in the H9C2 cardiomyoblasts, a significant increase in Mfn 1 
expression occurred following 120 hours treatment in the Girardi cells [0.2 µM: 173.00 ± 
1.99%, (p < 0.01) and 1.0 µM: 135.80 ± 7.89%, (p < 0.05) compared to the control group 
(100%) (Figure 5.3). Further analysis of Mfn 1 expression within concentration groups 
demonstrated that protein levels substantially increased over time, suggesting that cumulative 
DOX treatment elevates Mfn 1 expression. However, Mfn 2 expression was significantly 
reduced in both a time- and dose- dependent manner (Figure 5.4). These results demonstrate 
that the Girardi cells are still able to try maintain mitochondrial dynamics in the presence of 
chronic DOX treatment via the upregulation of Mfn 1, but mitochondrial fusion requires the 
assembling activities of both Mfn 1 and Mfn 2 (Papanicolaou et al., 2012). Therefore similar 
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to the H9C2 cardiomyoblasts, these results together with the significant increase in Drp1 
expression suggest chronic DOX treatment in Girardi cells also disrupts mitochondrial 
dynamics.  
 
 
Figure 5.1: The effect of chronic doxorubicin treatment regimes on Drp1 expression in 
human-derived Girardi heart cells. (A) Lane profile analysis of Drp1. (B) Representative 
immunoblot of Drp1. TOMM20 served as the loading control. Girardi cells were treated daily 
with 0.2 and 1.0 µM DOX for 96 and 120 hours. Results are presented as mean ± SEM 
(n=3). *P < 0.05 and ***P< 0.001 vs. Control. $P < 0.05 and $$$P < 0.001 96 hr vs. 120 hr. ##P 
< 0.01 and ###P < 0.001 0.2 µM vs. 1.0 µM. Abbreviations – C: control, DOX: doxorubicin, 
Drp1: dynamin-related protein 1, hr: hour, vs: versus. 
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Figure 5.2: The effect of chronic doxorubicin treatment regimes on hFis1 expression 
in human-derived Girardi heart cells. (A) Lane profile analysis of hFis1. (B) 
Representative immunoblot of hFis1. TOMM20 served as the loading control. Girardi cells 
were treated daily with 0.2 and 1.0 µM DOX for 96 and 120 hours. Results are presented as 
mean ± SEM (n=3). $P < 0.51 96 hr vs. 120 hr. Abbreviations – C: control, DOX: doxorubicin, 
hFis1: mitochondrial fission factor 1, hr: hour, vs: versus 
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Figure 5.3: The effect of chronic doxorubicin treatment regimes on Mitofusin 1 
expression in human-derived Girardi heart cells. (A) Lane profile analysis of Mitofusin 1. 
(B) Representative immunoblot of Mitofusin 1 TOMM20 served as the loading control. 
Girardi cells were treated daily with 0.2 and 1.0 µM DOX for 96 and 120 hours. Results are 
presented as mean ± SEM (n=3). **P < 0.01 and  ***P< 0.001 vs. Control. $$P < 0.01 and 
$$$P < 0.001 96 hr vs. 120 hr. ##P < 0.01 0.2 µM vs. 1.0 µM. Abbreviations – C: control, DOX: 
doxorubicin, hr: hour,  vs: versus. 
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Figure 5.4: The effect of chronic doxorubicin treatment regimes on Mitofusin 2 
expression in human-derived Girardi heart cells. (A) Lane profile analysis of Mitofusin 2. 
(B) Representative immunoblot of Mitofusin 2. TOMM20 served as the loading control. 
Girardi cells were treated daily with 0.2 µM and 1.0 µM DOX for 96 and 120 hours. Results 
are presented as mean ± SEM (n=3). *P < 0.05  and ***P< 0.001 vs. Control. #P < 0.05 0.2 
µM vs 1.0 µM.  Abbreviations – C: control, DOX: doxorubicin, hr: hour, vs: versus. 
 
 Evaluation of Mitochondrial Morphology  
 
In order to establish whether chronic DOX treatment induced any changes in mitochondrial 
morphology, cells where stained as previously described with MitoTracker green and 
visualized with fluorescence microscopy. However, since the Girardi cells were extremely 
sensitive to DOX with a high rate of cell death, not enough cells could be visualized on the 
small area of the 8-well chamber slide. Furthermore, those cells that were either in the control 
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group and/or did survive, did not provide adequate images where mitochondrial morphology 
could be assessed. Therefore colocalization of DOX with the mitochondria could not be 
performed on the Girardi cells.  Mitochondrial load was rather used to determine the number 
of mitochondria present following chronic DOX treatment (Figure 5.5). Cells were again 
stained with MitoTracker green and analyzed by flow cytometry. Following 1.0 µM DOX 
treatment significant increased in fluorescence at the 96 hour [117.40 ± 10.05%,  (p < 0.05)] 
and 120 hour [291.70 ± 31.24%,  (p < 0.01)] time points in comparison to the control (100%). 
As the mitochondria become more fragmented, mitochondrial load increases. Therefore these 
results suggest that mitochondrial fission increases following DOX treatment, in a time- and 
dose- dependent manner. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.5: The effect of chronic doxorubicin treatment regimes on mitochondrial load 
in human-derived Girardi heart cells. Girardi cells were treated daily with 0.2 and 1.0 µM 
DOX for 96 and 120 hours, followed by staining with MitoTracker Green and assessed using 
flow cytometry (n=3). *P < 0.05 and **P< 0.01 vs. Control. ##P < 0.01 0.2 µM vs. 1.0 µM. 
Abbreviations – C: control,  DOX: doxorubicin,  hr: hour., vs: versus. 
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The Effect of Chronic DOX Treatment Regimes on the Ubiquitin Proteasome Pathway   
 
Evaluation of E3 ligase expression  
 
Evaluation of the E3 ligase, MARCH5 expression in Girardi cells was assessed with western 
blotting. MARCH5 expression was demonstrated to be significantly elevated following 
chronic DOX treatment. Although no significance was obtained in the low concentration 
group following 96 hours [140.80 ± 14.37%], treatment with the highest concentration of 
DOX significantly increased MARCH5 expression [211.60 ± 8.63%, (p < 0.01)] at the same 
time point compared to the control (100%) (Figure 5.6). Similarly, further analysis showed 
that following 120 hours of treatment, MARCH5 was significantly elevated as the 
concentration DOX increased [0.2 µM: 173.50 ± 2.92%, (p < 0.01) and 1.0 µM: 220.00 ± 
9.01%, (p < 0.01)].  
 
Since mitochondrial fission activates mitophagy, mitophagic activity following chronic DOX 
treatment was also assessed. The expression of the E3 ubiquitin ligase, Parkin was used as a 
marker for mitophagy and evaluated with western blotting (Figure 5.7). Although Parkin 
expression was initially statistically upregulated following 96 hours treatment with the lowest 
dose of DOX [146.30 ± 7.92%, (p < 0.01)] versus the control group (100%), additional 
analysis between groups demonstrated that Parkin expression was significantly 
downregulated as the concentration of DOX increased [0.2 µM: 146.30 ± 7.92% and 1.0 µM: 
77.94 ± 6.02%, (p < 0.001 0.2 µM vs. 1.0 µM)]. Conversely, following 120 hours of 
treatment, Parkin expression remained elevated at the low [112.90 ± 3.92%, (p < 0.05)] and 
high [128.50 ± 0.99%, (p < 0.001)] concentration group compared to the control, and was 
significantly upregulated in a dose-dependent manner (p < 0.05). These results suggest that 
mitophagic activity is dependent on the cumulative, concentration of DOX rather that 
treatment time.  Mitophagy activity was extremely sporadic in the Girardi cell model, 
compared to results obtained in the H9C2 cardiomyoblasts.  
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Figure 5.6: The effect of chronic doxorubicin treatment regimes on MARCH5 
expression in human-derived Girardi heart cells. (A) Lane profile analysis of MARCH5. 
(B) Representative immunoblot of MARCH5. GAPDH served as the loading control. Girardi 
cells were treated daily with 0.2 µM and 1.0 µM DOX for 96 and 120 hours. Results are 
presented as mean ± SEM (n=3). ***P< 0.001 vs Control. ##P < 0.01 0.2 µM vs 1.0 µM.  
Abbreviations – C: control, DOX: Doxorubicin, hr: hour, MARCH5: membrane-associated 
RING finger 5, vs: versus.  
 
 
 
Stellenbosch University  https://scholar.sun.ac.za
 150
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.7: The effect of chronic doxorubicin treatment regimes on Parkin expression 
in human-derived Girardi heart cells. (A) Lane profile analysis of Parkin. (B) 
Representative immunoblot of Parkin. GAPDH served as the loading control. Girardi cells 
were treated daily with 0.2 µM and 1.0 µM DOX for 96 and 120 hours. Results are presented 
as mean ± SEM (n=3). *P < 0.05, **P < 0.01 and ***P< 0.001 vs Control. $P < 0.05 and  $$$P 
< 0.001 96 hr vs 120 hr. #P < 0.05 and  ###P < 0.001 0.2 µM vs 1.0 µM. Abbreviations – C: 
control, DOX: Doxorubicin, hr: hour, vs: versus. 
  
Evaluation of K48 Protein Ubiquitination 
 
The K48 ubiquitin antibody detects proteins with have been tagged with polyubiquitin chains, 
and targeted for proteasomal degradation. K48 ubiquitination was significantly increased at 
the 0.2 µM [130.30 ± 2.26%, (p < 0.01)] and 1.0 µM [172.80 ± 7.25%, (p < 0.001)] 
concentration groups following 96 hours of treatment compared to the control group (100%) 
(Figure 5.8a).  However after 120 hours of treatment, elevated ubiquitination was only 
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observed in the 1.0 µM group [127.30 ± 1.45%, (p < 0.001)] versus the control. Analysis 
within concentration groups demonstrated that over time, K48 ubiquitination was 
significantly reduced (p < 0.001), which is opposite to the augmented ubiquitination observed 
over time in the H9C2 model (Figure 3.14, pg. 62). Additionally, as seen in the representative 
immunoblot image (Figure 5.8b), a difference in protein tagging was observed across the two 
concentration groups. Low concentrations of DOX resulted tagging of proteins with the 
molecular weight of ±63 kDa and 130 – 245 kDa. Whereas treatment with the higher 
concentrations of DOX resulted in reduced ubiquitination over time of proteins with a 
relatively higher molecular weight range, which is suggestive of myofibrillar protein 
targeting.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.8:  The effect of chronic doxorubicin treatment regimes on K48 ubiquitination 
in human-derived Girardi heart cells. (A) Lane profile analysis of K48 Ubiquitin. (B) 
Representative immunoblot of K48 ubiquitination. GAPDH served as the loading control. 
Girardi cells were treated daily with 0.2 µM and 1.0 µM DOX for 96 and 120 hours. Results 
are presented as mean ± SEM (n=3). **P < 0.01 and ***P< 0.001 vs Control. $$$P < 0.001 96 
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hr vs 120 hr. ##P < 0.01 and  ###P < 0.001 0.2 µM vs 1.0 µM Abbreviations – C: control, DOX: 
doxorubicin, hr: hour, vs: versus.  
 
Evaluation of the 26S Proteasome    
 
Chronic DOX treatment significantly reduced the activity of all three catalytic sites over time 
as the concentration of DOX increased relative to the controls (100%). However, the activity 
of both the chymotrypsin-like site (Figure 5.9), and the trypsin-like site (Figure 3.10) 
significantly increased after 120 hours at the 0.2 µM concentration compared to their 
respective activity following 96 hours of treatment with the same concentration (p < 0.01) 
and (p < 0.05). Caspase-like activity was initially elevated [125.60 ± 8.40%, (p < 0.05)] 
following treatment with the lower dose of DOX for 96 hours compared to the control, and 
significantly reduced following 120 hours [90.93 ± 3.66%, (p < 0.001 0.2 µM vs. 1.0 µM)] 
(Figure 5.11). Although proteasome activity was also inhibited in the H9C2 cells after 
treatment, inhibition was more pronounced in the Girardi heart cells. These results further 
demonstrate the heightened Girardi cell sensitivity to DOX treatment.   
 
 
Figure 5.9:  The effect of chronic doxorubicin treatment regimes on chymotrypsin-like 
catalytic activity in human-derived Girardi heart cells. Girardi cells were treated daily 
with 0.2 µM and 1.0 µM DOX for 96 and 120 hours. Results are presented as mean ± SEM 
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(n=3). **P < 0.01 and ***P< 0.001 vs Control. $$P < 0.01 96 hr vs 120 hr. ###P < 0.001 0.2 µM 
vs 1.0 µM. Abbreviations – C: control, DOX: doxorubicin, hr: hour, vs: versus.  
 
Figure 5.10:  The effect of chronic doxorubicin treatment regimes on trypsin-like 
catalytic activity in human-derived Girardi heart cells. Girardi cells were treated daily 
with 0.2 µM and 1.0 µM DOX for 96 and 120 hours. Results are presented as mean ± SEM 
(n=3). ***P< 0.001 vs Control. $P < 0.05 and  $$P < 0.01 96 hr vs 120 hr. ###P < 0.001 0.2 µM 
vs 1.0 µM. Abbreviations: C: control, DOX: doxorubicin, hr: hour., vs.: versus. 
 
 
 
 
 
 
 
 
 
Figure 5.11:  The effect of chronic doxorubicin treatment regimes on caspase-like 
catalytic activity in human-derived Girardi heart cells. Girardi cells were treated daily 
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with 0.2 µM and 1.0 µM DOX for 96 and 120 hours. Results are presented as mean ± SEM 
(n=3). ***P < 0.001 vs Control. $$$P < 0.001 96 hr vs 120 hr. ###P < 0.001 0.2 µM vs 1.0 µM. 
Abbreviations – C: control, DOX: doxorubicin, hr: hour, vs: versus.  
 
The Effect of Chronic DOX Treatment Regimes on Autophagy 
 
Following chronic DOX treatment, the expression of the two biomarkers for the autophagic, 
LC-3 (Figure 5.12) and p62 (Figure 5.13), were assessed by western blotting. As mentioned 
earlier, there are many accepted methods in which LC3 expression can be interpreted and this 
study chose to analyze the LC3-II/LC3-I ratio (Figure 5.12). LC3 lipidation was significantly 
reduced over time following treatment with 0.2 µM DOX [45.42 ± 2.16%, (p < 0.01 96 hr vs. 
120 hr)]. However following treatment with 1.0 µM DOX, LC3 lipidation was significantly 
elevated after 96 hours [113.30 ± 6.23%, (p < 0.05)] and 120 hours [120.20 ± 3.55%, (p < 
0.05)] of treatment in comparison to the control (100%). These results demonstrated that flux 
through the autophagic pathway is dependent on both the concentration of DOX 
administrated and the treatment duration. Low, chronic DOX administration significantly 
reduced LC3 lipidation, while high, chronic DOX treatment augmented autophagy. These 
results are different to those observed in the H9C2 cardiomyoblasts, where LC3 lipidation 
incrementally increased in a time- and dose- dependent manner.  P62 promotes the formation 
of protein aggregates, and directs them to the autophagosome through its interactions with 
LC3.  
 
Thereafter p62, along with the targeted and defective cargo are engulfed and subsequently 
degraded by the autophagolysosome (Ichimura et al., 2008). Since LC3 lipidation was 
previously shown to be inhibited with low, chronic administration of DOX, it is not 
surprising that p62 significantly accumulated over time following treatment with 0.2 µM [96 
hrs.: 75.00 ± 0.93% and 120 hrs.: 116.70 ± 5.77%, (p < 0.01 96 hr vs. 120 hr)]. However 
following high, chronic DOX administration p62 continued to accumulate, and a significant 
increase in protein expression was observed following 120 hours [112.30 ± 2.39%, (p < 0.01 
vs. Control)]. It is important to note that even though p62 accumulated over time, p62 
expression was initially downregulated after 96 hours of treatment [0.2 µM: 75.00 ± 0.93%, 
(p < 0.01) and 1.0 µM: 38.92 ± 5.78%, (p < 0.001)] compared to the control.  
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Figure 5.12: The effect of chronic doxorubicin treatment regimes on LC3 expression 
in human-derived Girardi heart cells. (A) Lane profile analysis of LC3-II/LC3-Ratio. (B) 
Representative immunoblot of LC3-I and LC3-II. GAPDH served as the loading control. 
Girardi cells were treated daily with 0.2 µM and 1.0 µM DOX for 96 and 120 hours. Results 
are presented as mean ± SEM (n=3). **P < 0.05 and ***P < 0.01 vs Control. $P < 0.05 and 
$$$P < 0.001 96 hr vs 120 hr. #P < 0.05 and  ###P < 0.001 0.2 µM vs 1.0 µM. Abbreviations – 
C: control, DOX: doxorubicin, hr: hour, LC3: microtubule –associated protein light chain 3, 
vs.: versus. 
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Figure 5.13:  The effect of chronic doxorubicin treatment regimes on p62 expression 
in human-derived Girardi heart cells. (A) Lane profile analysis of p62. (B) Representative 
immunoblot of p62. GAPDH served as the loading control. Girardi cells were treated daily 
with 0.2 µM and 1.0 µM DOX for 96 and 120 hours. Results are presented as mean ± SEM 
(n=3). **P < 0.01 and ***P < 0.001 vs Control. $$$P < 0.001 96 hr vs 120 hr. ### P < 0.001 0.2 
µM vs 1.0 µM.  Abbreviations – C: control, DOX: doxorubicin, hr: hour, vs.: versus.   
 
The Effect of Chronic DOX Treatment Regimes on Mitochondrial Biogenesis  
 
Western blotting was used to assess the transcription factor, PGC-1α (peroxisome 
proliferator-activated receptor gammer co-activator 1-alpha), an important protein involved 
in regulating mitochondrial biogenesis. PGC-1α controls the synthesis of new mitochondrial 
by coordinating the transcription of both the mitochondrial and nuclear genomes (Baker et 
al., 2007; Puigserver et al., 1998). Compared to the control group (100%), PGC-1α  
expression was significantly downregulated following 96 hours of with 0.2 µM DOX [31.61 
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± 3.02%, (p < 0.001)]. However no significant difference was observed at the 1.0 µM group 
at the same time point [80.12 ± 4.46%]. Following 120 hours of treatment results obtained 
demonstrated that PGC-1α levels were significantly downregulated at both the low [41.69 ± 
6.67%,  (p < 0.001)] and high [48.40 ± 3.24%, (p < 0.001)] concentration groups (Figure 
5.14).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.14: The effect of chronic doxorubicin treatment regimes on PGC-1α 
expression in human-derived Girardi heart cells. (A) Lane profile analysis of PGC-1α. (B) 
Representative immunoblot of PGC-1α. GAPDH served as the loading control. Girardi cells 
were treated daily with 0.2 µM and 1.0 µM DOX for 96 and 120 hours. Results are presented 
as mean ± SEM (n=3). ***P < 0.001 vs Control. $$$P < 0.001 96 hr vs 120 hr.  ##P < 0.01 0.2 
µM vs 1.0 µM. Abbreviations – C: control, DOX: Doxorubicin, hr: hour, PGC-1α: peroxisome 
proliferator-activated receptor gamma co-activator 1-alpha, vs: versus.   
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The Effect of Chronic DOX Treatment Regimes on Apoptosis 
 
In order to further validate the results obtained from the Caspase-Glo 3/7 Assay, the 
expression of cleaved-caspase 3 was analyzed with immunoblotting (Figure 5.15). As seen in 
the results from the Caspase-Glo assay, caspase 3 cleavage was elevated in the 0.2 µM group 
following both 96 hours [102.00 ± 1.76%] and 120 hours [122.30 ± 3.36%] of treatment, 
although no significance was observed when compared to the control (100%). However, as 
the treatment duration increased, a significant reduction in caspase cleavage was observed at 
both the low [86.28 ± 5.76%,  (p < 0.01 96 hr vs. 120 hr.] and high [91.73 ± 4.50%, (p < 0.01 
96 hr vs. 120 hr], which further corresponds to the results obtained from the Caspase-Glo 
assay. These results suggest that apoptosis decreases over time as the concentration of DOX 
increases. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.15: The effect of chronic doxorubicin treatment regimes on apoptosis in 
human-derived Girardi heart cells. Girardi cells were treated daily with 0.2 µM and 1.0 
µM DOX for 96 and 120 hours. Results are presented as mean ± SEM (n=3). ◊P< 0.001. 
Abbreviations: C = control, DOX = doxorubicin, hr = hour. 
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The Effect of Chronic DOX Treatment Regimes on Oxidative Stress  
 
Evaluation of Antioxidant Capacity (ORAC assay)  
 
Results from the ORAC assay indicated that the antioxidant capacity was significantly 
increased following 0.2 µM DOX treatment for 96 hours [488.90 ± 2.07 µmol TE/L, (p < 
0.001)] and 120 hours [456.40 ± 1.30 µmol TE/L, (p < 0.001)] compared to the control 
[260.50 ± 18.65 µmol TE/L] respectively (Figure 5.16). However, following 120 hours of 
treatment antioxidant capacity was significantly reduced compared to the same concentration 
group after 96 hours of exposure [0.2 µM: 267.70 ± 6.97 µmol TE/L and 1.0 µM: 218.00 ± 
7.29 µmol TE/L, (p < 0.001 96 hr vs. 120 hr)]. These results indicate that although cells 
initially try to survive under these harsh environmental conditions, as the concentration of 
DOX increases over time the antioxidant capacity is severely diminished. This suggests that 
cumulative and chronic doses of DOX impair the cells ability to cope under conditions of 
oxidative stress.  
 
 
 
 
 
 
 
 
 
 
Figure 5.16: The effect of chronic doxorubicin treatment regimes on antioxidant 
capacity in H9C2 cardiomyoblasts. Cells were treated daily with 0.2 µM and 1.0 µM DOX 
for 96 and 120 hours. Following treatment the oxygen radical absorbance capacity (ORAC) 
of each treatment group was determined with a fluorometric assay (n=3). ***P < 0.001 vs 
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Control. $$$P < 0.001 96 hr vs 120 hr. Abbreviations – C: control, DOX: doxorubicin,  hr: 
hour, TE/L: Trolox equivalent per litre, vs: versus. 
 
Evaluation of Oxidative Damage (TBARS assay)  
 
MDH is a natural by-product of lipid peroxidation, and is used as an indicator for oxidative 
damage. Lipid peroxidation was significantly reduced following treatment with 0.2 µM DOX 
for 96 hours [0.71 ± 0.05 µmol/L, (p < 0.01)] in comparison to the untreated control [1.33 ± 
0.09 µmol/L] (Figure 5.17). No significance difference was however observed following 1.0 
µM at the same time point [1.30 ± 0.16 µmol/L]. Treatment with the high DOX also induced 
no lipid peroxidation, and significance was only observed following 120 hours [0.61 ± 0.07 
µmol/L, (p < 0.001)] compared to the control group. These results suggest DOX induces no 
lipid peroxidation or oxidative damage within the Girardi heart cells.   
 
 
 
 
 
 
 
 
 
 
 
Figure 5.17: The effect of chronic doxorubicin treatment regimes on lipid peroxidation 
in human-derived Girardi heart cells. Girardi cells were treated daily with 0.2 µM and 1.0 
µM DOX for 96 and 120 hours. Following treatment the concentration of thiobarbituric acid 
reacting substance (TBARS) per sample was determined (n=3). **P < 0.01 and ***P < 0.001 
vs Control. $P < 0.05 and $$$P < 0.001 96 hr vs 120 hr. ###P < 0.001 0.2 µM vs 1.0 µM 
Abbreviations – C: control, DOX: doxorubicin,  hr: hour, MDA: Malondialdehyde, vs.: versus.  
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Evaluation of Oxidative Status (GSH assay)  
 
Determination of reduced glutathione (GSH) to oxidized glutathione (GSSG) was assessed 
using the GSH:GSSG ratio. This assay could not be performed successfully in the Girardi 
heart cells. For reasons unknown the results from the assay yielded negative results, which 
could not be statistically analyzed.  
 
The Effect of Chronic DOX Treatment Regimes on the Endoplasmic Reticulum  
 
Evaluation of BiP Expression  
 
BiP is an ER-associated E3 ubiquitin ligase, which is activated under conditions of ER Stress 
and regulates UPR signaling (Minamino et al., 2010). The effect of chronic DOX treatment 
on BiP expression was evaluated with western blotting (Figure 5.18). Following 96 hours of 
treatment with 0.2 µM DOX [] and 1.0 µM DOX [] BiP expression progressively decreased 
compared to the untreated control (100%). However, after 120 hours BiP expression 
moderately elevated at both concentration groups (p < 0.001 96 hr vs. 120 hr), with 
significance observed only in the 0.2 µM DOX group [119.00 ± 6.08%, (p < 0.05)] in 
comparison to the control.  Since BiP is not activated after 96 hours treatment suggests that 
no ER stress has been induced by DOX.  Yet following the most chronic treatment with 
DOX, BiP expression is significantly upregulated thereby suggesting ER stress is produced 
under conditions of chronic-DOX induced cardiotoxicity.   
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Figure 5.18: The effect of chronic doxorubicin treatment regimes on BiP expression in 
human-derived Girardi heart cells. (A) Lane profile analysis of BiP. (B) Representative 
immunoblot of BiP. GAPDH served as the loading control. Girardi cells were treated daily 
with 0.2 µM and 1.0 µM DOX for 96 and 120 hours (n=3). *P < 0.05, **P < 0.01 and ***P < 
0.001 vs Control. $$$P < 0.001 96 hr vs 120 hr. ###P < 0.001 0.2 µM vs 1.0 µM. Abbreviations 
– BiP: binding immunoglobulin protein,  C: control, DOX: doxorubicin, hr: hour, vs: versus.  
 
Evaluation of ATF4 Expression  
 
ATF4 downstream UPR protein activated via the PERK-elF2α-ATF4 axis of the UPR 
pathway. To examine whether chronic DOX-induced cardiotoxicity influenced ATF4 
expression by ER stress, western blotting analysis was performed (Figure 5.19). Compared to 
the control (100%), relatively no change in ATF expression was observed following 
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treatment. Except for treatment with the most cumulative, chronic concentration of DOX, 
which significantly reduced ATF4 expression in comparison to the control [62.10 ± 5.23%, 
(p < 0.001)]. In addition, the evaluation of ATF4 expression between groups demonstrated 
that after 120 hours of treatment, ATF4 was significantly reduced as the concentration of 
DOX increased (p < 0.01). These results are similar to those observed in the H9C2 
cardiomyocytes and suggest that chronic DOX treatment may inhibit downstream UPR 
signaling.    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.19: The effect of chronic doxorubicin treatment regimes on ATF4 expression 
in human-derived Girardi heart cells. (A) Lane profile analysis of ATF4. (B) 
Representative immunoblot of ATF4. GAPDH served as the loading control. Girardi cells 
were treated daily with 0.2 µM and 1.0 µM DOX for 96 and 120 hours (n=3). ***P < 0.001 vs 
Control. ##P < 0.01 0.2 µM vs 1.0 µM. Abbreviations – ATF4: activating transcription factor 4, 
C: control, DOX: doxorubicin, hr: hour, vs: versus. 
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Evaluation of ER Load  
 
As previously discussed, ER load, an indicator for ER expansion, was used as an additional 
marker to evaluate ER stress. Results from flow cytometry analysis demonstrate that ER load 
was significantly increased after 96 hours of treatment with both the 0.2 µM DOX [162.40 ± 
9.43%, (p < 0.05)] and 1.0 µM DOX [172.70 ± 9.11%, (p < 0.01)] when compared to the 
control (100%), (Figure 5.20). Whereas after 120 hours, ER load was significantly increased 
following treatment with only the highest concentration of DOX [258.30 ± 14.89%, (p < 0.01 
vs. Control)]. Treatment with the highest concentration of DOX induced ER stress at both 
time points, which correlates to the increase in BiP observed after 120 hours. Together with 
results discussed above, this study showed that only chronic DOX treatment induces ER 
stress activation of the UPR in Girardi heart cells.  
 
 
 
 
 
 
 
 
 
 
 
Figure 5.20: The effect of chronic doxorubicin treatment regimes on ER load in 
human-derived Girardi heart cells. Girardi cells were treated daily with 0.2 µM and 1.0 µM 
DOX for 96 and 120 hours. Following treatment cell were stained with ER-tracker and mean 
fluorescence intensity was measured by flow cytometry (n=3). *P < 0.05 and **P < 0.01 vs 
Control. $$P < 0.01 and $$$P < 0.001 96 hr vs 120 hr. ##P < 0.01 0.2 µM vs 1.0 µM. 
Abbreviations – C: control, DOX: doxorubicin, ER: endoplasmic reticulum, hr: hour,  vs: 
versus. 
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The Effect of Chronic DOX Treatment Regimes on Intracellular and Mitochondrial 
Calcium Levels  
 
Calcium is an essential component of the excitation-contraction coupling process, and a 
disruption of intracellular calcium levels has previously been associated with contractile 
dysfunction and the pathogenesis of heart failure (Rossini et al., 1986).  Given the role ER 
stress, oxidative stress and mitochondrial dysfunction play in disrupting calcium homeostasis 
this study chose to investigate the effects of chronic DOX cardiotoxicity on calcium activity 
within the cells. Due to financial constraints this study could not investigate the effects of 
chronic DOX treatment on mitochondrial calcium levels. 
 
Following chronic DOX administration the intracellular calcium levels were determined 
using flow cytometry (Figure 5.21). Results demonstrated that intracellular calcium levels 
were significantly increased over time following treatment with 0.2 µM DOX (p < 0.05 96 hr 
vs. 120 hr), however no significance was observed when compared to the control group 
(100%). Following treatment with 1.0 µM DOX significantly and progressively increased 
cytosolic calcium levels following 96 hours [319.40 ± 8.34%, (p < 0.001)] and 120 hours 
[581.00 ± 10.50%, (p < 0.001)] of administration compared to the control. Overall these 
results indicate that elevated cytosolic calcium is not only highly dependent on duration of 
DOX treatment, but also on the concentration of DOX administrated, which is comparable to 
results obtained from the H9C2 cell line.  
 
 
 
 
 
 
 
 
 
Stellenbosch University  https://scholar.sun.ac.za
 166
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.21: The effect of chronic doxorubicin treatment regimes on intracellular 
calcium in human-derived Girardi heart cells. Girardi cells were treated daily with 0.2 µM 
and 1.0 µM DOX for 96 and 120 hours. Following treatment H9C2 cardiomyoblasts were 
stained with the specific intracellular calcium dye, Calcium Green and mean fluorescence 
intensity was measured using flow cytometry (n=3). ***P < 0.001 vs Control. $P < 0.05 and  
$$P < 0.01 96 hr vs 120 hr. ###P < 0.001 0.2 µM vs 1.0 µM. Abbreviations – C: control, DOX: 
doxorubicin, hr: hour.  
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APPENDIX B – Protocols 
 
Protocol 1: Cell Culture 
 
Before any work or experiments were carried out under the hoods, hands were washed and 
sterile gloves were put on. Hands with gloves were washed again and sprayed with 70% 
ethanol before laminar hoods were cleaned. Hoods were sprayed and wiped down with 70% 
ethanol, and hands were sprayed again each time before placing them under the hood in 
order to maintain a sterile environment 
 
 Growth medium pre-heated to 37˚C in bead bath 
 Remove cryovile (freezing tube) containing H9C2 cardiomyoblasts/Girardi’s from liquid 
nitrogen freezing chamber 
 Cryovile containing 1ml of FBS/DMSO with 1 x 106  cells thawed at room temperature 
 8 ml of growth medium (see Appendix C) added to 1 x 75cm2 flask 
 Thawed cells added to 75cm2 flask 
 Gently swirl flask to ensure the equal distribution of cells  
 Cells incubated at 37˚C in a 5% CO2 atmosphere 
 Following day, check to ensure cells have plated. Pre-heat growth medium and PBS (see 
Appendix C). 
 Refresh growth medium; Growth medium discarded and cell monolayer rinsed with 8 ml 
warm PBS. 8 ml of new, warm and sterile growth medium added to falcon tube.  
 Cells placed back into incubator 
 Growth medium refreshed every 2 days hereafter, until desired confluency established. 
Subcultering (seeding for experiments) 
 
 Growth medium, PBS and Trypsin pre-heated to 37˚C in bead bath 
 Remove growth medium from 75cm2 flask containing cells (75 – 80 % confluent) 
 Rinse cell monolayer with warm, sterile PBS 
 Discard PBS 
 Add 4 ml with Trypsin 
 Incubate cells at 37˚C for ± 5 minutes in cell shaker.  
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 Using microscope monitor flask intermittently, to check if cells have lifted.  
  Add 8 ml growth medium to 75cm2 flask in order to neutralize trypsin 
 Decant into 50 ml falcon 
 Count cells using haemocytometer (see protocol 2) 
 Pipette desired density of cells into flasks/plates required for experiments: 
 
Flask/plate Cell Density 
6-well plate 200 – 250 000 
12-well plate 250 – 300 000 
96-well plate 30 000 
25cm2 flask 350 – 450 000 
 
 New culture flask/plate with appropriate amount of growth medium incubated at 37˚C in 
a 5% CO2 atmosphere. Cell growth was monitored until desired confluency was 
established and experimental protocols were carried out.  
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Protocol 2: Cell counting with haemocytometer 
 
 Clean haemocytometer with ethanol before use 
 Breath on the coverslip and place on haemocytometer (breathing enables the coverslip to 
stick to the surface of the plate) 
 A sample (10-15ul) of  resuspended cell solution added to each chamber, until both 
counting grids are covered.  
 Check for bubbles – if bubbles form, redo above 3 steps 
 Total number of cells are counted under the microscope 
a. Count cells in each block of A first (record number) 
b. Then count cells in each of block B (record number) 
  Average number of cells calculated. This average was then multiplied by 1 x 104 in order 
to calculate the number of cells per milliliter of the original cell suspension  
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Protocol 3: Doxorubicin dose-response treatment protocol 
 
  Cells were cultured in 24-well plates as previously described 
 Once desired confluency was established cells were treated with increasing concentration 
of DOX (as indicated in the figure below) for 72, 96 and 120 hours (1 x 24 well plate = 1 
time point). 
 
 
 
 Treatment was made up fresh each day throughout treatment protocol. 
 Following last day of treatment, specific experiments were carried out 
 
  
 
C 
0.2 
μM 
0.4 
μM 
0.6 
μM 
0.8 
μM 
1.0 
μM 
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Protocol 4: MTT Assay 
 
 Prepare the following MTT solutions (see appendix C);  
o 1% Isopropanol 
o 0.1% Triton  
o Isopropanol/Triton solution in 50/1 ratio 
o 1% MTT (0.01g/1ml PBS) – this solution must be made fresh before use, and 
covered in foil to protect from light.  
 Cells were cultured and treated as previously described in protocol 3 
 Following last day of treatment, cell growth medium was discarded.  
 DO NOT rinse cell monolayer with PBS (this will prevent cells from lifting/loosening) 
 Turn off hood light (remember MTT is light sensitive) 
 1% MTT added to each well  
 Cover plates in foil and place in humidified incubator (37˚C) for two hours 
 After two hours:  
o If some cells have loosened: 
 Contents of wells transferred to corresponding, labeled eppendorf tubes 
 Epi’s are placed in centrifuge and spun down for 2 min at 1000 rpm 
 Supernatant discarded 
 2ml isopropanol:triton solution added to each epi 
 Cells resuspended 
 Contents of epi’s added back into corresponding wells  
 Plates covered in foil and placed on belly dancer for 5 min 
o If no cells have loosened: 
 Contents of cell discarded 
 2ml isopropanol:triton solution added to each well 
 plates covered in foil and placed on belly dancer for 5 min 
 Absorbency read at 540 nm on spectrophotometer, using isopropanol:triton solution as 
blank. If any absorbency values are greater than one, the supernatant must be diluted. 
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Protocol 5: Caspase-Glo® 3/7 Assay  
 
 Allow the Caspase-Glo® Reagent to thaw to room temperature ± 45 minutes before 
beginning assay  
 Cells cultured and treated as previously described in protocol 2 
 Remove culture plate from incubator, and allow for 10 minutes to equilibrate to room 
temperature 
 Transfer 100 µl of cell growth media to the corresponding well of the white-walled 96-
well plate (supplied by Promega) 
 Add 100 µl of Caspase-Glo® reagents to each well of white-walled 96-well plates 
 Place plate on belly dancer at 300-500 rpm for ± 30 seconds, in order to mix well 
contents  
 Incubate plates in the dark for 1 hour at a constant temperature 
 Using luminometer plate reader, measure the caspase luminescence 
 
Protocol 6: Doxorubicin main experimental treatment protocol 
Following MTT and Caspase-Glo® 3/7 assay’s the following time points and DOX 
concentrations were selected to continue with for the remainder of the study; 
o 96 and 120 hour treatment times 
o 0.2 µM and 1.0 µM DOX concentrations 
 Cells were cultured as previously described in protocol 1  
 Once desired confluency was established, cells were treated daily with 0.2 µM and 1.0 
µM DOX for 96 and 120 hours 
 Fresh treatment was made up daily 
 Following last day of treatment, specific experiments were carried out accordingly 
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Protocol 7: Assessment of Mitochondrial and ER Load with Flow Cytometry  
 
 For this technique cells were cultured in 25 cm2 flasks and treated as previously described 
in protocol 5. The mitochondrial specific dye, MitoTracker® Green FM and the ER 
specific dye, ER-TrackerTM Blue-White were used to measure mitochondrial and ER load 
respectively 
 
 PBS, Trypsin and Growth medium were pre-heated to 37˚C in bead bath 
 Growth medium was discarded and cells were rinsed with warm, sterile PBS 
 2 ml trypsin was incubated with cells for 2-3 minutes, until cells detached from the flask 
surface 
 4 ml culture medium was added to cell suspension to neutralize trypsin. Cell suspension 
transferred to corresponding 15 ml falcon tube and centrifuged for 3 minutes at 1500 rpm 
 Decant supernatant 
 Cells resuspended in 500 µL PBS 
 Prepare 1-5 mM DMSO stock solution of Mitotracker (see Appendix C) 
 MitoTracker® and ER-TrackerTM were directly added into the cell suspension at final 
concentration of 0.5 µM and 1.0 µM respectively and incubated for 15 minutes at room 
temperature (see appendix C for dye preparation)  
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 Analysis followed on the flow cytometer (BD FASCAria I) immediately after incubation. 
Cells resuspended/vortexed again in order to prevent clumping and blocking of the 
stream.  
 A minimum of 10 000 cells were collected using the 470 nm and 490 nm laser and the 
430-640 nm emission filters. Fluorescence intensity signal was measured using the 
geometric mean on the intensity histogram.  
  
Protocol 8: Assessment of Intracellular Calcium with Flow cytometry   
 
For this technique cells were cultured in 25 cm2 flasks and treated as previously described in 
protocol 5. The dye, Calcium GreenTM -5N AM was used specifically to measure intracellular 
calcium following  
 
 PBS, Trypsin and Growth medium were pre-heated to 37˚C in bead bath 
 Growth medium was discarded and cells were rinsed with warm, sterile PBS 
 2 ml trypsin was incubated with cells for 2-3 minutes, until cells detached from the flask 
surface 
 4 ml culture medium was added to cell suspension to neutralize trypsin. Cell suspension 
transferred to corresponding 15 ml falcon tube and centrifuged for 3 minutes at 1500 rpm 
 Decant supernatant 
 Cells resuspended in 500 µL PBS 
 Prepare 1-5 mM DMSO stock solution of Calcium GreenTM (see Appendix C) 
 5 µM Calcium GreenTM was directly added to cell suspension and left to incubate for 20 
minutes at room temperature (see appendix C for dye preparation) 
 Analysis followed on the flow cytometer (BD FASCAria I) immediately after incubation. 
Cells resuspended/vortexed again in order to prevent clumping and blocking of the 
stream.  
 A minimum of 10 000 cells were collected using the 488 nm laser and 530/30 nm 
emission filters. Fluorescence intensity signal was measured using the geometric mean on 
the intensity histogram.  
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Protocol 9: Visualization of mitochondria and ER morphology with fluorescence 
microscopy 
 
For this technique cells were cultured in 8-chamber slides and treated as previously described 
in protocol 5. The mitochondrial specific dye, MitoTracker® Green FM and the ER specific 
dye, ER-TrackerTM Blue-White were used to measure mitochondrial and ER load 
respectively. 
 
  PBS, Trypsin and Growth medium were pre-heated to 37˚C in bead bath 
 Growth medium was discarded and cells were rinsed with warm, sterile PBS 
 Prepare 1-5 mM DMSO stock solution of Mitotracker (see Appendix C) 
 MitoTracker® and ER-TrackerTM were directly added to the adherent cells at final 
concentration of 0.5 µM and 1.0 µM respectively and incubated for 20 minutes at room 
temperature (see appendix C for dye preparation)  
 Cells were visualized with the fluorescence microscope at 60 X magnification with the 
FITC and DAPI excitation filters respectively. Z-stack images were acquired.  
 
Protocol 10: Visualization of intracellular calcium 
 
For this technique cells were cultured in 8-chamber slides and treated as previously described 
in protocol 5. The dye, Calcium GreenTM -5N AM was used specifically to measure 
intracellular calcium following treatment.  
 
  PBS, Trypsin and Growth medium were pre-heated to 37˚C in bead bath 
 Growth medium was discarded and cells were rinsed with warm, sterile PBS 
 Prepare 1-5 mM DMSO stock solution of Mitotracker (see Appendix C) 
 5 µM Calcium GreenTM was directly added to cell suspension and left to incubate for 20 
minutes at room temperature (see appendix C for dye preparation) 
 Cells were visualized with the confocal fluorescence microscope at 60 X magnification 
with the 488 nm laser and 534-569 excitation filter. 
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Protocol 11: Visualization of mitochondrial calcium 
 
For this technique cells were cultured in 8-chamber slides and treated as previously described 
in protocol 5. The dyes, MitoTracker® Green FM and Rhod-2 AM cell permeant were used 
specifically to colocalize and measure mitochondrial calcium following treatment.   
 
  PBS, Trypsin and Growth medium were pre-heated to 37˚C in bead bath 
 Growth medium was discarded and cells were rinsed with warm, sterile PBS 
 Prepare 1-5 mM DMSO stock solution of MitoTracker® Green and Rhod-2 (see 
Appendix C) 
 0.5 µM MitoTracker® Green and 4 µM Rhod-2 was directly added to adherent cells and 
left to incubate for 20 minutes at room temperature (see appendix C for dye preparation) 
 Cells were visualized with the confocal fluorescence microscope at 60 X magnification 
with the 488 nm and 561 nm lasers and 575-635 and 534-569 excitation filters. 
Colocalization of PE-Texas Red and FITC specific excitation filters were used to 
determine specific mitochondrial calcium. 
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Protocol 12: ORAC Assay  
 
This experiment was performed at the Oxidative Stress Research Center at the Cape 
Peninsular University of Technology. The following protocol was provided by CPUT.   
 
Cells were cultured in 6-well plates and treated as previously described in protocol 5. This 
assay runs at 37 °C. Do not use the first two columns and the last column of plate as the 
machine will provide an inaccurate read. Switch on the plate reader and Fluoroskan 30 
minutes before beginning experiment.  
 
Sample Preparation:  
 Following treatment, cells were washed with PBS. 
 75 µL PBS added to each well (Please note: 2 wells combined = 1 sample. Therefore 
total PBS/sample in Epi = 150 µL)  
 Cells scraped using cell scraper (no RIPA or TRYPSIN should be used) 
 Cells added to their corresponding, iced epi’s  
 Sonicate cells  
 Centrifuge cells at 1500 rpm for 3 minutes 
 Aliquot and store supernatant at -80°C until required for assay.  
 
Procedure: 
 ORAC assay performed in black 96-well plate 
 Prepare the following reagents (see appendix C) 
o PBS (75 mM, pH 7.4) 
o Fluorescein Stock (Sigma #F6377) 
o Fluorescein working solution  
o Peroxyl radical (Sigma #440914) / AAPH 
o Trolox (standard) 250 µM stock (Sigma #238831) 
 Prepare Antioxidant standard curve: 
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Epi Concentration 
(µM) 
Trolox stock 
(µL) 
Phosphate 
buffer (uL) 
Well 
A 0 0 750 A1-3 
B 83 125 625 A4-6 
C 167 250 500 A7-9 
D 250 375 375 A10-12 
E 333 500 250 B1-3 
F 417 625 125 B4-6 
 
 Spin down samples – they must not be turbid 
 Add 6 mL phosphate buffer to the AAPH weighed earlier, mix well. Put solution in 
water bath at 37 °C until needed. 
 Add 12 µL standards to each well 
 Add 12 µL of controls per well 
 Add 12 µL of samples per well in triplicate 
 Add 138 µL of fluorescein working solution to each well using a multichannel pipette 
 Add 50 µL of the AAPH solution to each well using a multichannel (add this solution 
AT the plate reader) 
 Put the plate into the plate reader  
 Read for 2 hours (excitation = 485 nm and emission = 530 nm)  
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Protocol 13: TBARS assay   
 
This experiment was performed at the Oxidative Stress Research Center at the Cape 
Peninsular University of Technology. The following protocol was provided by CPUT.   
 
Cells were cultured in 6-well plates and treated as previously described in protocol 5.  
 
Sample Preparation:  
 Following treatment, cells were washed with PBS. 
 75 µL PBS added to each well (Please note: 2 wells combined = 1 sample. Therefore 
total PBS/sample in Epi = 150 µL)  
 Cells scraped using cell scraper (no RIPA or TRYPSIN should be used) 
 Cells added to their corresponding, iced epi’s  
 Sonicate cells  
 Centrifuge cells at 1500 rpm for 3 minutes 
 Aliquot and store supernatant at -80°C until required for assay.  
 
Procedure: 
 Set waterbath to 100°C 
 Prepare TBARs reagents (see appendix C) 
o 4 mM BHT 
o 0.2 M ortho-phosphoric acid 
o 0.1 M NaOH 
o TBA Reagent 
o Saturated NaCl  
 Use 2 ml epi’s for remainder of experiment, and punch holes in their lids. 
 Let 50 µL water/PBS be the blank 
 Transfer 50 µL of sampler into corresponding epi (with hole in the lid) 
 Add 6.25 µL BHT to each sample  
 Add 50 µL ortho-phosphoric acid to each sample  
 Vortex epi’s 
 Add 6,25 µL TBA reagent to each sample  
 Add 30 µL of n-butanol and 50 µL saturated NaCl  
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 Vortex epi’s 
 Heat samples in 100°C waterbath for 45 minutes (be strict with time and degrees for each 
repeat) 
 Transfer 75 µL of separated butanol phase into white 96-well plate 
 Read absorbency at 532-573 nm 
 
Protocol 14: Glutathione Assay    
 
This experiment was performed at the Oxidative Stress Research Center at the Cape 
Peninsular University of Technology. The following protocol was provided by CPUT.   
 
Cells were cultured in 6-well plates and treated as previously described in protocol 5.  
Sample Preparation:  
 Following treatment, cells were washed with PBS. 
 75 µL PBS added to each well (Please note: 2 wells combined = 1 sample. Therefore 
total PBS/sample in Epi = 150 µL)  
 Cells scraped using cell scraper (no RIPA or TRYPSIN should be used) 
 Cells added to their corresponding, iced epi’s  
 Sonicate cells  
 Centrifuge cells at 1500 rpm for 3 minutes 
 Aliquot and store supernatant at -80°C until required for assay.  
Procedure: 
 The following reagents where prepared prior to experiment by staff at CPUT: 
o Buffer A (500 nM NaPO4, 1mM EDTA, pH 7.4) 
o 1 mM NADPH in 12 mL Buffer A 
o M2VP (30 mM in 0.1 M HCl) 
o DTNB (0.3 mM in Buffer A) 
o Standard solution prepared in Buffer A 
 GSH = 2 µM  
 GSSG = 1.5 µM  
o 1 mL Glutathione reductase (16 µL in 984 µl Buffer A)  
 Prepare GSH standards as follows:  
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 Blank 1 2 3 4 5 
GSH (µL) 0 167 333 500 667 833 
Buffer A (µL) 1000 833 667 500 333 167 
 
 Prepare GSSG standard as follows: 
 
 Blank 1 2 3 4 5 
GSSG (µL) 0 167 333 500 667 833 
Buffer A (µL) 1000 833 667 500 333 167 
 
Apply the following procedure for both the GSH and GSSG 96-well plates: 
 
 Add 50 µL standards/samples to the wells of a 96-well plate 
 Add 50 µL of the DTNB using a multichannel 
 Add 50 µL of the glutathione reductase using a multichannel 
 Mix briefly and incubate for 5 minutes at 25 °C in a preheated BioTek plate reader 
 Add 50 µL NADPH to each well as quickly as possible (30 seconds max) 
 Measure absorbance at 412 nm every 30 seconds for 3 minutes 
 Use linear slope of the standards to calculate concentration of samples 
  
Stellenbosch University  https://scholar.sun.ac.za
 182
Protocol 15: Proteasome-GloTM assay  
 
 
For this technique cells were cultured in clear-bottomed, sterile 96-well plates and treated as 
previously described in protocol 5. Three different catalytic activities were assessed in this 
assay; chymotrypsin-like, casapse-like and trypsin-like catalytic activities, therefore 1 x 96-
well plate represented 1 catalytic site.  
Preparation of Proteasome-GloTM reagent:  
 
Protocol according to manufacturers instructions 
 
 Thaw the Proteasome-Glo Buffer 
 Allow the buffer and the Luciferin Detection Reagent to set to room temperature  
 Add appropriate volume of the buffer to the detection reagent (in amber bottle) 
 Thaw appropriate substrate (chymotrypsin-like, trypsin-like or caspase-like) and let it 
equilibrate to the room temperature. Vortex briefly before use 
 Prepare the Proteasome-Glo Reagent by adding the substrate (chymotrypsin-like, trypsin-
like or caspase-like) to the Luciferin Detection Reagent. Remember to label reagent bottle 
so you know which substrate was used. 
 
 Allow the Proteasome-Glo Reagent to sit at room temperature for 1 hour before use.   
 
 
Proteasome-Glo 
Assay 
Substrate Volume of 
substrate added 
Substrate 
concentration 
in reagent 
Chymotrypsin-Like 
Assay 
Suc-LLVY-
Glo 
50ul 40uM 
Trypsin-Like Assay Z-LRR-Glo 100ul 30uM 
Caspase-Like 
Assay 
Z-nLPnLD-
Glo 
50ul 40uM 
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Procedure: 
 
Protocol according to manufacturers instructions 
 
 Following treatment, remove growth medium.  
 Add 50 μl growth medium to each 96-well using multichannel pipette  
 Use multichannel pipette to add 50ul of Proteasome-Glo Reagent to each 96-well. Be 
careful not to cross contaminate. 
 Gently mix the well contents using plate shaker at 300-500rmp for 30seconds 
 Incubate at room temperature for 20-30minutes. Temperature fluctuations will affect the 
luminescent readings, so constant-temperature incubator may be required if room 
temperature constantly changes 
 Record luminescence with plate-reading luminator 
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Protocol 16: Western Blotting  
 
For this technique cells were cultured in 6-well plates and treated as previously described in 
protocol 5. 
Cell harvesting and preparation of lysates: 
 Work on ice at all times 
 Following last day of treatment, old  growth medium is discarded 
 Monolayer of cells is quickly washed 3 x with ice cold PBS (to ensure all FBS is removed 
from cells) 
 PBS discarded 
 50 µL of RIPA buffer is added to the monolayer of cells 
 Plates/flasks are swirled around to ensure entire base is covered with RIPA buffer and left 
for 3 -5 minutes 
 Cells are scraped from the surface of the plate/flasks using a sterile cell scraper 
 Scraped cells are pipetted into their corresponding, chilled epi’s  
 Epi’s can be stored in the -80˚C until further experiments are carried out 
Bradford protein quantification:  
 Work on ice at all times to prevent the proteins from denaturing 
 Cell samples are thawed (if frozen) and placed on ice 
 Cell samples are sonnicated in order to rupture cell walls and release proteins 
 After sonication, samples are centrifuged at 8000rpm for 10minutes 
 Using Bradford working solution, make up the standard curve in 7 different eppendorf 
(epi) tubes as follows:  
 
Epi Distilled Water BSA Bradford Reagent 
1 0ul 100ul 900ul 
2 20ul 80ul 900ul 
3 40ul 60ul 900ul 
4 60ul 40ul 900ul 
5 80ul 20ul 900ul 
6 90ul 10ul 900ul 
7 100ul 0ul 900ul 
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(BLANK) 
 
 Vortex solutions thoroughly 
 Leave solutions to stand on ice for a few minutes 
 Samples from previous protocol are used to prepare for protein determination 
o Pipette 5	μl from each centrifuged sample into a new epi 
o Add 95 μl distilled water to the epi 
o Add 900 μl Bradford reagent to the epi 
o Vortex solutions 
 Read absorbance values at 595 nm 
o Use epi #7 to zero the spectrophotometer  
o Read and record values for standard curve first 
o Read and record values for samples second 
 Using excel, plot standard curve (x-axis = protein concentration, y-axis = the mean OD). 
Add in the absorbance values for the samples and determine final calculation for protein 
concentration in μl/ug 
 Once the concentration of each sample has been determined, pipette desired amount into 
a new eppendorf tube and add required amount of sample buffer  
 Freeze and store protein samples in -80˚C freezer until needed 
 
Preparation and loading of polyacrylamide gels: 
 Prepare the following solutions (see appendix C) 
o 1.5 M Tris-HCl (ph. 8.8) 
o 0.5 M Tris-HCl (ph. 6.8) 
o 10% Sodium dodecyle sulfate (SDS) 
o 10% Ammonium persufate (APS) 
o 1 X Running buffer 
o 10 X Running buffer 
o 1 x TBS 
o 10 X TBS-T 
o 5% Milk blocking solution  
 Clean glass plates with 70% alcohol 
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 Assemble glass places and place onto plastic apparatus with rubber and firmly clip it into 
place 
 Check for leaks using distilled water. If leaks, reassemble glass plates and apparatus. If 
there is no leak, shake out water and absorb any remaining water with a paper towel.  
 Make up desired separating gel (see appendix C). Ensure that temed is added last. 
 Using squeeze pipette, add separating gel into the assembly. Avoid making bubbles 
 Add iso-butanol using squeeze pipette. Iso-butanol ensure that the gel sets in a straight 
line and prevent the oxidation of the gel 
 Allow gel to set for 30-40 minutes 
 Rinse of iso-butanol with dH2O 
 Make up stacking gel 
 Using squeeze pipette, add stacking gel on top of separating gel.  
 Immediately add 10/15 well combs into stacking gel at an angle (prevent formation of 
bubbles). Do not push too deep or push combs in too fast  
 Allow gel to set. While gel is setting prepare 10 x running buffer and thaw samples 
 Denature samples by boiling at 95˚C for 5 minutes.  
 Centrifuge samples for 1 minute at 5000 rpm 
 Remove combs from gel gently and rinse with dH2O. Use blotting paper to drain water 
that remains in each well 
 Take glass off assembly and place onto U-shaped Core-latch and then click to secure. Fill 
with 10 x running buffer and check for leaks.  
 Place apparatus into the tank and add 10 x running buffer into the middle compartment 
until it overflows into the wells 
Loading the protein samples: 
 Place yellow guide on top of the apparatus (over the middle compartment) 
 Using 20 μl pipette, add 6 μl pre-stained marker into the first well on the left 
 Add samples into the next wells, using a new pipette head for each sample 
 Once all the samples have been loaded, remove well guide and add running buffer to the 
outer compartments (1/2 = 2 gels, full = 4 gels) 
 Place green lid on apparatus (red to red, black to black) 
 Connect electrodes to electrophoresis machine 
 Allow samples to run for 10minutes at 400mA and 100V 
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 After 10minutes, run samples for 50minutes at 400mA and 200V 
Protein transfer with Bio-Rad Trans-Blot Turbo System 
 After gels have run for 60 minutes, take Bio-Rad midi transfer pack out of the fridge 
 Open transfer pack 
 Take out trans-blot turbo system cassettes. Open the cassettes and wipe dry 
 Place blotting paper and transfer membrane down inside the cassette 
 Roll out bubbles with roller 
 Place gel on top of transfer membrane, carefully so as not to break the gel 
 Place ‘top’ blotting paper from transfer pack on top of the gel 
 Roll out bubbles with roller 
 Soak up excess transfer buffer with paper towel 
 Close cassette, and place back into trans-blot turbo system 
 Set system: 12 minutes, 12 V and 12 A 
 Wait to transfer to complete. During this time make up 5% milk blocking solution 
 Once transfer is complete, rinse membrane 3 x 5 minutes with TBS-T  
 Place membrane in blocking solution for 2 hours 
Specific binding of protein: 
 Wash membrane 3 x for 5minutes each with TBS-T 
 Make primary antibody in a 50ml falcon tube (keep cold) (see appendix C) 
 After washing, place membrane in primary antibody tube. Place falcon tube on rotating 
machine for minimum of 8 hours, or overnight in walk in fridge (4˚C).  
 Wash membrane 3 x for 5 minutes each with TBS-T 
 Make up secondary antibody in 50ml falcon tube (see appendix C) 
 After washing, place membrane in secondary antibody for 1hour on rotating belly dancer 
Exposure with Bio-Rad ChemiDocTM XRS+ System: 
 Prepare ECL cocktail (see appendix C) 
 Discard secondary antibody, and rinse membrane 3 x 5 minutes with TBS-T 
 Drain excess TBS-T off membrane using paper towel 
 Add 500 µL ECL cocktail to membrane, and leave on for 1 minute 
 Lift membrane, and drain excess ECL  
 Open bottom draw of ChemiDoc, and place membrane inside 
 Open Image LabTM Software 
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 Select single channel analysis   Chemi  blots 
 Set pictures to be taken every 5 seconds, for 300 seconds (total for 30 pictures)   
 Align the membrane and Select ‘run protocol’ 
 Collect images 
Stripping membranes 
 After developing rinse ECL off membrane with distilled water 3 x 3 minutes 
 Rinse membrane in NaOH for a few minutes 
 Rinse membrane with distilled water 3 x 3 minutes 
 Place membrane in blocking solution for 2 hours 
 Rinse membrane with TBS-T 3 x for 5minutes each 
 Place membrane in primary antibody overnight 
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APPENDIX C - Reagent and Solution Preparation   
Preparation of cell culture solutions 
Growth Medium 
 500 ml high glucose DMEM 
 1 % (5.5 ml) Antibiotic Antimyocotic (AA) (100X) 
 10% (50 ml) fetal bovine serum (FBS) 
 Aliquot into 50 ml falcon tubes and store at -4°C until needed 
1X Phosphate buffered saline solution (PBS) 
 Dissolve the following in 1L distilled water (dH2O): 16 g NaCl (sodium chloride), 0.4 g 
KCl (potassium chloride), 2.88 g Na2HPO4 (di sodium hydrogen phosphate) and 0.48 g 
KH2PO4 (potassium dihydrogen phosphate) 
 Adjust pH to 7.4 
 Add 1L dH2O 
 Autoclave solution 
 Aliquot into 50 ml falcon tubes and store at -4°C until needed 
 
Preparation of Doxorubicin Stock Solution [3.4 mM] 
 
Doxorubicin Hydrochloride (DOX) is light sensitive and the following method should 
therefore be performed in appropriate lighting conditions 
 
 Under sterile conditions dissolve 10 mg of DOX in 5071 µL growth medium  
 Vortex solution and ensure all powder is completely dissolved 
 Aliquot into 0.5 ml eppendorf tubes and store at -20°C until needed 
 In order to avoid freeze-thaw cycles, 60 µL aliquots were made 
 Protect epi's from light, and cover in foil.  
 
Preparation of 95% Ethanol (1L) 
 Dilute 950 ml 100% ethanol with 50 ml dH2O 
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Preparation of 70% Ethanol (1L) 
 
 Dilute 700 ml 100% ethanol with 300 ml dH2O 
Preparation of MTT solutions 
1% Isopropanol  
 1 ml concentrated HCl + 99 ml Isopropanol 
20....... % Triton 
  0.1 ml of Triton-X-100 + 99.9 ml dH2O 
Isopropanol/Triton solution (50/1)  
 50 ml isopropanol + 1 ml 0.5% Triton 
1% MTT:  
 0.01g MTT in 1 ml PBS. Cover in foil, as solution is light sensitive. NOTE: 0.01g MTT 
enough for 2 x wells in 6-well plate 
 
Preparation of 1mM MitoTracker® Green FM stock solution 
 
 MitoTracker® Green FM MW = 671.88 
 Add 74.41 µL DMSO to 50 µg (packaged by supplier) MitoTracker® Green FM stock 
powder 
 Vortex until dissolved 
 Aliquot to prevent freeze-thaw cycles, protect from light and store at -20°C 
 
Preparation of 0.5 µM MitoTracker® Green FM working solution 
 
 Dissolve 0.25 µL of MitoTracker® Green FM stock solution (1mM) in 500 µl PBS  
 
Preparation of 1.0 µM ER-TrackerTM Blue-White working solution 
 
 50 µL of ER-TrackerTM Blue-White supplied as 1 mM stock solution by Molecular 
Probes 
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 Dissolve 0.5 µL of ER-TrackerTM Blue-White in 500 µL PBS  
 
Preparation of 5 mM Calcium GreenTM -5N AM stock solution 
 
  Calcium GreenTM -5N AM MW = 1290.98 
 Add 77.40 µL of DMSO to 500 µg , Calcium GreenTM -5N AM stock powder 
 Vortex until dissolved 
 Aliquot to prevent freeze-thaw cycles, protect from light and store at -20°C 
Preparation of 5 µM Calcium GreenTM -5N working solution  
 
 Dissolve 0.5 µL Calcium GreenTM -5N in 500 µL PBS  
 
Preparation of 1 mM Rhod-2 AM, cell permeant stock solution  
 
 Rhod-2 AM MW = 1123.96 
 Add 889.7 µl DMSO to 1 mg of Rhod-2 AM stock powder 
 Vortex until dissolved 
 Aliquot to prevent freeze-thaw cycles, protect from light and store at -20°C 
 
Preparation of 4 µM Rhod-2 AM, cell permeant working solution  
 
  Dissolve 2 µL of Rhod-2 AM in 500 µL PBS 
 
Preparation of ORAC assay reagents 
Phosphate buffer 75 mM, pH 7.4: 
 Weigh 1.035g sodium di-hydrogen orthophosphate-1-hydrate in 100 mL ddH2O and mix 
until dissolved. 
 Weigh 1.335g di-sodium hydrogen orthophosphate dehydrate (Merck #5822880EM) in 
100 mL ddH2O and mix until dissolved. 
 Mix 18 mL of 1st solution with 82 mL 2nd solution 
 Check pH – adjust with phosphate buffer 
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 Store at 4 °C 
Fluorescein Stock: Sigma #F6377 
 Dissolve 0.0225g in 50 mL phosphate buffer (above) 
 Store at 4 °C in a brown bottle (reused for 1 year) 
Fluorescein Working Solution: 
 Take 10 µL of the stock and add it to 2 mL phosphate buffer (epi) 
 Then take 240 µL of this and dilute in 15 mL phosphate buffer (15 mL falcon) 
Peroxyl radical: Sigma #440914 25 mg/mL 
 Weigh 150 mg of AAPH into a 15 mL falcon tube 
 Only add solute later on 
Trolox (standard): 250 µM stock    Sigma # 238831 
 Weigh 0.00312 g and add 50 mL phosphate buffer 
 Mix until dissolved 
 Should give an absorbance of 0.670 at 289nm 
 
Preparation of TBARS reagents  
BHT 
 Dissolve BHT in 100% ethanol to a final concentration of 4 mM  
Ortho-phosphoric acid (0.2 M) 
 CPUT supplies 14.6M stock solution 
 Add 684.93 µL of stock solution to 50 mL dH2O 
NaOH (0.1 M) 
 Dissolve 0.792 g of NaOH in 50 µL ortho-phosphoric acid 
TBA Reagent  
 Concentration of 0.11 M TBA in 0.1 M NaOH  
Saturated NaCl  
 Add 10g of NaCl to 25 ml of dH2 
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Preparation of western blot reagents 
RIPA  
 Prepare 50 mM Tris-HCl: add 790 mg Tris to 75 mL dH2O. Add 900 mg NaCl and stir. 
Adjust pH to 7.4 using HCl. Pour the prepared Tris-HCl into a 100 mL beaker. 
 Add the following in the same order that they appear: 
 Volume Final Concentration 
NP-40 10 mL 1% 
Na-deoxycholate 2.5 mL 0.25% 
EDTA 1 mL 1 mM 
Phenylmethylsulponyl Fluoride (PMSF) 1 mL 1 mM 
Leupeptin 1 µL 1 µg/mL 
SBTI-1 80 µL 4 µg/mL 
Benzamidine 100 µL 1 mM 
Na3VO4 1 mL 1 mM 
NaF 500 µL 1 mM 
 
 Add 1000 µL Triton-X-1000 to the solution and fill up to the mL mark with dH2O 
 Mix thoroughly. 
 Aliquot the RIPA into 1 mL epi's tubes 
 
Bradford working solution 
 Dissolve 200 mg Comassie Brilliant Blue G250 in 100 mL 95% Ethanol  
 Mix on stirrer 
 Add 200 mL 85% ortho-phosphoric acid  
o 85% ortho-phosphoric acid: 120 mL O-P in 30 ml dH2O) 
 transfer solution into brown/light protected bottle 
 Add 1.7 L dH2O 
 Mix on stirrer 
 Filter solution until brown (± 7 times) 
 
Laemmli’s sample buffer stock solution  
 Mix the following together in a beaker: 
Stellenbosch University  https://scholar.sun.ac.za
 194
o 3.8 mL distilled water 
o 1 mL 0.5M Tris-HCl (pH 6.8) 
o 0.8 mL glycerol 
o 1.6 mL 10% (w/v) SDS 
o 0.4 mL 0.05% (w/v) Bromophenol blue 
 Note: For use in western blotting, make a working solution by adding 150 µL β-
mercaptoethanol to 850 µL Laemmli’s stock solution 
 
21....... M Tris-HCl (ph. 8.8) 
 Weigh out 68.1 g Tris (1.124 M) and 1.5 g SDS (0.3%) into a glass beaker 
 Add 400 ml dH2O 
 Adjust pH to 8.8 
 Add 100 ml dH2O to make up final volume 
 Store at room temperature 
 
0.5 M Tris-HCl (pH 6.8)  
 Weigh out 30.3 g Tris (0.5M) and 2 g SDS (0.4%) into glass beaker 
 Add 80 ml dH2O  
 Adjust pH to 6.8 
 Add 20 ml dH2O to make up final volume 
 Store at room temperature 
 
10% Sodium dodecyle sulfate (SDS) 
 Dissolve 50 g SDS in 500 ml dH2O 
 Store at room temperature 
 
10% Ammonium persulfate (APS) 
 Dissolve 0.1 g APS in 100 µL dH2O 
 Store in fridge at -4°C 
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1 x Running buffer  
 Weigh out 60.6 g Tris and  288 g glycine 
 Add to 1.5L dH2O 
 Add 20 g SDS 
 Adjust the pH to 8.6 
 Fill up to the 2L mark dH2O. 
 
10 x Running buffer 
 Dissolve 100 ml 1 x Running buffer in 900 ml dH2O 
 
1 X TBS 
 Weigh out 48.4 g TRIS (trizma base) and 32 g NaCl into a glass beaker 
 Add 1L dH2O 
 Stir until dissolved, and adjust pH 7.6 
 Add 1L dH2O 
 Store at room temperature 
1 x TBS-T 
 Dissolve 200ml 1 X TBS in 1900 ml dH2O 
 Add 2 ml Tween  
 Mix thoroughly 
 Can be stored at room temperature (± 1 week) 
 
5% Milk blocking solution  
 Weigh out 5g non-fat, dry instant milk powder into glass beaker 
 Add 100 ml TBS-T and mix well  
 100 ml blocking solution per membrane 
 
Stripping buffer  
 Dissolve 4 g NaOH pellets in 500 ml dH2O 
 Store at room temperature 
 
Stellenbosch University  https://scholar.sun.ac.za
 196
Preparation of acrylamide separating gel: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Preparation of 4% acrylamide stacking gel (enough for 4 gels) 
 
 
 
 
 
 
 
 
 
 
Preparation of primary and secondary antibodies 
 
All antibodies diluted in TBS-T. Primary antibodies can be reused 5-6 times, but must be 
stored at -4°C. Secondary antibodies cannot be reused.  
 
 10% acrylamide 
(separating) gel 
15% acrylamide 
(separating) gel 
dH2O 3.85 ml 1.1 ml 
1.5M Tris-HCL (ph. 8.8) 2.5ml 2.5 ml 
10% SDS 100 µl  100 µl 
40% Acrylamide 2.5 ml  2.5 ml 
10% APS 50 µl  50 µl  
Temed 5 µl  2 µl  
 Stacking Gel  
dH2O 6.1 ml 
0.5M Tris-HCL (ph. 6.8) 2.5 ml 
10% SDS 100 µl  
40% Acrylamide 1 ml  
10% APS 100 µl  
Temed 20 µl  
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Primary 
Antibody 
Primary 
Antibody 
Dilution 
Secondary 
Antibody 
Secondary 
Antibody 
Dilution 
Molecular 
Weight 
(kDa) 
ATF-4 1/1000 Anti-Rb IgG 1/10 000 49 
BiP 1/1000 Anti-Rb IgG 1/10 000 78 
Cleaved 
Caspase 3 
1/1000 Anti-Rb IgG 1/10 000 17, 19 
Drp1 1/1000 Goat anti-Ms IgG 1/2000 82 
GAPDH 1/1000 Anti-Rb IgG 1/10 000 37 
K48 ubiquitin 1/1000 Anti-Rb IgG 1/ 10 000 Whole lane 
LC3 1/1000 Anti-Rb IgG 1/10 000 14, 16 
MARCH5 1/1000 Anti-Rb IgG 1/10 000 31 
Mitofusion 1 
1/10 000 Goat anti-Rb 
HRP 
1/1000 86 
Mitofusion 2 1/ 1000  Anti-Rb IgG 1/2000 80 
p-62 1/1000 Anti-Rb IgG 1/10 000 62 
Parkin 1/1000 Anti-Rb IgG 1/10 000 52 
PGC-1α 1/1000 Anti-Rb IgG 1/10 000 130 
hFis1 
1/ 10 000 Goat anti-Rb 
HRP 
1/1000 Spec: 17 
Nonspec: 25  
Tomm20 
1/1000 Anti-Rb IgG 1/3000 Spec: 16  
Nonspec : 
25  
  
Stellenbosch University  https://scholar.sun.ac.za
 198
Appendix D - List of Reagents and Materials  
 
Reagents Catalogue Number Company 
AAPH (2,2'-azobis(2-amidino-
propane) dihydrochloride) 
44091 Sigma-Aldrich 
Antibiotic-Antimyocotic (AA) 100x 15240-062 Invitrogen-Gibco 
Acrylamide A3699 Sigma 
Ammonium Persulphate (APS) A3678 Sigma 
BHT (2, 6-di-tert-butyl-4-
methyphenol) 
B1378 Sigma-Aldrich 
BLUeye pre-stained protein ladder PM007-0500 GeneDirex 
Bovine Serum Albumin (BSA) A4503 Sigma 
Calcium-GreenTM -5N, AM, cell 
permeant  
C-3739 Molecular Probes 
Caspase-Glo® 3/7 Assay  G8091 Promega 
ClarityTM Western ECL Substrate 170-5061 Bio-Rad 
Dulbecco’s Modified Eagles Medium 
(DMEM), high Glucose 
41965-039 Invitrogen-Gibco 
DTNB (5 5'-dithiobis(2-nitrobenzoic 
acid)) 
D8130 Sigma-Aldrich 
Doxorubicin (DOX)  D1515 Sigma 
ER-TrackerTM Blue-White DPX E-12353 Molecular Probes 
Fetal Bovine Serum (FBS) BC/S0615-HI Biochrom 
Fluorescein F6377 Sigma-Aldrich 
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Glutathione Reductase G3664 Sigma-Aldrich 
Hydrochloric Acid (HCl) UN1789 Merck 
M2VP (1—methyl-2-vinylpyridinium) 69701 Sigma-Aldrich 
Mitotracker® Green FM M-7514 Molecular Probes 
MTT (Thiazolyl Blue Tetrazolium 
Bromide)  
M2003 Sigma-Aldrich 
NADPH (β-nicotinamide adenine 
dinucleotide) 
N7505 Sigma-Aldrich 
Ortho-phosphoric acid 100563 Merck 
Penicillin-Streptomycin  (PenStrep) 10378-016 Invitrogen-Gibco 
Ponceau S Solution P5447 Sigma 
Proteasome-GloTM Assay G8531 Promega 
Rhod-2, AM, cell permeant R-1244 Molecular Probes 
Sodium Dodecyle Sulphate (SDS) L3771 Sigma 
TBA (2-thiobarbituric acid) T5500 Sigma-Aldrich 
Temed T9281 Sigma 
Trizma-base 93304 Fluka 
Trolox 238813 Sigma-Aldrich 
Trypsin-EDTA (0.25%)  25200072 Invitrogen-Gibco 
Tween 20 T6146 Sigma 
 
Primary Antibodies Catalogue Number Company 
ATF-4 11815 Cell Signaling 
BiP 3177 Cell Signaling 
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Cleaved Caspase 3 9661 Cell Signaling 
Drp1 Ab56788 Abcam 
GAPDH 2118 Cell Signaling 
K48 ubiquitin 4289 Cell Signaling 
LC3 2775 Cell Signaling 
MARCH5 Ab77585 Abcam 
Mitofusion 1 Ab129154 Abcam 
Mitofusion 2 Ab124773 Abcam 
p-62 5114 Cell Signaling 
Parkin 2132 Cell Signaling 
PGC-1α 2178 Cell Signaling 
hFis1 Ab71498 Abcam 
Tomm20 Ab56783 Abcam 
 
 
Secondary Antibodies Catalogue Number Company 
Anti-rabbit IgC, AP-linked antibody 7054 Cell Signaling 
Goat anti-Mouse IgG H&L (HRP) Ab97040 Abcam 
Goat anti-Rabbit IgG H&L (HRP)  Ab97069 Abcam  
 
Western Blotting Catalogue Number Company 
Trans-Blot TurboTM Mini PDVF 
Transfer Pack 
170-4156 Biorad 
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Materials Catalogue Number Company 
25 cm2 sterile tissue culture flask 
(vent cap) 
707003 
Nest 
Biotechnology  
75 cm2 sterile tissue culture flask 
(vent cap) 
708003 
Nest 
Biotechnology 
5 ml Serological Pipette 500052 White Sci 
10 ml Serological Pipette 500053 White Sci 
25 ml Serological Pipette 500055 White Sci 
BD Falcon conical centrifuge tubes 
(15 ml)  
352099 Corning 
BD Falcon conical centrifuge tubes 
(50 ml) 
352070 Corning 
Cell Scrapers 710011 
Nest 
Biotechnology  
Nunc® Lab-Tek® 8-well Chamber 
Slide™  
C7182 Sigma-Aldrich 
Reagent Reservoirs 95128085 Thermo Scientific 
Sterile, 6-well culture plate (flat 
bottomed) 
703001  
Sterile, 96-well culture plate (Flat 
bottomed) 
701001 
Nest 
Biotechnology 
Sterile, black 96-well clear bottomed 
culture plate 
CL S3603 -48EA 
Nest 
Biotechnology  
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